<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">BMC Syst Biol</journal-id>
    <journal-id journal-id-type="iso-abbrev">BMC Syst Biol</journal-id>
    <journal-title-group>
      <journal-title>BMC Systems Biology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1752-0509</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">4578257</article-id>
    <article-id pub-id-type="pmid">26391647</article-id>
    <article-id pub-id-type="publisher-id">211</article-id>
    <article-id pub-id-type="doi">10.1186/s12918-015-0211-x</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Review</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Cava</surname>
          <given-names>Claudia</given-names>
        </name>
        <address>
          <email>claudia.cava@ibfm.cnr.it</email>
        </address>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bertoli</surname>
          <given-names>Gloria</given-names>
        </name>
        <address>
          <email>gloria.bertoli@ibfm.cnr.it</email>
        </address>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Castiglioni</surname>
          <given-names>Isabella</given-names>
        </name>
        <address>
          <email>isabella.castiglioni@ibfm.cnr.it</email>
        </address>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <aff id="Aff1">Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Milan, Italy </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>21</day>
      <month>9</month>
      <year>2015</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>21</day>
      <month>9</month>
      <year>2015</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2015</year>
    </pub-date>
    <volume>9</volume>
    <elocation-id>62</elocation-id>
    <history>
      <date date-type="received">
        <day>14</day>
        <month>5</month>
        <year>2015</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>9</month>
        <year>2015</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© Cava et al. 2015</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p>Development of human cancer can proceed through the accumulation of different genetic changes affecting the structure and function of the genome. Combined analyses of molecular data at multiple levels, such as DNA copy-number alteration, mRNA and miRNA expression, can clarify biological functions and pathways deregulated in cancer. The integrative methods that are used to investigate these data involve different fields, including biology, bioinformatics, and statistics.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p>These methodologies are presented in this review, and their implementation in breast cancer is discussed with a focus on integration strategies. We report current applications, recent studies and interesting results leading to the identification of candidate biomarkers for diagnosis, prognosis, and therapy in breast cancer by using both individual and combined analyses.</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p>This review presents a state of art of the role of different technologies in breast cancer based on the integration of genetics and epigenetics, and shares some issues related to the new opportunities and challenges offered by the application of such integrative approaches.</p>
      </sec>
    </abstract>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2015</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p>Breast Cancer (BC) is the most common cancer in women and the second most common cause of cancer mortality among females [<xref ref-type="bibr" rid="CR1">1</xref>]. Classification of BC is currently based on histological types and molecular subtypes in order to reflect the hormone-responsiveness of the tumour. The three most common histological types include invasive ductal carcinoma, ductal carcinoma in situ and invasive lobular carcinoma. The molecular subtypes of BC, which are based on the presence or absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor-2 (HER2), include luminal A (ER+ and/or PR+; HER2–), luminal B (ER+ and/or PR+; HER2+), basal-like (ER–, PR–, and HER2–), and HER2-enriched (ER–, PR–, and HER2+) subtypes [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. This classification reflects the BC heterogeneity and the complexity of diagnosis, prognosis, and treatment of BC.</p>
    <p>High-throughput approaches allow today a tumour to be investigated at multiple levels: (i) DNA with copy number alteration (CNA), ii) epigenetic alterations, specifically, DNA methylation, histone modifications and microRNA (miRNA) expression level alterations, and (iii) mRNA, with gene expression (GE) de-regulation. These high-throughput approaches redefined the different types of BC in terms of classification, showing the presence of only two BC profiles with different prognosis [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref>].</p>
    <p>Development of human cancer can proceed through the accumulation of genetic and epigenetic changes affecting the structure and function of the genome. Several studies have reported that the epigenetic silencing of one allele may act in concert with an inactivating genetic alteration in the opposite allele, thus resulting in total allelic loss of the gene [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Birgisdottir et al. [<xref ref-type="bibr" rid="CR9">9</xref>] have reported hypermethylation and deletion of the <italic>BRCA1</italic> promoter and suggested Knudson's two 'hits' in sporadic BC [<xref ref-type="bibr" rid="CR9">9</xref>]. Li et al. [<xref ref-type="bibr" rid="CR10">10</xref>] were focused on the expression of <italic>beclin 1</italic> mRNA and they demonstrated that loss of heterozygosity and aberrant DNA methylation might be the possible reasons of the decreased expression of <italic>beclin 1</italic> in the BC. In BC, a biallelic inactivation of the FHIT gene could be a consequence of epigenetic inactivation of both parental alleles, or epigenetic modification of one allele and deletion of the remaining allele [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
    <p>In 2006, Feinberg et al. suggested that epigenetics and genetics should be combined or integrated in order to achieve better understanding of cancer [<xref ref-type="bibr" rid="CR12">12</xref>]. A systems biology approach has been employed to explore the functional relationships among multidimensional “omics” technologies. This approach has been demonstrated to be important for addressing a patient to the optimal treatment in a personalized way, in order to improve the efficacy of the treatment for that patient [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
    <p>This review refers to current studies of genetic and epigenetic changes associated with BC, focusing in particular on the processes controlled by CNA, epigenetic alterations (DNA methylation, histone modifications and miRNAs), and GE. Several approaches combining genetic and epigenetic data, in particular regarding CNA and miRNA deregulation, have been considered with the final purpose to identify new biomarkers for BC diagnosis and prognosis suitable to be translated into a clinical environment. Furthermore, experimental and computation methods used for the study and the analysis of these biomarkers are presented. We also discuss the biological insights and clinical impact from such analyses as well as the future challenges of these combination approaches.</p>
    <sec id="Sec2">
      <title>Copy number alterations in BC</title>
      <sec id="Sec3">
        <title>Biological insights</title>
        <p>CNAs are alterations of the DNA of a genome that result in a cell having an abnormal number of copies of one or more sections of the DNA. They have been identified as causes of cancer diseases and developmental abnormalities (e.g. [<xref ref-type="bibr" rid="CR14">14</xref>]). Changes in DNA copy number (CN) can occur in specific genes or involve whole chromosomes, usually genomic regions between 1kbp and 1Mbp in length [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
        <p>Figure <xref rid="Fig1" ref-type="fig">1</xref> shows an example of a wild type (WT) cell with two copies of DNA segments that suffer of alterations in tumour cells bringing deletions (CN = 0; CN = 1) or amplifications (CN = 3; CN = 4) of the DNA section.<fig id="Fig1"><label>Fig. 1</label><caption><p>Copy Number alterations. WT cell, since diploid organisms, carry two copies of each gene (red segments). Deletions in tumour cells lead to no copy (CN = 0) or one copy (CN = 1) of this section of DNA, rather than two copies (CN = 2). Amplifications in tumour cells lead to three (CN = 3) or more copies (CN = 4) of DNA section</p></caption><graphic xlink:href="12918_2015_211_Fig1_HTML" id="MO1"/></fig></p>
        <p>The ability of cancer cells to accumulate genetic alterations is crucial for the development of cancer in order to inactivate tumour suppressor genes (TSGs) and activate oncogenes (OGs).</p>
        <p>In BC, several genetic alterations have been found.</p>
        <p>Frequent CN deletions between axillary lymph node metastasis and BC primary tumours were revealed, including aberrations at 6q15-16, containing the gene <italic>PNRC1</italic> (a putative tumour suppressor) [<xref ref-type="bibr" rid="CR15">15</xref>]. Amplification and overexpression of the <italic>HER2</italic> (HER2/neu, <italic>ERBB2</italic>) oncogene on chromosome 17q12 has been observed in 15–25 % of invasive BC [<xref ref-type="bibr" rid="CR16">16</xref>]. <italic>HER2</italic>-amplified (HER2+) has been associated with poor prognosis in BC [<xref ref-type="bibr" rid="CR17">17</xref>], amplification of the <italic>HER2</italic> gene leading to <italic>HER2</italic> protein levels 10–100 times greater than normal levels [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
        <p>EGFR amplification has been frequently associated with indices of poor prognosis in BC patients, such as large tumour size, high histological grade, high proliferative index, HER2 negative, upregulation of PR [<xref ref-type="bibr" rid="CR19">19</xref>], and negative ER status [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
        <p>In the same region of <italic>HER2</italic> (17q12–21) other genes have been found co-amplified or deleted, e.g. topoisomerase (<italic>TOP2A</italic>) [<xref ref-type="bibr" rid="CR21">21</xref>]. Different studies observed the possibility of guiding therapy based on <italic>TOP2A</italic> status [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p>
        <p>A recent study has shown alterations of <italic>PIK3CA</italic> and <italic>MET</italic> in BC [<xref ref-type="bibr" rid="CR24">24</xref>]. High CN of <italic>PIK3CA</italic> and <italic>MET</italic> was associated to a poor prognosis, and these alterations occur often in triple receptor negative BC [<xref ref-type="bibr" rid="CR24">24</xref>]. Alterations were also found at 9q31.3-33.1, where the genes <italic>DBC1</italic> and <italic>DEC1</italic> (regulators of apoptosis) are located [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
        <p>OGs activation by genomic amplification occurs in the members of different oncogene families, e.g. <italic>MYC</italic> and <italic>CCND. MYC</italic> is a key regulator of cell growth, proliferation, metabolism, differentiation, and apoptosis [<xref ref-type="bibr" rid="CR25">25</xref>]. This oncogene is located on chromosome 8q24, and several mechanisms are implicated in its deregulation in BC, including gene amplification and traslocations. <italic>MYC</italic> amplification plays a role in BC progression because it has been detected in the more aggressive phenotype of ductal carcinoma in situ [<xref ref-type="bibr" rid="CR26">26</xref>] or in invasive processes [<xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR29">29</xref>].</p>
        <p>Gene amplification of <italic>CCND1</italic> has been observed in a subgroup of BCs with poor prognosis and associated with resistance to tamoxifen [<xref ref-type="bibr" rid="CR30">30</xref>]. Region of amplification is 11q13, and <italic>CCND1</italic> acts as a cell cycle regulator, promoting progression through the G<sub>1</sub>-S phase [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
        <p>Higher <italic>ESR1</italic> gene amplification is found in BC with <italic>CCND1</italic> gene amplification in comparison with tumours without <italic>CCND1</italic> gene amplification [<xref ref-type="bibr" rid="CR32">32</xref>]. Amplification of <italic>ESR1</italic> has been associated with negative ER [<xref ref-type="bibr" rid="CR32">32</xref>]. The gene <italic>TSPAN1</italic> (on 1p34.1) has been found deleted in metastasizing BC and might represent an important TSG [<xref ref-type="bibr" rid="CR33">33</xref>]. Another gene, <italic>EMSY</italic> was found involved in sporadic BC. <italic>EMSY</italic> amplification has been shown to be associated with a poor prognosis [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
        <p>Compared to non-metastatic invasive ductal carcinoma, metastatic invasive ductal carcinoma showed a unique pattern of CNAs, including gains at 2p24-13, 2q22-33, 9q21-31, 12q21-23, 17 q23-25 and loses at 11q23-ter, 14q23-31, 20p11-q12, 2q36-ter, 8q24-ter, 9q33-ter, 2p11-q11, and 12q13 [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p>
        <p>Table <xref rid="Tab1" ref-type="table">1</xref> reports a synthesis of the considered mutated genes in BC, with their genetic alterations due to CNs.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Genes mutated and their alterations in BC</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Genes</th><th>Genetic alterations</th><th>References</th></tr></thead><tbody><tr><td>MYC</td><td>Amplifications and translocations</td><td>[<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>CCND1</td><td>Amplifications and Translocations</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td>HER2</td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td>TOP2A</td><td>Amplifications or Deletions</td><td>[<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td><italic>PIK3CA, MET</italic></td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr><td><italic>PNRC1</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td><italic>DBC1</italic> and <italic>DEC1</italic>
</td><td>Amplifications or Deletions</td><td>[<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td><italic>TSPAN1</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td><italic>EGFR</italic></td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td>ESR1</td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td><italic>EMSY</italic></td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec4">
        <title>Experimental methods</title>
        <p>Current experimental methods for the identification of CNA include cytogenetic techniques, microarrays, and sequencing-based computational approaches.</p>
        <p>Karyotyping is a cytogenetic technique performing a standardized and effective single cell screening in order to identify significant genomic aberrations in pathological and in normal samples.</p>
        <p>In a standard karyotyping, a dye like Giesma or Quinacrine is used to stain bands on the chromosomes. Each chromosome presents banding pattern for detecting CNAs. Thus, any alteration in banding pattern represents a CNA [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
        <p>Spectral karyotyping (SKY technique) is a novel technique for chromosome analysis [<xref ref-type="bibr" rid="CR37">37</xref>], based on the approach of the fluorescence <italic>in situ</italic> hybridization technique (FISH). Sky refers to the multicolour-FISH technique where each chromosome is represented with different colours (a dye with different fluorophores). This technique is used to identify CNAs in cancer cells and in other disease conditions when other techniques are not enough accurate [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
        <p>Resolution is the main limitation of both techniques, the chromosome profile obtained by karyotyping being not enough sensitive to notice short and relevant abnormalities [<xref ref-type="bibr" rid="CR38">38</xref>].</p>
        <p>Hybridization-based microarray approaches, including array comparative genomic hybridization (array CGH) and Single Nucleotide Polymorphism (SNP) microarrays, have been used as an alternative technology to conventional cytogenetic approaches [<xref ref-type="bibr" rid="CR39">39</xref>]. They are able to infer CNAs (amplifications and deletions) compared to a reference sample. Array CGH platforms compare quickly and efficiently two labelled samples (different fluorophores - test and reference). Denaturation of the DNA in single stranded allows the hybridization of the two samples to microarrays containing DNA sequence probes of known genome position (e.g. bacterial artificial chromosomes, cDNAs, or more recently, oligonucleotides). By using a fluorescence microscope and a dedicated computer software, the signal ratio of different coloured fluorescents is measured in order to identify chromosomal differences between the two sources. An important consideration is the consequence of the reference sample on the CN profile. A comprehensive-characterized reference is the key for the correct interpretation of array CGH data [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
        <p>SNP-arrays have a higher resolution than CGH-arrays, and can be used to identify allele-specific information. SNP microarray has few key differences from CGH technologies. Probe designs are specific to single-nucleotide differences between DNA sequences.</p>
        <p>Ultimately, next generation sequencing (NGS) have replaced microarrays as the platform for discovery and genotyping, and present considerable computational and bioinformatics challenges.</p>
      </sec>
      <sec id="Sec5">
        <title>Computational methods</title>
        <p>We can summarize CNA analysis from microarray in three steps: 1) normalization, 2) probe-level modelling, and 3) CN estimation [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
        <p>The target of normalization is to remove non relevant effects, such as the GC content of the fragment amplified by PCR, technical variations between arrays occurring from differences in sample preparation or labelling, and array production or scanning differences [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
        <p>Probe-level modelling is usually performed at two levels: single locus and multilocus. Single locus modelling measures the CN of a specific target fragment or DNA probe locus in order to produce a raw fragment CN. Multilocus modelling combines the raw CNs of neighbouring fragments or DNA probe loci into a “meta-probe set” which determines the CN of the whole region [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p>
        <p>Computerized methods to estimate CNs (e.g. segmentation) performs the detection of break points which separate neighbouring regions based on the Log ratio of probe intensity [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p>
        <p>Several methods are suitable for analysing CNA on microarray data.<list list-type="simple"><list-item><label>i)</label><p>The first CNA analysis method has been developed by Affymetrix: Chromosome Copy Number Analysis Tool [<xref ref-type="bibr" rid="CR43">43</xref>]. Normalization is performed by quantile normalization. Modelling uses robust multichip average. CN estimation can be done subsequently with an arbitrary algorithm.</p></list-item><list-item><label>ii)</label><p> DNA-Chip Analyzer (dChip) [<xref ref-type="bibr" rid="CR44">44</xref>] normalizes using an invariant set method which corresponds to a normalization of the arrays based on the identification of a common baseline array and on adjustment of all the other arrays relative to the baseline array. Modelling is based on a model-based expression index (MBEI) for single-locus. This output is then used by a Hidden Markov Model (HMM) to infer CNs [<xref ref-type="bibr" rid="CR44">44</xref>].</p></list-item><list-item><label>iii)</label><p>  Copy Number Analyser for GeneChip arrays (CNAG) [<xref ref-type="bibr" rid="CR45">45</xref>] normalizes the arrays in order to have the same mean signal intensity for all autosomal probes. This allows fragment probes comparable between arrays to be obtained. The signal intensity ratios is corrected for the differences in PCR product length and GC content. An HMM algorithm is applied to infer CNs along each chromosome.</p></list-item><list-item><label>iv)</label><p>  Birdsuite's Birdseye [<xref ref-type="bibr" rid="CR46">46</xref>] normalizes using quantile normalization. Modelling and segmentation are performed together at the multi-loci level. HMM estimates CNs.</p></list-item><list-item><label>v)</label><p>Copy-number estimation using Robust Multichip Analysis (CRMA) [<xref ref-type="bibr" rid="CR47">47</xref>] has been developed as an extension of the RMA model. Normalization is obtained by allelic cross-hybridization correction (ACC). Modelling uses robust multichip average (RMA). CNA analysis can be done using an arbitrary segmentation algorithm.</p></list-item></list></p>
        <p>Given the different existing computational methods for CNA detection using SNP arrays, researchers have the problem to choose the optimal tool for their analyses.</p>
        <p>With the aim of offering a support to bioinformatics researches and to answer to their emerging needs to choose among different CNA detection algorithms, the CNV Workshop was developed [<xref ref-type="bibr" rid="CR48">48</xref>]. It represents the first cohesive and convenient platform for detection, annotation, and assessment of the biological and clinical significance of structural variants [<xref ref-type="bibr" rid="CR48">48</xref>]. The purpose of the platform is to process data from a wide variety of SNP arrays, and to implement different normalization and CN estimation algorithms.</p>
        <p>Since one of the main problem in the choice of the tool is the detection of discrepancies among different platforms [<xref ref-type="bibr" rid="CR49">49</xref>], some studies have compared the different analysis using the same data set. Although limited to few methods, due to the high computational cost, several studies allowed the assessment of advantages and disadvantages of some techniques [<xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR51">51</xref>].</p>
        <p>Baross et al.[<xref ref-type="bibr" rid="CR49">49</xref>] found that CNAG, dChip, CNAT and GLAD are suitable for high-throughput processing of Affymetrix 100 K SNP array data for CN analysis. However, the tools revealed considerable variations in the numbers of putative CNA. dChip found more CNA than the other tested tools. The highest rate of false positive candidate deletion calls was produced by CNAG. In general, the performance of all tools in the detection of single copy deletions was better than that of single copy duplications. The authors recommend also the use of reference data set for accurate analysis, processed in the same laboratory and ideally from samples with an ethnic composition similar to the sample set.</p>
        <p>Eckel-Passow et al. [<xref ref-type="bibr" rid="CR50">50</xref>] provided a description of four freely-available software packages (PennCNV, Aroma. Affymetrix, Affymetrix Power Tools (APT), and Corrected Robust Linear Model with Maximum Likelihood Distance (CRLMM)) that are commonly used for CNA analysis of data generated from Affymetrix Genome-Wide Human SNP Array 6.0 platform. APT obtained the best performance with respect to bias. However, PennCNV and Aroma.Affymetrix had the smallest variability associated with the median locus-level CN.</p>
        <p>Zhang et al. [<xref ref-type="bibr" rid="CR51">51</xref>] assessed four software programs currently used for CNA detection: Birdsuite (version 1.5.2), PennCNV-Affy (a trial version), HelixTree (Version 6.4.2), and Partek (Version, 6.09.0129). They evaluated the accuracy in detecting both rare and common CNVs in the Affymetrix 6.0 platform. They found considerable variations among the programs in the number of CNAs. Birdsuite obtained the highest percentages of known HapMap CNAs containing more than twenty markers in two reference CNA datasets. In the tested rare CNA data, Birdsuite and Partek had higher positive predictive values than the other tools.</p>
        <p>Other methods exist for analysing CNA on NGS and they are not described in this review. However, most of the more recent algorithms for CNA discovery are modelled on computational methods which were first used to analyse capillary sequencing reads and fully sequenced large-insert clones [<xref ref-type="bibr" rid="CR39">39</xref>].</p>
      </sec>
      <sec id="Sec6">
        <title>Therapeutic approach</title>
        <p>A future challenging direction is the discovery of gene CN changes for the development of therapies. For example, duplication of one gene encoding a specific receptor can be associated with a particular pathology. Thus, compounds that down regulate receptor expression may lead benefit in patients.</p>
        <p>Cancer is the prime case in which CNAs have been shown to drive disease [<xref ref-type="bibr" rid="CR52">52</xref>] and therapies where overexpressed or amplified oncogenic drivers are targeted have been already considered. In particular, in BC, the gene encoding epidermal growth factor receptor (<italic>EGFR</italic>) results to be amplified, and small molecules such as gefitinib, erlotinib, lapatinib, and cetuximab have been applied to inhibit <italic>EGFR</italic> with benefits for patients [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p>
        <p><italic>ERBB2,</italic> encoding HER2, is amplified in 30 % of BC [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. In the therapy of HER2-amplified BC, trastuzumab, an anti-HER2 antibody, has been used [<xref ref-type="bibr" rid="CR56">56</xref>]. Pertuzumab, a humanized monoclonal antibody, binds HER2, and like trastuzumab, it stimulates antibody-dependent, and cell mediated-cytotoxicity [<xref ref-type="bibr" rid="CR57">57</xref>]. Pertuzumab and trastuzumab binds to different HER2 epitopes acting in the same way. When given together, they operate reinforcing antitumor activity [<xref ref-type="bibr" rid="CR58">58</xref>].</p>
        <p>These proven benefits, although limited to few genes involved in BC, raise the exciting possibility that targeting amplified disease drivers may offer opportunities for therapy development in BC where effective treatments are still limited.</p>
      </sec>
    </sec>
  </sec>
  <sec id="Sec7">
    <title>Epigenetic alterations in BC</title>
    <sec id="Sec8">
      <title>DNA methylation and histone modifications</title>
      <p>DNA methylation and histone modifications play a crucial role in the maintenance of cellular functions and identity. In particular, the main cellular networks affected by epigenetics are cell cycle, apoptosis, DNA repair, detoxification, inflammation, cell adhesion and invasion.</p>
      <p>In cancer, the DNA methylation and histone modifications are perturbed, leading to significant changes in GE, which confer to the tumoral cells advantages in proliferation and maintenance of tumoral phenotype. For instance, the genomic inactivation of a tumor suppressor gene (p53, BRCA1,…) or the activation of an oncogene (i.e., Myc) contribute to the malignant transformation. Epigenetic changes differ from genetic changes mainly because they occur at a higher frequency than genetic changes, they are reversible upon treatment with pharmacological agents and occur at defined regions in a gene.</p>
      <p>DNA methylation refers to the addition of a methyl group (−CH<sub>3</sub>) covalently to the base cytosine (C) in the dinucleotide 5′-CpG-3′. CpGs islands are in the promoter region of many genes [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Most CpG dinucleotides in the human genome are methylated, and often leads to silencing of GE. The observation that CpGs islands of housekeeping genes are mainly unmethylated, and the methylation is associated with loss of GE led to the hypothesis that DNA methylation plays an important role in regulating GE [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>].</p>
      <p>Figure <xref rid="Fig2" ref-type="fig">2</xref> shows how DNA methylation affects GE. Methyl groups in the recognition elements of transcription factors inhibits the binding of transcription factors to DNA, thus resulting in reduced transcriptional activity.<fig id="Fig2"><label>Fig. 2</label><caption><p>DNA methylation regulating GE. Methylated CpG restricts the binding between transcription factor and the gene promoter. Unmethylated CpG allows accessing of transcription factors to the gene promoter</p></caption><graphic xlink:href="12918_2015_211_Fig2_HTML" id="MO2"/></fig></p>
      <p>Histones are considered DNA-packaging protein components of chromatin, able to regulate chromatin dynamics. In fact they are subjected to several post-translational modifications, occurring at the amino-terminal end of the histone tail protruding from the surface of the nucleosome [<xref ref-type="bibr" rid="CR61">61</xref>]. The modifications of histone tails, including lysine acetylation, lysine and arginine methylation, lysine ubiquitylation, phosphorylation, sumoylation, and ribosylation, can significantly affect the expression of genes in a dynamic manner [<xref ref-type="bibr" rid="CR61">61</xref>]. The most studied histone epigenetic alterations are acetylation/deacetylation, and methylation/demethylation. In BC, abnormal histone modification and DNA hypermethylation are frequently associated to epigenetic silencing of tumor suppressor genes and genomic instability [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p>
      <sec id="Sec9">
        <title>Biological insights</title>
        <p>The distribution of methylated and unmethylated CpGs in the genome shows different patterns of methylation confirming tissue-specific manner [<xref ref-type="bibr" rid="CR64">64</xref>].</p>
        <p>DNA methylation biomarkers for early detection and prognosis of cancer have been studied in the last years. Table <xref rid="Tab2" ref-type="table">2</xref> shows genes differentially methylated in BC.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Genes differentially methylated in BC</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Genes</th><th>Biological effects</th><th>References</th></tr></thead><tbody><tr><td><italic>RASSF1A</italic> and <italic>CCND2</italic>
</td><td>Significantly more methylated in the ER+ than ER− cancers</td><td>[<xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td><italic>PGR, TFF1, CDH13, TIMP3, HSD17B4, ESR1</italic> and <italic>BCL2</italic>
</td><td>The inverse correlations were found between their hypermethylation and ER expression</td><td>[<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td><italic>ESR1, TGFBR2, PTGS2</italic> and <italic>CDH13</italic>
</td><td>They were associated with PR expression</td><td>[<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td><italic>FAM124B</italic>, <italic>ST6GALNAC1</italic>, <italic>NAV1</italic> and <italic>PER1</italic>
</td><td>The methylation status were quite different between ER+/PR+ and ER−/PR− BC</td><td>[<xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td><italic>RASSF1A, CCND2, TWIST, HIN1</italic></td><td>Low levels of methylation were detected in normal control samples</td><td>[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td><italic>CCND2, RASSF1A, APC</italic> and <italic>HIN1</italic>
</td><td>Able to distinguish between invasive carcinomas, fibroadenomas, and normal tissue</td><td>[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td><italic>ITIH5</italic>, <italic>DKK3</italic>, and <italic>RASSF1A</italic></td><td>Early detection of BC</td><td>[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td><italic>APC</italic>, <italic>BIN1</italic>, <italic>BMP6</italic>, <italic>BRCA1</italic>, <italic>CST6</italic>, <italic>ESR-b</italic>, <italic>GSTP1</italic>, <italic>P16</italic>, <italic>P21</italic> and <italic>TIMP3</italic>
</td><td>Able to distinguish between cancerous and normal tissues</td><td>[<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td><italic>CST6</italic></td><td>Differentially methylated between BC and control plasma samples</td><td>[<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr></tbody></table></table-wrap></p>
        <p>Fackler et al. [<xref ref-type="bibr" rid="CR65">65</xref>] found that promoter methylation of 4 genes <italic>(</italic>RASSF1A, CCND2, TWIST, HIN1<italic>)</italic> was more frequently detected in tumor than in normal tissue. In another study [<xref ref-type="bibr" rid="CR66">66</xref>], 4 genes <italic>CCND2, RASSF1A, APC</italic> and <italic>HIN1</italic> were able to classify between invasive carcinomas, fibroadenomas, and normal tissue. 10 hypermethylated genes, <italic>APC</italic>, <italic>BIN1</italic>, <italic>BMP6</italic>, <italic>BRCA1</italic>, <italic>CST6</italic>, <italic>ESR-b</italic>, <italic>GSTP1</italic>, <italic>P16</italic>, <italic>P21</italic> and <italic>TIMP3,</italic> were identified to distinguish between cancerous and normal tissues [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
        <p>Several studies provide strong evidence of DNA methylation signatures with prognostic role. DNA methylation status of the <italic>PITX2</italic> in BC cell lines is negatively associated with PITX2 mRNA expression and with poor prognosis [<xref ref-type="bibr" rid="CR68">68</xref>].</p>
        <p>Previous studies observed several candidate methylation sites that are associated with the hormone receptor status of BC. <italic>RASSF1A</italic> and <italic>CCND2</italic> were significantly more methylated in the ER+ than ER− BC [<xref ref-type="bibr" rid="CR69">69</xref>], whereas the inverse correlations were identified between hypermethylation of the <italic>PGR, TFF1, CDH13, TIMP3, HSD17B4, ESR1</italic> and <italic>BCL2</italic> genes and ER status [<xref ref-type="bibr" rid="CR70">70</xref>]. Hypermethylation of the <italic>ESR1, TGFBR2, PTGS2</italic> and <italic>CDH13</italic> genes was associated with PR status [<xref ref-type="bibr" rid="CR70">70</xref>].</p>
        <p>Li et al. [<xref ref-type="bibr" rid="CR71">71</xref>] used 27 K arrays in a small sample of ER/PR+ and ER/PR BC samples, and identified and validated four genes: <italic>FAM124B</italic> and <italic>ST6GALNAC1</italic> were significantly hypermethylated, and <italic>NAV1</italic> and <italic>PER1</italic> were significantly hypomethylated in ER+/PR+ BC.</p>
        <p>Fang et al. [<xref ref-type="bibr" rid="CR72">72</xref>] used genome wide analysis to characterize BCs based on their metastatic potential. The study found a coordinated methylation of a large number of genes discovering a “methylator” phenotype. The methylator phenotype was associated with low metastatic risk and survival.</p>
        <p>Identification of promoter methylation of biomarker genes in the DNA of bodily fluids, like serum or plasma, is a rapidly growing research field in cancer detection.</p>
        <p>The principle is based on evidence that solid malignant tumors release significant amounts of cell-free DNA into the bloodstream through cellular necrosis or apoptosis [<xref ref-type="bibr" rid="CR73">73</xref>].</p>
        <p>The analysis of the methylation patterns of cell-free DNA by a blood-based test could become a screening tool. In particular, DNA methylation in circulating free DNA from blood of BC was investigated. ITIH5<italic>,</italic> DKK3, and RASSF1A promoter methylation from serum were identified as candidate biomarkers for the early detection of BC [<xref ref-type="bibr" rid="CR74">74</xref>].</p>
        <p><italic>CST6</italic> has been identified by two independent dataset as being differentially methylated between BC and control plasma samples [<xref ref-type="bibr" rid="CR75">75</xref>].</p>
        <p><italic>SOX17</italic> promoter is highly methylated in primary BCs, in circulating tumor cells isolated from patients with BC, and in corresponding cell-free DNA samples [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
        <p>Similar studies on plasma identified hypermethylation status of KIF1A [<xref ref-type="bibr" rid="CR77">77</xref>], and HYLA2 locus [<xref ref-type="bibr" rid="CR78">78</xref>] in BC suggesting methylation level in blood having a power to distinguish very early BC cases from controls.</p>
        <p>Non-invasive technique such as blood-test screening is a more suitable and cost-efficient methodology compared to mammography and magnetic resonance imaging.</p>
        <p>Actually, in clinical use no specific methylation biomarker has been yet validated, due to the reduced number of matched normal DNA samples in cohorts.</p>
        <p>Characterizing more than 880 human BC, Elsheikh et al. have demonstrated that histone acetylation and methylation patterns represent an early sign of BC [<xref ref-type="bibr" rid="CR79">79</xref>]. Low levels of acethylated lysine and methylated lysine and arginine were described to have prognostic value, i.e. of triple-negative carcinomas and HER2-positive BC subtype [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>].</p>
      </sec>
      <sec id="Sec10">
        <title>Experimental methods</title>
        <p>In recent years three major technologies have been employed in DNA methylation analysis: chemical treatment with bisulphite (BS), methylation-specific enzyme digestion, and affinity enrichment [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>].</p>
        <p>The first category includes an assay to characterize methyl cytosine by treatment of genomic DNA with BS. BS treatment converts unmethylated cytosine residues to uracil, without recognizing methyl cytosine residues, which are protected against this treatment.</p>
        <p>Methylated and unmethylated DNA can be distinguished by the employment of sequence analysis (e.g. NGS, microarray). PCR amplicons created after BS conversion can be hybridized to microarrays containing methylation-specific oligonucleotides (MSO; 19–23 nucleotides) to query DNA methylation status [<xref ref-type="bibr" rid="CR83">83</xref>]. BS-based methods cannot distinguish between methylcitosine and other variants (e.g. hydroxymethylcytosine) [<xref ref-type="bibr" rid="CR84">84</xref>].</p>
        <p>The second category includes methylation-sensitive restriction endonucleases, which distinguish sequences based on methylation status; furthermore methylcytosine could be identified by immunoprecipitation with antibodies or by affinity purification on methyl-binding protein beads.</p>
        <p>Restriction endonucleases and microarray are also combined for high-throughput examination of the methylation status [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. A limitation in utilizing restriction endonucleases is that enzymes identify only a limited fraction of genome CpG sites [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. A methodology [<xref ref-type="bibr" rid="CR87">87</xref>] with multiple enzyme-mediated restrictions was proposed, leads to a better coverage of all CpG dinucleotides in mammalian genomes.</p>
        <p>A third category, enrichment techniques, include methylated DNA immunoprecipitation (MeDIP). Genomic DNA is immunoprecipitated with a monoclonal antibody that specifically identifies 5-methylcytidine. The immunoprecipitated fraction can be detected by PCR in order to identify the methylation state of individual regions [<xref ref-type="bibr" rid="CR88">88</xref>].</p>
        <p>A combination approach of MeDIP and methylation-sensitive restriction endonucleases was developed, promising to quickly compare methylomes at lower cost [<xref ref-type="bibr" rid="CR89">89</xref>]. Alternatively, MeDIP can be combined with large-scale analysis (e.g. microarrays) [<xref ref-type="bibr" rid="CR88">88</xref>].</p>
        <p>Many of the techniques proposed for DNA methylation profiling can be combined with NGS technologies [<xref ref-type="bibr" rid="CR90">90</xref>].</p>
      </sec>
      <sec id="Sec11">
        <title>Computational methods</title>
        <p>Bioinformatics research has been focused on the prediction of DNA methylation information with a dual purpose: i) accurate DNA methylation predictions could replace experimental data, and ii) DNA methylation prediction algorithms from training data can give additional information of an epigenetic mechanism.</p>
        <p>A large number of computational predictive models have been developed to identify CpG dinucleotides methylated or unmethylated [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>], CpG islands (or CpG-rich regions) methylated or unmethylated [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>], and CpG islands (or CpG-rich regions) differentially methylated in different tissue/cell types or phenotypes [<xref ref-type="bibr" rid="CR95">95</xref>]. Most of them use DNA sequence characteristics combined with a machine-learning algorithm.</p>
        <p>Combination approaches of computational and experimental methods can speed up genome-wide DNA methylation profiling and detect crucial factors or pathways driving DNA methylation patterns. However DNA methylation prediction shows some difficulties: i) DNA methylation of the sampled cells need to be averages across cells, ii) there are differences across tissues, iii) DNA methylation can have unstable position, and iv) can be not well located in a genomic locus [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>].</p>
        <p>A key step for accurate computational predictive models is a correct features selection.</p>
        <p>The features can be grouped into two categories: genetic and epigenetic features. Given a region of interest (a CpG island or a genomic region around a particular CpG dinucleotide), the genetic features include: i) general features of the region of interest (e.g., length, and distribution of the CpG dinucleotides in the region), ii) DNA sequence composition of the region of interest, iii) patterns of conserved transcription factor binding sites or conserved elements within or near the region of interest, iv) structural and physicochemical properties of the region of interest, v) functional annotations of nearby genes, vi) single nucleotide polymorphisms of the region of interest, and vii) the conservation of the region of interest among species [<xref ref-type="bibr" rid="CR98">98</xref>].</p>
        <p>Epigenetic features are also crucial in order to fully characterize DNA methylation status.</p>
        <p>DNA methylation, as an epigenetic phenomenon, is affected by some other epigenetic factors, such as histone methylation and histone acetylation.</p>
        <p>Statistical methods related to differential DNA methylation data analysis cover a number of different approaches. In particular, these methods are accessible to the user by Bioconductor/R. Table <xref rid="Tab3" ref-type="table">3</xref> shows some methods and packages currently available for methylation differential analysis, such as Wilcoxon rank sum test (implemented in methyAnalysis package) [<xref ref-type="bibr" rid="CR99">99</xref>], <italic>t</italic>-test (implemented in methyAnalysis, CpGAssoc, RnBeads, and IMA package [<xref ref-type="bibr" rid="CR99">99</xref>–<xref ref-type="bibr" rid="CR102">102</xref>]), Kolmogorov-Smirnov Tests ([<xref ref-type="bibr" rid="CR100">100</xref>]), permutation test (implemented in CpGAssoc package [<xref ref-type="bibr" rid="CR101">101</xref>]), empirical Bayes method (implemented in RnBeads, IMA and minfi package [<xref ref-type="bibr" rid="CR101">101</xref>–<xref ref-type="bibr" rid="CR103">103</xref>]), and bump hunting method (implemented in bumphunter and minfi package [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Packages and methods for methylation differential analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Package</th><th>Method</th><th>References</th></tr></thead><tbody><tr><td>methyAnalysis</td><td>Wilcoxon rank sum test</td><td>[<xref ref-type="bibr" rid="CR100">100</xref>]</td></tr><tr><td>methyAnalysis, CpGAssoc, RnBeads, and IMA</td><td><italic>t</italic>-test</td><td>[<xref ref-type="bibr" rid="CR100">100</xref>–<xref ref-type="bibr" rid="CR102">102</xref>]</td></tr><tr><td>-</td><td>Kolmogorov-Smirnov test</td><td>[<xref ref-type="bibr" rid="CR104">104</xref>]</td></tr><tr><td>CpGAssoc</td><td>permutation test</td><td>[<xref ref-type="bibr" rid="CR101">101</xref>]</td></tr><tr><td>RnBeads, IMA and minfi</td><td>empirical Bayes</td><td>[<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]</td></tr><tr><td>bumphunter and minfi</td><td>bump hunting</td><td>[<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]</td></tr></tbody></table></table-wrap></p>
        <p>Wilcoxon rank sum test detect statistically significant sites according to the absolute difference between the average methylation levels of the analysed groups [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. This method can have a limitation in case of low or unbalance number of samples groups [<xref ref-type="bibr" rid="CR107">107</xref>].</p>
        <p><italic>t</italic>-test is statistically inefficient in the presence of heterogeneity of methylation variability and shows many false positives, particularly for studies with smaller sample sizes [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>].</p>
        <p>Kolmogorov-Smirnov test is another commonly used test that quantifies distributional differences. However, the Kolmogorov-Smirnov test considers each CpG marker as a sampling unit and its naive application is not valid [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>].</p>
        <p>Permutation test is a resampling-based nonparametric test which permutes data following the null hypothesis of equal data distributions between groups [<xref ref-type="bibr" rid="CR112">112</xref>].</p>
        <p>Different number of empirical Bayes models were proposed for differential methylation analysis, with different statistical distribution assumptions [<xref ref-type="bibr" rid="CR113">113</xref>]. Teng et al. [<xref ref-type="bibr" rid="CR113">113</xref>] constructed five empirical Bayes models based on either a gamma distribution or a log-normal distribution, for the detection of differential methylated loci. They observed that log-normal, rather than gamma, could be a more accurate and precise method.</p>
        <p>Bump hunting method used in bumphunter and minfi packages based the correlations of methylation levels between nearby CpG locus, and, for each locus, a linear model was used to estimate the coefficient of difference in methylation levels between the cancer group and the normal groups [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR107">107</xref>].</p>
        <p>A comparison study among these six statistical approaches was proposed [<xref ref-type="bibr" rid="CR114">114</xref>]. Finally, different approaches were recommended for different applications: the bump hunting method is better for small sample size; the empirical Bayes methods are suggested when DNA methylation levels are independent across CpG loci, while only the bump hunting method is suggested when DNA methylation levels are correlated across CpG loci. All methods are found suitable for medium or large sample sizes [<xref ref-type="bibr" rid="CR114">114</xref>].</p>
      </sec>
      <sec id="Sec12">
        <title>Therapeutic approach</title>
        <p>Cancer was the first group of diseases to be associated with DNA methylation. Numerous genes have been identified as being differentially methylated in BC, with a crucial roles in DNA repair, apoptosis, hormone receptor, and cell cycle. These TSGs may be good therapeutic targets through regulation of methylation activity by DNA methyltransferase inhibitors. Human DNA methylation is catalysed by enzymes of the DNA cytosine methyltransferases family including DNMT1, DNMT3A, DNMT3B and DNMT3L [<xref ref-type="bibr" rid="CR115">115</xref>]. A lower DNA methyltransferase activity increases expression of silenced genes such as TSGs reactivating expression of key genes.</p>
        <p>Previous studies [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>] were reported in BC focusing on action of DNA methyltransferase compound inhibitors.</p>
        <p>Key targets for potential DNA demethylation agents are DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (decitabine), zebularine, and SGI-110 [<xref ref-type="bibr" rid="CR117">117</xref>]. The mechanism of action of these pro-drugs is similar since they need to be incorporated into DNA to act as inhibitors of DNMTs [<xref ref-type="bibr" rid="CR115">115</xref>].</p>
        <p>Decitabine shows activity against hematologic malignancy and low-dose correlates with changes in GE induced by a reduction in DNA methylation.</p>
        <p>A phase I clinical and pharmacodynamic trial was proposed in order to assess the feasibility of delivering a dose of decitabine combined with carboplatin [<xref ref-type="bibr" rid="CR116">116</xref>]. Decitabine showed some limitations for treatment of advanced solid tumors (e.g. BC): i) weak stability, ii) lack of specificity for cancer cells, and iii) rapid inactivation by the action of cytidine deaminase [<xref ref-type="bibr" rid="CR117">117</xref>].</p>
        <p>Zebularine and SGI-110 are more selective for cancer cells and have higher resistance to deamination. In particular, Zebularine [<xref ref-type="bibr" rid="CR118">118</xref>] showed an antitumor effect in a mouse model. In zebularine-treated mices, the oral treatment with zebularine showed a significant delay in tumor growth [<xref ref-type="bibr" rid="CR118">118</xref>]. In combination with decitabine, zebularine has proven a significant inhibitory effect on cell proliferation and colony formation in MDA-MB-231 BC cell line through induction of ER alpha and PR mRNA expression [<xref ref-type="bibr" rid="CR119">119</xref>]. Unfortunately, toxicity remain its main limitation [<xref ref-type="bibr" rid="CR118">118</xref>].</p>
        <p>SGI-110 [<xref ref-type="bibr" rid="CR120">120</xref>], a 5′-AzapG-3′ dinucleotide, induces expression of the <italic>p16</italic> tumor suppressor gene, and inhibit tumor cell growth. This short oligonucleotide is resistant to cytidine deaminase deamination which may potentially increase its resistance, enhance bioavailability, and make the drug more efficacious.</p>
        <p>DNA methyltransferase inhibitors can have side effects as the concomitant activation of both TSGs and OGs. The combination of chemotherapeutic agents and of DNA methyltransferase inhibitors could be efficacious [<xref ref-type="bibr" rid="CR115">115</xref>].</p>
        <p>Although the benefits of DNA methyltransferase inhibitors were demonstrated, toxicity, lack of specificity and low stability are issues to be solved in order to improve BC treatment [<xref ref-type="bibr" rid="CR121">121</xref>].</p>
        <p>Histone acetylation process is controlled by the balanced activity of histone acetyltransferases and histone deacetylases (HDACs). The HDAC family is divided into zinc-dependent enzymes (classes I, IIa, IIb, and IV, of which there are 11 subtype enzymes) and zinc-independent enzymes (class III, also called sirtuins), requiring NAD<sup>+</sup> for their catalytic activity. Over the past decade, a number of HDAC inhibitors have been designed and synthesized, based on HDAC chemical structures. Some of these HDAC inhibitors are able to modify the chromatin structure, causing re-expression of aberrantly silenced genes, which in turn is associated with growth inhibition and apoptosis in cancer cells [<xref ref-type="bibr" rid="CR122">122</xref>]. In ER-negative BC, the treatment with specific HDAC inhibitors reactivates ERα and progesterone receptor (PR) gene expression, which are known to be aberrantly silenced in BC. Preclinical studies of HDAC inhibitors combined with DNMT inhibitors or with anti-tumoral treatment (i.e., tamoxifen) have demonstrated a higher safety, tolerability and clinical effectiveness than single treatment [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec13">
      <title>microRNA deregulation in BC</title>
      <sec id="Sec14">
        <title>Biological insights</title>
        <p>miRNAs are small noncoding RNAs (20–22 nucleotides long) that are excised from longer (60–110 nucleotides) RNA precursor [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>] and act in different biological functions including development, proliferation, differentiation and cell death [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. miRNAs are major regulators of GE. Many evidences indicate that their deregulation is associated to several steps of cancer initiation and progression. In comparison with other approaches targeting single genes, they are certainly more stable thanks to their small size [<xref ref-type="bibr" rid="CR127">127</xref>], and are able to discriminate different BC subtypes.</p>
        <p>Blenkiron et al. found deregulated miRNAs between basal and luminal BC [<xref ref-type="bibr" rid="CR128">128</xref>]. Iorio et al. [<xref ref-type="bibr" rid="CR129">129</xref>], Lowery et al. [<xref ref-type="bibr" rid="CR130">130</xref>] and Mattie et al. [<xref ref-type="bibr" rid="CR131">131</xref>] identified miRNAs that were able to classify ER, PR and HER2/neu receptor status, respectively. Gregory et al. [<xref ref-type="bibr" rid="CR132">132</xref>] found <italic>miR-200</italic> associated with the BC luminal subtype. Reduced expression of <italic>miR-145</italic> and <italic>miR-205</italic> was found to play a role in basal like triple negative tumours (ER-/PR-/HER2-) while are normally expressed in normal myoepithelial cells [<xref ref-type="bibr" rid="CR133">133</xref>].</p>
        <p>miRNAs can be also prognostic and predictive biomarkers. Zhou et al. [<xref ref-type="bibr" rid="CR134">134</xref>] found <italic>mir-125b</italic> as useful indicator for poorly response to taxol-based treatments in vivo. The overexpression of <italic>miR-181a</italic> has been correlated with lymph node metastasis [<xref ref-type="bibr" rid="CR135">135</xref>]. <italic>miR-106b-25</italic> expression was proven significantly predictor of good relapse time [<xref ref-type="bibr" rid="CR136">136</xref>], while <italic>miR-375</italic> was found negatively regulate ER expression [<xref ref-type="bibr" rid="CR137">137</xref>].</p>
        <p>miRNAs with a role in metastasis in BC include <italic>miR-7</italic> [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>], <italic>miR-17/20</italic> [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR141">141</xref>], <italic>miR-22</italic> [<xref ref-type="bibr" rid="CR142">142</xref>–<xref ref-type="bibr" rid="CR144">144</xref>], <italic>miR-30</italic> [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR146">146</xref>], <italic>miR-31</italic> [<xref ref-type="bibr" rid="CR147">147</xref>–<xref ref-type="bibr" rid="CR149">149</xref>], <italic>miR-126</italic> [<xref ref-type="bibr" rid="CR150">150</xref>], <italic>miR-145</italic> [<xref ref-type="bibr" rid="CR151">151</xref>], <italic>miR-146</italic> [<xref ref-type="bibr" rid="CR152">152</xref>], <italic>miR-193b</italic> [<xref ref-type="bibr" rid="CR153">153</xref>], <italic>miR-205</italic> [<xref ref-type="bibr" rid="CR154">154</xref>], <italic>miR-206</italic> [<xref ref-type="bibr" rid="CR155">155</xref>], <italic>miR-335</italic> [<xref ref-type="bibr" rid="CR156">156</xref>], <italic>miR-448</italic> [<xref ref-type="bibr" rid="CR157">157</xref>], <italic>miR-661</italic> [<xref ref-type="bibr" rid="CR158">158</xref>] and <italic>let-7</italic> [<xref ref-type="bibr" rid="CR159">159</xref>].</p>
        <p>miRNAs can be easily extracted and detected from blood [<xref ref-type="bibr" rid="CR160">160</xref>], circulating exomes [<xref ref-type="bibr" rid="CR161">161</xref>], saliva [<xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>], and even sputum [<xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR165">165</xref>]. Several studies demonstrated that circulating miRNAs reflect the pattern observed in the tumour tissues (e.g. [<xref ref-type="bibr" rid="CR167">167</xref>]), thus opening the possibility to use circulating miRNAs as biomarkers for diagnosis and prognosis. Lodes et al. [<xref ref-type="bibr" rid="CR166">166</xref>] provided an evidence on using serum miRNAs as biomarkers to discriminate between normal and patients in many cancer diseases including breast, prostate, colon, ovarian, and lung cancer. They showed that it is sufficient 1 mL of serum to detect miRNA expression patterns, without the need of amplification techniques. Recently, an analysis of circulating miRNAs have led to identify <italic>mir-21</italic>, <italic>miR-92a</italic> [<xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR168">168</xref>], <italic>miR-10b</italic>, <italic>miR-125b</italic>, <italic>miR-155</italic>, <italic>miR-191</italic>, <italic>miR-382</italic> [<xref ref-type="bibr" rid="CR169">169</xref>] and <italic>miR-30a</italic> [<xref ref-type="bibr" rid="CR170">170</xref>] as candidate biomarkers for early detection of BC. Circulating miRNAs have also been associated with disease prognosis and response to treatment. Madhavan et al. [<xref ref-type="bibr" rid="CR171">171</xref>] found circulating miRNAs as marker of disease free survival and overall survival. Plasma <italic>miR-10b</italic> and <italic>miR-373</italic> were found associated with the development of metastases [<xref ref-type="bibr" rid="CR172">172</xref>] while <italic>miR-125b</italic> [<xref ref-type="bibr" rid="CR173">173</xref>] and <italic>miR-155</italic> [<xref ref-type="bibr" rid="CR174">174</xref>] have been found correlated to chemotherapy response.</p>
        <p>Table <xref rid="Tab4" ref-type="table">4</xref> reports a synthesis of the considered miRNAs deregulated in BC, with their principal biological effects.<table-wrap id="Tab4"><label>Table 4</label><caption><p>miRNAs deregulated in BC</p></caption><table frame="hsides" rules="groups"><thead><tr><th>MiRNAs</th><th>Biological effect</th><th>References</th></tr></thead><tbody><tr><td><italic>miR-200</italic></td><td>It associated with the luminal subtype</td><td>Gregory et al. [<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td><italic>miR-145 and miR-205</italic></td><td>It associated with basal like triple negative tumours</td><td>Sempere et al. [<xref ref-type="bibr" rid="CR133">133</xref>]</td></tr><tr><td><italic>miR-125b</italic></td><td>It can predict poor response to taxol-based treatment <italic>in vivo</italic>
</td><td>Zhou et al. [<xref ref-type="bibr" rid="CR134">134</xref>]</td></tr><tr><td><italic>miR-181a</italic></td><td>It correlated with lymph node metastasis</td><td>Taylor et al. [<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td><italic>miR-106b-25</italic></td><td>It can significantly predict a good relapse time</td><td>Smith et al. [<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td><italic>miR-31</italic></td><td>It controls metastasis and increases the survival of patients</td><td>Valastyan et al. [<xref ref-type="bibr" rid="CR147">147</xref>]</td></tr><tr><td><italic>let-7</italic></td><td>It suppressed metastasis</td><td>Yu et al. [<xref ref-type="bibr" rid="CR159">159</xref>]</td></tr><tr><td><italic>miR-375</italic></td><td>It negatively regulate ER expression</td><td>de Souza et al. [<xref ref-type="bibr" rid="CR137">137</xref>]</td></tr><tr><td><italic>miR-10b, miR-155</italic></td><td>They correlate with metastasis</td><td>Mar-Aguilar et al. [<xref ref-type="bibr" rid="CR169">169</xref>]</td></tr><tr><td><italic>miR-21</italic></td><td>It associated with cell migration and invasion</td><td>Si et al. [<xref ref-type="bibr" rid="CR168">168</xref>]</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec15">
        <title>Experimental methods</title>
        <p>Many technologies for detecting miRNAs have been developed, including RT-PCR, <italic>in situ</italic> hybridization, microarray, and NGS [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
        <p>RT-PCR is a sensitive and precise technology but it is also an expensive and low-throughput method [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
        <p><italic>In situ</italic> hybridization is based on labelled complementary strands for the sequences of interest (e.g. miRNA) in a portion or section of tissue [<xref ref-type="bibr" rid="CR175">175</xref>]. The small size of the mature miRNA presents problems for conventional <italic>in situ</italic> hybridization methods and it is semi-quantitative.</p>
        <p>Microarrays have several limitations as those due to background or cross-hybridization problems. Moreover, microarrays and other techniques can provide analyses only on known miRNAs [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
        <p>Contrarily, sequence-based methods allow the identification of unknown miRNAs and early overcome other methods. Stark et al. [<xref ref-type="bibr" rid="CR176">176</xref>], by using deep sequencing, discovered and quantified new miRNAs. Similarly, Farazi et al. [<xref ref-type="bibr" rid="CR177">177</xref>], generated a miRNA signature able to differentiate ductal breast carcinoma <italic>in situ</italic>, invasive ductal breast carcinoma and normal tissue.</p>
        <p>Also deep sequencing may be a powerful method to study circulating miRNAs. Several studies investigated correlations among miRNAs in the serum of BC with clinicopathological indices [<xref ref-type="bibr" rid="CR178">178</xref>] and found miRNAs associations with overall survival [<xref ref-type="bibr" rid="CR179">179</xref>].</p>
        <p>Despite the high potential and promising results of these methods in clinical applications, there are still some problems that need to be addressed, e.g. the lack of inconsistency for some results between different studies. Standardization of procedures for sample conservation, preparation and/or processing [<xref ref-type="bibr" rid="CR180">180</xref>], and the use of different quality controls for data normalization [<xref ref-type="bibr" rid="CR181">181</xref>] could be effective in reducing these limitations.</p>
      </sec>
      <sec id="Sec16">
        <title>Computational methods</title>
        <p>There are two different approaches to examine both miRNA and mRNA expression profiles.</p>
        <p>A first approach considers either a miRNA or an mRNA first, and then applies ad-hoc strategies, such as computational or experimental methods, in order to obtain miRNA-mRNA pair information [<xref ref-type="bibr" rid="CR182">182</xref>, <xref ref-type="bibr" rid="CR183">183</xref>].</p>
        <p>A second approach examines miRNA and mRNA regulatory pairs together [<xref ref-type="bibr" rid="CR184">184</xref>–<xref ref-type="bibr" rid="CR187">187</xref>].</p>
        <p>Computational methods play important roles in the identification of new miRNAs. These methods can be divided into three major categories: 1) sequence or structure conservation-based, 2) machine learning-based method, 3) and non-comparative methods.</p>
        <p>Sequence or structure conservation-based methods are based on sequence/structure conservation as techniques to find miRNAs. The principle is the nature of conservation across different species for most of the known miRNAs. Comparative genomics filter out sequence/structure conservation that are not evolutionarily conserved in related species [<xref ref-type="bibr" rid="CR188">188</xref>]. Examples of such computational methods, focusing on the secondary structure of RNA and looking for conserved hairpin structures between related species, are Srnaloop [<xref ref-type="bibr" rid="CR189">189</xref>], MiRscan [<xref ref-type="bibr" rid="CR190">190</xref>], and miRseeker [<xref ref-type="bibr" rid="CR191">191</xref>]. One of the first study related to these methods was by Lee and Ambros [<xref ref-type="bibr" rid="CR192">192</xref>]. The authors, using bioinformatics techniques, searched for sequences conserved between the <italic>C. elegans</italic> and <italic>C. briggsae</italic> genomes. They focused on premiRNA sequences and secondary structures with similar characteristics to <italic>lin-4</italic> and <italic>let-7</italic>, the first two miRNAs found on that time.</p>
        <p>Several web based software tools have been developed to find new miRNA genes, based on sequence and secondary structure similarities with known miRNAs [<xref ref-type="bibr" rid="CR189">189</xref>–<xref ref-type="bibr" rid="CR191">191</xref>, <xref ref-type="bibr" rid="CR193">193</xref>]. However, the limit of these approaches was demonstrated by Bentwich et al., showing the possibility that large quantity of nonconserved miRNAs could be missed by the use of this tool [<xref ref-type="bibr" rid="CR194">194</xref>].</p>
        <p>Free energy (or Gibbs free energy) can be used as feature for miRNA target prediction. It shows how strong the binding of a miRNA with its target is by predicting how the miRNA and its candidate target will hybridize. The free energy of miRNA-mRNA binding is normally assigned by the RNAfold program-Vienna RNA Package [<xref ref-type="bibr" rid="CR195">195</xref>].</p>
        <p>Machine learning-based methods do not necessarily depend on sequence conservation. A classifier is constructed on a training dataset, that contains a set of known miRNA sequences (positive training dataset), and on a set consisting of mRNAs, tRNAs and rRNAs (negative training dataset). The information given to the classifier can be, for instance, the position of the mature sequence or the folding energy. The classifier, by describing a candidate miRNA with this set of features, is able to predict true and false miRNA sequences [<xref ref-type="bibr" rid="CR196">196</xref>]. The limit of this approach is the choice of negative set. As example, we do not know a priori if a particular sequence can generate functional miRNAs [<xref ref-type="bibr" rid="CR197">197</xref>]. Several studies have tried to overcome this kind of problems with the use of only positive models [<xref ref-type="bibr" rid="CR198">198</xref>, <xref ref-type="bibr" rid="CR199">199</xref>]. However, the results were poorer than those found by approaches that consider both positive and negative training sets [<xref ref-type="bibr" rid="CR199">199</xref>].</p>
        <p>Different classification methods are currently available based on machine learning, e.g. SVM, neural networks, HMM, and Naive Bayes (NB), and several tools based on machine learning have been developed and released to the research community, e.g. RNAmicro [<xref ref-type="bibr" rid="CR200">200</xref>], MiRFinder [<xref ref-type="bibr" rid="CR201">201</xref>], ProMir [<xref ref-type="bibr" rid="CR202">202</xref>], MiRRim [<xref ref-type="bibr" rid="CR203">203</xref>], SSCprofiler [<xref ref-type="bibr" rid="CR204">204</xref>], HHMMiR [<xref ref-type="bibr" rid="CR205">205</xref>] and BayesMiRNAFind [<xref ref-type="bibr" rid="CR206">206</xref>].</p>
        <p>Non-comparative methods use intrinsic structural features of miRNA, and include algorithms like PalGrade [<xref ref-type="bibr" rid="CR207">207</xref>], Triplet-SVM [<xref ref-type="bibr" rid="CR208">208</xref>], miPred [<xref ref-type="bibr" rid="CR209">209</xref>], miR-abela [<xref ref-type="bibr" rid="CR210">210</xref>], and HHMMiR [<xref ref-type="bibr" rid="CR211">211</xref>]. These methods are able of detecting a large number of miRNAs that seem to be unique to primates.</p>
        <p>Bentwich et al. [<xref ref-type="bibr" rid="CR207">207</xref>] developed PalGrade by integrating bioinformatics predictions with microarray analysis and sequence-directed cloning. This approach allowed the detection of 89 human miRNAs, 53 of them being not conserved beyond primates.</p>
        <p>Xue et al. [<xref ref-type="bibr" rid="CR208">208</xref>] proposed an <italic>ab initio</italic> classification of real pre-miRNA from other hairpin sequences with similar stem-loop features. SVM was applied on these features to classify real vs pseudo pre-miRNAs achieving 90 % of accuracy.</p>
        <p>Ng et al. [<xref ref-type="bibr" rid="CR209">209</xref>] employed a Gaussian Radial Basis Function kernel (RBF) as a similarity measure for 29 global and intrinsic hairpin folding attributes. They tested the model on 123 human <italic>pre-miRs</italic> and 246 pseudo hairpins, reporting 84.55 %, 97.97 %, and 93.50 % in sensitivity, specificity and accuracy, respectively.</p>
        <p>Sewer et al. [<xref ref-type="bibr" rid="CR210">210</xref>] developed miR-abela to detect human miRNAs. They focused on particular properties of some genomic regions around already known miRNAs, and were able to predict between 50–100 novel pre-miRNAs, 30 % of them already found as new in other studies.</p>
      </sec>
      <sec id="Sec17">
        <title>Therapeutic approach</title>
        <p>miRNAs may have a crucial role in guiding treatment decisions. miRNAs can be therapeutic agents in cancer for two major characteristics: (1) their expression is deregulated in cancer compared to normal tissues, and (2) cancer phenotype can be changed by targeting miRNA expression [<xref ref-type="bibr" rid="CR196">196</xref>].</p>
        <p>Compared to gene profiles, miRNA-based therapeutics have several advantages, as for example their ability to target multiple genes, frequently in the context of a network. miRNAs regulating the network of genes and cellular pathways play a crucial role in BC pathogenesis and therapy.</p>
        <p>There are two strategies for developing miRNA-based therapies: i) by the introduction of miRNA-mimic oligonucleotides, which mimic miRNA expression, up-regulating miRNA, and ii) by the introduction of miRNA inhibitor oligonucleotides to inhibit the expression of the miRNA of interest. However, some major obstacles for the use of miRNA therapeutics exist, including the tissue-specific delivery [<xref ref-type="bibr" rid="CR211">211</xref>, <xref ref-type="bibr" rid="CR212">212</xref>], and the fact that erroneous targeting of miRNAs may cause toxic phenotypes [<xref ref-type="bibr" rid="CR213">213</xref>].</p>
        <p>For an effective drug-design of miRNA-targeted therapies in BC, it could be useful to understand the interplay between miRNAs and mRNAs leading to BC, thus studying the networks of gene controlled by each miRNA of interest. miRNA and their targets can form complex regulatory networks, and the comprehension of miRNA-target relation will help the development of personalized and tailored therapies [<xref ref-type="bibr" rid="CR213">213</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec18">
      <title>Gene expression deregulation in BC</title>
      <sec id="Sec19">
        <title>Biological insights</title>
        <p>GE profiling in BC has been widely demonstrated to generate different prognostic and diagnostic gene signatures. However, molecular tests have a potential not only for diagnosis but also for tailoring treatment plans, in particular with the aim of reducing resistance, non-response and toxicity [<xref ref-type="bibr" rid="CR214">214</xref>]. Most of the tests either focus on gene expression microarrays or quantitative reverse transcription (qRT)-PCR analyses.</p>
        <p>van't Veer et al. [<xref ref-type="bibr" rid="CR215">215</xref>] obtained one of the prognostic signature for BC currently available on the market: MammaPrint. Microarray analysis of 78 BC patients with no systemic therapy led to the identification of a list of 70 genes able to predict the prognosis of the disease. The test was independently validated in a cohort of 295 early stage invasive BC, and results proved that the signature was an independent prognostic marker in BC [<xref ref-type="bibr" rid="CR216">216</xref>]. A second independent validation study was performed by the TRANSBIG Consortium [<xref ref-type="bibr" rid="CR217">217</xref>] in a cohort of 302 adjuvantly untreated patients, and was followed by additional validation studies [<xref ref-type="bibr" rid="CR218">218</xref>–<xref ref-type="bibr" rid="CR220">220</xref>]. MammaPrint was developed by Agendia, a laboratory in Amsterdam, approved in 2007 by the U.S. Food and Drug Administration (FDA) and then released commercially. This is a microarray-based test assessing the risk that a BC can metastasize to other parts of the body.</p>
        <p>Paik et al. [<xref ref-type="bibr" rid="CR221">221</xref>] developed Oncotype DX, a qRT PCR-based signature which measures the expression level of 21 genes (16 target + 5 reference genes). The test is able to predict chemotherapy benefits and the likelihood of distant BC recurrence. This is the first genomic biomarker assay which is commercially available for BC treatment as support of chemotherapy. Three separate studies containing 447 BC patients allowed to identify the 21-gene profile, which were divided into 16 target and 5 reference genes. The test was then validated using 668 node negative, ER positive, tamoxifen treated patients from NSABP B-14. An Oncotype DX Recurrence Score (ODRS) was defined and measured, as expression of a risk percentage for the development of distant metastases [<xref ref-type="bibr" rid="CR222">222</xref>]. Oncotype DX was subsequently evaluated in the NSA BP-B20 trial, a study that explored the benefit of chemotherapy plus tamoxifen, and proved the accuracy of the biomarker. Currently, the Oncotype DX assay is performed in the licensed Genomic Health laboratory, which is the laboratory where the assay was developed.</p>
        <p>Prediction Analysis of Microarray (PAM50), by using qRT-PCR assay, measures the expression of 55 (50 target and 5 reference genes) to identify the intrinsic subtypes of BC: luminal A, luminal B, HER2-enriched, and basal-like [<xref ref-type="bibr" rid="CR223">223</xref>]. The gene signature was developed by analysing 189 BC samples, and was then validated on 761 BCs for prognosis and on 133 BCs for prediction of response to a taxane and anthracycline regimen [<xref ref-type="bibr" rid="CR223">223</xref>]. NanoString’s Prosigna™ received a CE-mark designation for selling BC PAM50 in 2012, and received FDA clearance in 2013.</p>
        <p>Genomic Grade Index (GGI) [<xref ref-type="bibr" rid="CR4">4</xref>] is a 97 gene which measures the histological tumour grade. This test is based on the assumption that histological grade is a strong prognostic factor in ER positive BC. Sotiriou et al. [<xref ref-type="bibr" rid="CR4">4</xref>] found that GGI gene signature is able to classify BC as histological grades I and III. They used 64 samples of ER-positive BC tumours to select genes that were differentially expressed (DE) between histologic grade I and III tumours, and to generate the gene signature. Data from 597 independent tumours were then used to evaluate GGI and to also demonstrate that GGI can separate histological grade 2 BC into low or high categories with different clinical outcomes. The results of the BIG-1-98 study (55 endocrine-treated patients) [<xref ref-type="bibr" rid="CR224">224</xref>] demonstrated that the GGI is also a potential predictor of relapse for endocrine-treated BC patients. Ipsogen launched the MapQuant Dx (TM) genomic grade test by incorporating GGI. The test is currently used, in particular when tumor grade information can be decisive for prescribing a chemotherapy.</p>
        <p>Immunohistochemical (IHC) assay Mammostrat [<xref ref-type="bibr" rid="CR225">225</xref>] uses 5 immunohistochemical markers (SLC7A5, HTF9C, P53, NDRG1, and CEACAM5) to stratify patients on tamoxifen therapy into different risk groups, in order to inform treatment decisions. In the validation study, an analysis was performed on two independent data sets of 299 and 344 BC samples [<xref ref-type="bibr" rid="CR226">226</xref>]. Clarient launched on the market the Insight® Dx Mammostrat® Breast Cancer Recurrence test in 2010.</p>
        <p>Table <xref rid="Tab5" ref-type="table">5</xref> reports the considered commercially available tests, with their principal characteristics (e.g. number of genes, validation data sets).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Current commercially available genetic test for BC and their principal characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Author</th><th>N. genes</th><th>Samples used to generate BC signature</th><th>Independent validation study</th><th>Laboratory</th></tr></thead><tbody><tr><td rowspan="2">MammaPrint</td><td rowspan="2">van't Veer et al. [<xref ref-type="bibr" rid="CR215">215</xref>]</td><td rowspan="2">70</td><td rowspan="2">− 78 BC patients</td><td>− 295 early stage invasive BC.</td><td rowspan="2">Agendia</td></tr><tr><td>− 302 who had received loco-regional therapy but no systemic adjuvant therapy</td></tr><tr><td rowspan="2">Oncotype DX</td><td rowspan="2">Paik et al. [<xref ref-type="bibr" rid="CR221">221</xref>]</td><td rowspan="2">21</td><td rowspan="2">− 447 BC patients</td><td>− 668 node negative ER positive tamoxifen treated cases</td><td rowspan="2">Genomic Health</td></tr><tr><td>− 651 BC samples: 227 had been randomly assigned to tamoxifen adjuvant therapy and 424 to tamoxifen plus chemotherapy</td></tr><tr><td>PAM50</td><td>Parker et al. [<xref ref-type="bibr" rid="CR223">223</xref>]</td><td>50</td><td>− 189 BC patients</td><td>− 761 patients (no systemic therapy), 133 (neoadjuvant chemotherapy)</td><td>NanoString’s Prosigna™</td></tr><tr><td rowspan="2">Genomic Grade Index (GGI)</td><td rowspan="2">Sotiriou et al. [<xref ref-type="bibr" rid="CR4">4</xref>]</td><td rowspan="2">97</td><td rowspan="2">− 64 BC patients</td><td>− 597 BC</td><td rowspan="2">Ipsogen</td></tr><tr><td>− 55 endocrine-treated patients.</td></tr><tr><td>Mammostrat</td><td>Bartlett et al. [<xref ref-type="bibr" rid="CR225">225</xref>]</td><td>5</td><td>− 466 BC patients</td><td>− 299 BC, 344 BC</td><td>Clarient</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec20">
        <title>Experimental methods</title>
        <p>Understanding GE and how it changes under normal and pathological conditions is necessary to provide information about the expressed genes. Large scale GE data provide the activity of thousands of genes at once.</p>
        <p>Several techniques exist for studying and quantifying GE.</p>
        <p>Traditional methods focus on measuring the expression of one gene at a time, as, for example, the Northern Blotting and the Real-Time Quantitative Reverse Transcription PCR (RT-PCR).</p>
        <p>Northern blotting (called also RNA blot) was the first tool used to measure RNA levels, and, until the end of the 1990s, it was used extensively. It allows to quantify levels of mRNA by electrophoresis, which is able to separate RNA samples by size. The RNA of interest is revealed by a hybridization probe complementary to it. The first step of RNA blot is to denature the RNA into single strands. Hence, gel electrophoresis separates the RNA molecules according to their size. Subsequently, the RNA is transferred from the gel onto a blotting membrane, containing RNA bands originally on the gel. A probe complementary to the RNA of interest binds to a particular RNA sequence in the sample [<xref ref-type="bibr" rid="CR227">227</xref>]. The RNA-probe complexes can thus be detected using a variety of different chemistries or radionuclide labelling.</p>
        <p>RT-PCR is a major development of PCR technology, overcoming Northern blot as the method for RNA detection and quantification [<xref ref-type="bibr" rid="CR228">228</xref>]. It enables to monitor and measure a targeted DNA molecule generated during each cycle of PCR process. In RT-PCR, the mRNA must be converted to a double-stranded molecule by using the enzyme reverse transcriptase. This phase is followed by quantitative PCR (qPCR) on the cDNA with the detection and quantification of amplified products [<xref ref-type="bibr" rid="CR229">229</xref>]. The quantity of each specific target is obtained by measuring the increase in fluorescence signal from DNA-binding dyes or probes, during successive rounds of enzyme-mediated amplification. The limitation of this technique is the quantification of few genes at a time [<xref ref-type="bibr" rid="CR229">229</xref>].</p>
        <p>Several technologies such as microarray, Serial Analysis of Gene (SAGE), Cap Analysis of Gene Expression (CAGE) and Massively Parallel Signature Sequencing (MPSS) allow the mRNA expression data for hundreds of genes to be obtained in one single experiment [<xref ref-type="bibr" rid="CR230">230</xref>].</p>
        <p>The most commonly used technology to profile the expression of thousands of transcripts simultaneously is microarray. DNA microarray is an array of oligonucleotide probes bound to a chip surface [<xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>]. Labelled cDNA from a sample is hybridized to complementary probe sequences on the chip, and strongly associated complexes are identified by detection of fluorophore-, silver-, or chemiluminescence-labelled targets [<xref ref-type="bibr" rid="CR231">231</xref>, <xref ref-type="bibr" rid="CR232">232</xref>].</p>
        <p>Many variables influence the outcome of the experiments in microarray analysis, thus contributing to experimental errors and biological variations (for more details see [<xref ref-type="bibr" rid="CR233">233</xref>]).</p>
        <p>In contrast to microarray methods, sequence-based approaches directly determine the cDNA sequence [<xref ref-type="bibr" rid="CR234">234</xref>]. SAGE [<xref ref-type="bibr" rid="CR235">235</xref>], CAGE [<xref ref-type="bibr" rid="CR236">236</xref>], and MPSS [<xref ref-type="bibr" rid="CR237">237</xref>], all tag-based sequencing approaches, are based on Sanger sequencing technology.</p>
        <p>The development of novel high-throughput DNA sequencing methods, such as RNA-Seq (RNA sequencing), has provided new approaches for both mapping and quantifying transcriptomes. It has clear advantage over existing approaches: RNA-Seq is not limited to the detection of transcripts that correspond to existing genomic sequence, and it is suitable to discovery genomic sequences that are still unknown [<xref ref-type="bibr" rid="CR234">234</xref>].</p>
        <p>In RNA-Seq analysis, RNA is converted to a library of cDNA fragments with adaptors attached to one or both ends. Each molecule is then sequenced in a high-throughput way in order to obtain short sequences (reads 30–400 bp). Following sequencing, the resulting reads are mapped to the genome in order to produce a genome-scale transcription map consisting of both the transcriptional structure and the level of expression for each gene [<xref ref-type="bibr" rid="CR234">234</xref>]. Although RNA-Seq has many advantages with respect to the other methods, other issues must be overcome to achieve best practices in the measurement of gene expression, for instance, the lack of accurate methods able to identify and track the expression changes of rare RNA isoforms from all genes [<xref ref-type="bibr" rid="CR234">234</xref>].</p>
        <p>Table <xref rid="Tab6" ref-type="table">6</xref> reports a synthesis of the considered experimental methods for studying and quantifying GE, with their principal advantages and limitations.<table-wrap id="Tab6"><label>Table 6</label><caption><p>Principal experimental methods for GE quantification</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Method</th><th>Pros</th><th>Cons</th></tr></thead><tbody><tr><td rowspan="3">Northern Blotting</td><td>-Inexpensive</td><td>-low throughput</td></tr><tr><td rowspan="2">-detecting transcript size</td><td>-semiquantitative</td></tr><tr><td>-RNAase contamination</td></tr><tr><td rowspan="2">RT-PCR</td><td>-high sensitivity</td><td>-high variability</td></tr><tr><td>-high sequence specific</td><td>-normalizaton methods</td></tr><tr><td rowspan="3">Microarray</td><td>-measurement of the activity of thousands of genes at once</td><td>-high cost</td></tr><tr><td>-rapid</td><td>-analysis of Big data</td></tr><tr><td>-don't require large-scale DNA sequencing</td><td>-high Background noise</td></tr><tr><td rowspan="3">Sanger sequencing technology</td><td rowspan="3">-low Background noise</td><td>-only a portion of the transcript</td></tr><tr><td>-isoforms are generally indistinguishable from each other</td></tr><tr><td>-Low throughput</td></tr><tr><td rowspan="4">RNA-seq</td><td>-measurement of the activity of thousands of genes at once</td><td>-High cost</td></tr><tr><td>-require low amount of RNA</td><td rowspan="3">-Analysis of Big data</td></tr><tr><td>-high reproducibility</td></tr><tr><td>-Low Background noise</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec21">
        <title>Computational methods</title>
        <p>Microarray or RNA-sequencing technologies, as above reported, produce an overall design of all the transcriptional activity in a biological sample. However, these methods necessarily produce a large amount of data to be visualized, evaluated for their quality, normalized, filtered and interpreted.</p>
        <p>Hence, the data originated by platforms (such as microarrays or RNA-seq) must be pre-processed. Pre-processing step is crucial to normalize the data and to clean biological signal values from experimental noise [<xref ref-type="bibr" rid="CR238">238</xref>, <xref ref-type="bibr" rid="CR239">239</xref>].</p>
        <p>Data must be also reduced prior to be used in advanced analysis, and this can be accomplished in two different ways: 1) by dimensionality reduction methods, that do not modify the original representation of data, and 2) by dimensionality reduction techniques which involve modification or loss of information from the original data. Among this second category, there are those methods based on projection (e.g. principal component analysis) or compression (e.g. using information theory) [<xref ref-type="bibr" rid="CR240">240</xref>].</p>
        <p>One of the most validated method of the first category is feature selection technique. It is often used to identify key genes able to separate the samples into different classes (e.g. cancerous and normal cells), and to remove irrelevant genes. Golub et al. [<xref ref-type="bibr" rid="CR241">241</xref>] showed indeed that most genes are not significant in a problem of samples classification. However, feature selection is also important in order to obtain faster and efficient classification models, and to avoid over fitting.</p>
        <p>Three categories of feature selection methods can be used: filters, wrappers, and embedded methods [<xref ref-type="bibr" rid="CR242">242</xref>, <xref ref-type="bibr" rid="CR243">243</xref>].</p>
        <p>Filter methods find subset of genes dependent on the class label, and do not consider the relevance of genes in combination with other genes [<xref ref-type="bibr" rid="CR243">243</xref>]. Usually they are simple and fast.</p>
        <p>Filter methods include correlation-based feature selection (CFS) [<xref ref-type="bibr" rid="CR244">244</xref>], <italic>t</italic>-test [<xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR245">245</xref>], information gain [<xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR245">245</xref>], mutual information [<xref ref-type="bibr" rid="CR246">246</xref>], entropy-based methods [<xref ref-type="bibr" rid="CR247">247</xref>], Euclidian distance [<xref ref-type="bibr" rid="CR245">245</xref>], signal to noise ratio [<xref ref-type="bibr" rid="CR245">245</xref>], and significant analysis of microarrays [<xref ref-type="bibr" rid="CR248">248</xref>].</p>
        <p>Wrapper methods try to achieve the best combination of genes that may offer high classification accuracy. They include hybrid genetic algorithms [<xref ref-type="bibr" rid="CR249">249</xref>], particle swarm optimization [<xref ref-type="bibr" rid="CR250">250</xref>], successive feature selection (SFS) [<xref ref-type="bibr" rid="CR251">251</xref>] and GA-KDE-Bayes [<xref ref-type="bibr" rid="CR252">252</xref>]. However, this approach is less used, in particular in microarray analysis, due to its high computational costs [<xref ref-type="bibr" rid="CR243">243</xref>].</p>
        <p>Filter approach does not interact with the classifier, contrarily to wrapper and embedded techniques, usually resulting in lower performance.</p>
        <p>An intermediate approach between the lowest results of the filter methods and the high computational cost of the wrapper methods is represented by the embedded method. With this method, the feature selection procedure is inbuilt to a classifier. Classification trees like ID3, random forest, and Support Vector Machine (SVM) based on Recursive Feature Elimination (RFE) are all examples of embedded methods [<xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR245">245</xref>].</p>
        <p>The principle of the feature selection and validation techniques is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. A pre-processing step is performed: i) the quality of data is evaluated, ii) outliers are removed, and iii) data are normalized. Feature selection is performed. Usually, original data are divided into two data sets: a training set, subjected to the feature selection, and a testing set, used to evaluate the feature selection of the model with different validation techniques. Feature selection finds a subset of genes of interest, (e.g. a gene signature), and the validation of genes is performed. The most used validation techniques are cross-validation or leave one out validation [<xref ref-type="bibr" rid="CR243">243</xref>], even if several studies suggested the use of a 10-fold cross validation because they give a more biased but less variable estimate than the leave-one-out error (e.g. [<xref ref-type="bibr" rid="CR253">253</xref>]). When the feature selection of the model satisfies the required validation performance, the genes are defined and can be interpreted.<fig id="Fig3"><label>Fig. 3</label><caption><p>Feature selection model and validation. Feature selection acts on a training data set giving a gene signature. Gene signature is validated on a testing data set</p></caption><graphic xlink:href="12918_2015_211_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec22">
        <title>Therapeutic approach</title>
        <p>Drug compounds that facilitate and control tightly therapeutic GE are a promising target. Transcriptional gene regulatory system has been encoded within several viral vectors (eg. Tetracycline-based systems can regulate GE of particular targets with the use of cell-type-specific promoters) [<xref ref-type="bibr" rid="CR254">254</xref>].</p>
        <p>The regulation of GE systems is an attractive target for gene therapy development, and potential applications have been assessed in a wide variety of preclinical laboratory models of disease. The first study was performed by Hallahan et al. [<xref ref-type="bibr" rid="CR255">255</xref>], which described how TNF-a expression, under the control of the Egr-1 promoter, could be increased in response to ionizing X-ray radiation. This increase of TNF-a expression was associated with an improved control of tumour growth in comparison with X-ray radiation alone [<xref ref-type="bibr" rid="CR255">255</xref>]. Advantages from induction of GE by ionizing radiation include reduction of damage to adjacent healthy tissues [<xref ref-type="bibr" rid="CR254">254</xref>].</p>
        <p>Kan et al. [<xref ref-type="bibr" rid="CR256">256</xref>] have constructed a novel retroviral vector (MetXia-P450) encoding CYP2B6. This vector was used to transfect the human tumour cell lines HT29 and T47D. CYP2B6 metabolizes the prodrug cyclophosphamide (CPA) to produce phosphoramide mustard that cross-links DNA, thus leading to cell death. In order to evaluate safety and clinical response, MetXia-P450 entered Phase I clinical trials for nine BC patients and three melanoma patients with cutaneous tumours, with encouraging results.</p>
        <p>Although viral vectors are very efficient for gene transfer, their uses are still limited by safety concerns [<xref ref-type="bibr" rid="CR257">257</xref>]. As an alternative, non-viral BC gene therapy (e.g. naked DNA) is growing due to its safety profile, easy preparation procedures, and moderate costs. β-galactosidase (LacZ) expressing plasmid DNA has been successfully delivered in three patients by a needle-free jet injection to skin metastases from primary BC, and also to melanoma lesions in 14 patients. No side effects were observed. The transgene was detectable at messenger RNA (mRNA) and at protein levels in all patients.</p>
      </sec>
    </sec>
    <sec id="Sec23">
      <title>Copy number alterations and gene expression in BC</title>
      <sec id="Sec24">
        <title>Biological insights</title>
        <p>Several studies demonstrated that changes in DNA CN are translated into corresponding changes in GE [<xref ref-type="bibr" rid="CR258">258</xref>, <xref ref-type="bibr" rid="CR259">259</xref>]. Although it is possible that changes in specific DNA sequences (i.e. centromeres or telomeres) can have directly negative consequences [<xref ref-type="bibr" rid="CR260">260</xref>], the main responsible for the malignant phenotype has been proven to be the <italic>gene dosage hypothesis</italic>: alterations of gene copies change the expression levels of the involved gene [<xref ref-type="bibr" rid="CR261">261</xref>].</p>
        <p>Figure <xref rid="Fig4" ref-type="fig">4</xref> shows the principle consequences of an altered gene dosage. Specifically, figure 4.1) shows: i) WT condition where a correct number and expression of A and B gives a correct production of C; ii) how the amplification/over expression of gene copies (e.g. B) can cause an increased dosage of a single gene (e.g. C), and iii) how a deletion/under expression of gene copies (e.g. B) can cause a decreased dosage of a single gene (e.g. C) [<xref ref-type="bibr" rid="CR261">261</xref>]. Figure 4.2) shows how altered gene dosage can influence stoichiometry of protein complex DE that produces F. An amplification/over expression of protein D can inhibit the formation of protein complex DE, thus altering the pathway activity and the correct production of F. A deletion/under expression of protein D do not produce protein complex DE [<xref ref-type="bibr" rid="CR262">262</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>Consequences of gene dosage. <bold>1</bold>) WT cell: a correct number of gene copies and expression gives a correct production of C. Amplification/Over expression of B can increase the output. Under expression of B can diminish the production of C. <bold>2</bold>) WT cell: a correct number of gene copies and expression form a correct complex DE producing F. Amplification/Over-expression of D can interfere with stoichiometry of protein complex inhibiting F. Deletions/Under-expression of D not form complex DE and not produce F</p></caption><graphic xlink:href="12918_2015_211_Fig4_HTML" id="MO4"/></fig></p>
        <p>While useful information has been revealed by analysing GE profiles alone or CNA data alone, integrative analysis of CNA and GE data are necessary in order to have more information in gene characterization. Specifically, RNA data give information on genes that are up/down-regulated, but do not consider primary changes driving cancer from secondary modifications, such as proliferation and differentiation state. On the other hand, DNA data give information on amplifications and deletions that are drivers of cancer. Therefore, integrating DNA and RNA data can clarify genetic regulatory relationships in cancer cells [<xref ref-type="bibr" rid="CR262">262</xref>]. It is interesting that transcriptional changes for 10–63 % of genes occur in amplified regions, and, for 14–62 % of genes, in regions of loss [<xref ref-type="bibr" rid="CR263">263</xref>].</p>
        <p>Several studies showed that gains (or losses) in DNA genomics have consequences in the expression levels of genes in the implicated regions, which are increases or decreased, respectively [<xref ref-type="bibr" rid="CR264">264</xref>–<xref ref-type="bibr" rid="CR266">266</xref>]. If we consider individual genes, the situation is more complicated. For instances, 14 % of down-regulated genes can appear within regions of DNA gain, while 9 % of up-regulated genes can occur in regions of DNA loss [<xref ref-type="bibr" rid="CR266">266</xref>]. These findings suggest to take a particular attention in the integration of CNA and GE.</p>
        <p>The Cancer Genome Atlas project [<xref ref-type="bibr" rid="CR267">267</xref>] is generating multidimensional platforms including gene expression and CNA data for the same set of patients [<xref ref-type="bibr" rid="CR263">263</xref>]. Although it is possible to perform analysis with unpaired data [<xref ref-type="bibr" rid="CR263">263</xref>, <xref ref-type="bibr" rid="CR268">268</xref>, <xref ref-type="bibr" rid="CR269">269</xref>], the analysis is much more accurate when both types of data are available from the same patient. In this condition, the paired data analysis allows better statistical power and a reduction of false positives [<xref ref-type="bibr" rid="CR270">270</xref>, <xref ref-type="bibr" rid="CR271">271</xref>].</p>
        <p>Some studies have shown that integrating CNA information with GE data can often provide a powerful tool for identifying functionally relevant genes in cancer [e.g. 275–282]. Chen et al. [<xref ref-type="bibr" rid="CR272">272</xref>] found a list of eighteen genes for which a strong correlation between CNA and GE exists, using signal-to-noise ratio (SNR). They found one particular gene, <italic>RUNX3</italic>, which is involved in the control of the <italic>in vitro</italic> invasive potential of MDA-MB-231.</p>
        <p>Zhang et al. [<xref ref-type="bibr" rid="CR273">273</xref>] identified an 81-gene prognostic CN signature that was found highly correlated with GE levels (Cox regression P &lt; 0.05). This signature identified a subgroup of patients with increased probability of distant metastasis in an independent validation set of 113 patients.</p>
        <p>Andre et al. [<xref ref-type="bibr" rid="CR274">274</xref>] reported the level of mRNA expression, significantly correlated to the CAN, for <italic>VEGF</italic>, <italic>EGFR</italic>, and <italic>PTEN</italic>, using Algorithm Array CGH Expression integration tool (ACE-it). These genes could be targeted in triple-negative BC in clinical trials, and one of them, <italic>E2F3</italic>, can have a major role in a subset of triple-negative BC.</p>
        <p>Hyman et al. [<xref ref-type="bibr" rid="CR275">275</xref>] studied CNAs in 14 BC cell lines, and identified 270 differently expressed genes using signal-to-noise statistics (α value &lt;0.05). 91 of the 270 genes represented hypothetical proteins or genes with no functional annotation, whereas 179 genes had available functional information.</p>
        <p>Orsetti et al. [<xref ref-type="bibr" rid="CR276">276</xref>] presented a study on CNA on chromosome 1, the prevalent target of genetic anomalies in BC, and the CNA consequences at the RNA expression level in BC. They identified 30 genes showing significant over-expression. A discriminating score was applied by comparing the expression levels of the subgroup of samples presenting amplification and the expression levels of the subgroup of samples without amplification.</p>
        <p>Chin et al. [<xref ref-type="bibr" rid="CR277">277</xref>] associated CNA and GE profiles of genes linked to poor treatment response. They identified 66 genes in these regions whose expression levels were correlated with CN, using Pearson's correlation (FDR &lt; 0.01, Wilcoxon rank-sum test). Gene Ontology analyses of these genes showed that they are involved in nucleic acid metabolism, protein modification, signalling, and in the cell cycle and/or protein transport.</p>
        <p>Chin SF et al. [<xref ref-type="bibr" rid="CR278">278</xref>] evaluated genome-wide correlations between GE and CN by following an approach based on the Wilcoxon test. They showed strong statistical associations between either CN gain and over-expression (196 genes) or CN loss and under-expression (63 genes). Many well-known and potentially novel oncogenes and tumour suppressors were included in their analysis.</p>
        <p>Table <xref rid="Tab7" ref-type="table">7</xref> reports a synthesis of the considered genes based on the integration of CNA and GE.<table-wrap id="Tab7"><label>Table 7</label><caption><p>Gene signatures obtained by the Integration of CNA and GE</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Number of genes (gene signatures)</th><th>References</th></tr></thead><tbody><tr><td>1</td><td>Chen et al. [<xref ref-type="bibr" rid="CR272">272</xref>]</td></tr><tr><td>81</td><td>Zhang et al. [<xref ref-type="bibr" rid="CR273">273</xref>]</td></tr><tr><td>4</td><td>Andre et al. [<xref ref-type="bibr" rid="CR274">274</xref>]</td></tr><tr><td>270</td><td>Hyman et al. [<xref ref-type="bibr" rid="CR275">275</xref>]</td></tr><tr><td>30</td><td>Orsetti et al. [<xref ref-type="bibr" rid="CR276">276</xref>]</td></tr><tr><td>66</td><td>Chin et al. [<xref ref-type="bibr" rid="CR277">277</xref>]</td></tr><tr><td>259</td><td>Chin SF et al. [<xref ref-type="bibr" rid="CR278">278</xref>]</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec25">
        <title>Computational methods</title>
        <p>No experimental methods actually exist giving, in one single analysis, results about the integration of CNA and GE.</p>
        <p>Computational integrative methodologies between CNA and GE include a two-step approach, and joint analysis. Figure <xref rid="Fig5" ref-type="fig">5a</xref>) shows a two-step approach, combining the results from individual analysis of GE and CNA. Figure <xref rid="Fig5" ref-type="fig">5b</xref> shows a joint analysis obtaining directly the final result from the integration of GE and CNA.<fig id="Fig5"><label>Fig. 5</label><caption><p>Integration approaches between GE and CNA data <bold>a</bold> two-step approaches, <bold>b</bold> joint analysis</p></caption><graphic xlink:href="12918_2015_211_Fig5_HTML" id="MO5"/></fig></p>
        <p>There are different statistical measures to assess the CNA and GE relationship in order to quantify gene dosage effect. They include, in two-steps approaches, both regression and correlation-based analysis.</p>
        <p>Regression approaches model the dependence of RNA levels from DNA CN, and consider RNA levels as responses and DNA CN as predictors [<xref ref-type="bibr" rid="CR279">279</xref>]. These methods can be divided into: 1) univariate linear regression models, proposed to model the associations between individual CN and GE probes [<xref ref-type="bibr" rid="CR280">280</xref>], 2) multivariate linear regression models, integrating statistical power across multiple probes targeting adjacent genes or chromosomal positions [<xref ref-type="bibr" rid="CR281">281</xref>], and 3) nonlinear regression models.</p>
        <p>Most studies use linear regression models but regulatory mechanisms, contributing to gene expression changes (e.g. CNA, miRNA, DNA methylation), can give non linearity [<xref ref-type="bibr" rid="CR282">282</xref>]. Non linear relationship between CNA and GE have been investigated by Solvang et al. [<xref ref-type="bibr" rid="CR282">282</xref>], which focused on the identification of nonlinear relationships to explain the regulatory mechanisms of alteration of mRNA expressions in the cancer process.</p>
        <p>Correlation-based approaches have been used to study the relationship between CNAs and GE. For each pair of co-measured data, a correlation matrix was estimated reflecting the strength of association [<xref ref-type="bibr" rid="CR283">283</xref>]. Several studies have shown correlations between CNA and GE gene across samples e.g. [<xref ref-type="bibr" rid="CR277">277</xref>]. Other studies, like Tsafrir et al. [<xref ref-type="bibr" rid="CR284">284</xref>], identified a correlation along the genome by using filtered CNA and filtered GE. DR-Correlate [<xref ref-type="bibr" rid="CR285">285</xref>], a modified version of the Ortiz-Estevez algorithm, [<xref ref-type="bibr" rid="CR286">286</xref>] was used in a correlation-based analysis to examine the genome and to detect genes with high associations between CNA and GE. In order to improved correlation results, Schäfer et al<italic>.</italic> [<xref ref-type="bibr" rid="CR287">287</xref>] replaced the sample means with the reference medians in the correlation test, while Lipson et al<italic>.</italic> [<xref ref-type="bibr" rid="CR288">288</xref>] used a quantile-based analysis to obtain improved correlation coefficients.</p>
        <p>Table <xref rid="Tab8" ref-type="table">8</xref> reports a synthesis of the considered two-step analyses and types.<table-wrap id="Tab8"><label>Table 8</label><caption><p>Two step approaches to quantify gene dosage effect</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Analysis</th><th>Type</th><th>References</th></tr></thead><tbody><tr><td rowspan="3">- regression</td><td>• univariate linear</td><td rowspan="3">[<xref ref-type="bibr" rid="CR279">279</xref>–<xref ref-type="bibr" rid="CR282">282</xref>]</td></tr><tr><td>• multivariate linear</td></tr><tr><td>• nonlinear</td></tr><tr><td rowspan="4">- correlation</td><td>• signal-to-noise ratio</td><td rowspan="4">[<xref ref-type="bibr" rid="CR283">283</xref>–<xref ref-type="bibr" rid="CR288">288</xref>]</td></tr><tr><td>• Pearson's correlation</td></tr><tr><td>• Algorithm Array CGH Expression integration tool (ACE-it)</td></tr><tr><td>• discriminating score</td></tr></tbody></table></table-wrap></p>
        <p>Joint analysis uses CNA and GE data as paired data entries and not as separate structures. The discrepancy between the sample size and the number of genes is a problem that can cause high noise. Techniques such as Singular value decomposition (SVD) or Principal Component Analysis (PCA) are the most popular ones for reducing the dimension of gene data [<xref ref-type="bibr" rid="CR289">289</xref>, <xref ref-type="bibr" rid="CR290">290</xref>]. However, GE and CNA data are separately analysed using these methods.</p>
        <p>The generalized singular value decomposition (GSVD) is a popular regression framework used in joint analysis. With the purpose to identify variation patterns between two biological inputs, Berger et al. [<xref ref-type="bibr" rid="CR291">291</xref>] applied an iterative procedure based on the GSVD, projecting CNA/GSE data into different decomposition directions. GSVD was used in two BC cell lines and tumour datasets, thus obtaining gene subsets that were biologically validated.</p>
        <p>Soneson et al. [<xref ref-type="bibr" rid="CR292">292</xref>] applied PCA to reduce dimensions, and Canonical Correlation Analysis (CCA) to identify highly correlated CNA/GE pairs. Gonzalez et al. [<xref ref-type="bibr" rid="CR293">293</xref>] implemented the regularized CCA to identify the correlation between paired datasets. iCluster is a method able to generate a single integrated cluster assignment based on a simultaneous inference analysis from multiple data types [<xref ref-type="bibr" rid="CR294">294</xref>]. In BC, iCluster has been used to align concordant DNA CNA and gene GE changes, showing encouraging results [<xref ref-type="bibr" rid="CR294">294</xref>].</p>
        <p>Table <xref rid="Tab9" ref-type="table">9</xref> reports some software for the CNA and GE analysis and their method of integration type.<table-wrap id="Tab9"><label>Table 9</label><caption><p>Software for CNA and GE analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Software</th><th>Integration type</th><th>References</th></tr></thead><tbody><tr><td>Ace-it</td><td>two-step approaches</td><td>[<xref ref-type="bibr" rid="CR295">295</xref>]</td></tr><tr><td>Magellan</td><td>two-step approaches</td><td>[<xref ref-type="bibr" rid="CR296">296</xref>]</td></tr><tr><td>SODEGIR</td><td>two-step approaches</td><td>[<xref ref-type="bibr" rid="CR297">297</xref>]</td></tr><tr><td>Edira</td><td>two-step approaches</td><td>[<xref ref-type="bibr" rid="CR287">287</xref>]</td></tr><tr><td>CNAmet</td><td>two-step approaches</td><td>[<xref ref-type="bibr" rid="CR298">298</xref>]</td></tr><tr><td>iCLUSTER</td><td>joint analysis</td><td>[<xref ref-type="bibr" rid="CR294">294</xref>]</td></tr><tr><td>CONNEXIC</td><td>joint analysis</td><td>[<xref ref-type="bibr" rid="CR299">299</xref>]</td></tr><tr><td>Remap</td><td>joint analysis</td><td>[<xref ref-type="bibr" rid="CR281">281</xref>]</td></tr><tr><td>DR-Integrator</td><td>joint analysis</td><td>[<xref ref-type="bibr" rid="CR285">285</xref>]</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec26">
      <title>Integrating genetics and epigenetics in BC</title>
      <p>The development of BC is mediated by the cooperation, directly or indirectly, between genetic and epigenetic alterations of the cell [<xref ref-type="bibr" rid="CR300">300</xref>, <xref ref-type="bibr" rid="CR301">301</xref>].</p>
      <p>Sarkar et al. suggested that the epigenetic changes act as the initiating signal in the development of cancer progenitor cells and a combination of all genetic changes which are differentially expressed in the various cancer subtypes, could act on the cell vulnerable to epigenetic alterations [<xref ref-type="bibr" rid="CR301">301</xref>].</p>
      <p>Epigenetic mechanisms are tightly linked to one another and make the overall gene regulation system. The miR-29 family, for example, including miR-29a, miR-29b, and miR-29c, is a miRNA that collaborates with other epigenetic mechanisms. The expression of miR-29b is regulated by both histone modification [<xref ref-type="bibr" rid="CR302">302</xref>] and DNA methylation [<xref ref-type="bibr" rid="CR303">303</xref>]. miR-7/miR-218 can regulate DNA methylation and histone modification status by decreasing homeobox B3 (<italic>HOXB3</italic>) expression [<xref ref-type="bibr" rid="CR304">304</xref>].</p>
      <p>However, while classical epigenetic mechanisms, such as histone modification and DNA methylation, regulate expression at the transcriptional level, miRNAs act at the posttranscriptional level.</p>
      <p>Elucidating the basic mechanisms of post-transcriptional regulation of GE is essential to gain a full understanding of how GE is regulated at different levels, of the interplay between these mechanisms, and of the extensive contribution of post-transcriptional dysfunction in cancer.</p>
      <p>An impressive number of papers have been published on miRNAs increasing the number of scientific challenges, and we focused on the studies and methods applied to the combination miRNAs-mRNA, CNAs-miRNAs, and GE-genetic alterations-miRNAs.</p>
    </sec>
    <sec id="Sec27">
      <title>Integrated analysis of mRNA and miRNA in BC</title>
      <sec id="Sec28">
        <title>Biological insights</title>
        <p>The miRNA profile is more accurately associated with cell differentiation and cancer progression when compared with GE expression profile.</p>
        <p>The aberrant expression of miRNAs in cancer can lead to the altered expression of target mRNAs. miRNAs can also modulate multiple genes regulating entire networks. The interaction of a miRNA with its target mRNAs can lead to the repression or incentive of GE.</p>
        <p>In general, integration study of miRNA and mRNA may allow the identification of both biomarkers and networks involved in the development of cancer [<xref ref-type="bibr" rid="CR305">305</xref>, <xref ref-type="bibr" rid="CR306">306</xref>].</p>
        <sec id="FPar1">
          <title>Biomarkers</title>
          <p>Combination of miRNA and mRNA has still to be deeply explored in diagnostic and prognostic studies. Cascione et al. [<xref ref-type="bibr" rid="CR307">307</xref>] proposed a large-scale analysis of miRNA and cancer-focused mRNA expression in normal, triple negative tumour, and associated metastatic tissues in BC. Two miRNA signatures were identified, predictive of overall survival (<italic>P</italic> = 0.05) and distant-disease free survival (<italic>P</italic> = 0.009), respectively. Volinia et al. [<xref ref-type="bibr" rid="CR308">308</xref>] found 30 mRNAs and 7 miRNAs associated with overall survival, across different clinical and molecular subclasses of BCs. In addition, expression profiles from 8 BC datasets, different from those used for the miRNA extraction, were used for validation. Buffa et al. [<xref ref-type="bibr" rid="CR309">309</xref>] matched mRNA and miRNA global expression profiling, and four miRNAs were found independently associated with DRFS in ER-positive BC (3 novel and 1 known miRNA- miR-128a) and six miRNAs in ER-negative BC (5 novel and 1 known miRNA; miR-210). Van der Auwera et al. [<xref ref-type="bibr" rid="CR310">310</xref>] identified a set of 13 miRNAs whose expression differed between inflammatory BC (IBC) and non-IBC. Enerly et al. [<xref ref-type="bibr" rid="CR311">311</xref>] demonstrated, from the joint analysis of miRNA and mRNA data, a central role for miRNAs in regulating particular pathways. Hannafon et al. [<xref ref-type="bibr" rid="CR312">312</xref>] identified putative miRNAs by mRNA functional interactions in ductal carcinoma <italic>in situ</italic>: the three <italic>miRNAs miR-125b, miR-182</italic> and <italic>miR-183</italic>, and six of their putative target genes, <italic>MEMO1, NRIP1, CBX7, DOK4, NMT2</italic>, and <italic>EGR1</italic>.</p>
          <p>Luo et al. [<xref ref-type="bibr" rid="CR313">313</xref>] performed an integrated analysis of miRNAs and mRNA expression profiles in 12 BC cell lines, identifying 35 functional target genes of three significantly down-regulated miRNAs in invasive cell lines (miR-200c, miR-205, and miR-375).</p>
          <p>Several studies demonstrated the greater accuracy of miRNA expression levels compared with those of gene signatures. miRNA expression levels should directly represent the functional activity of the genes, while genes have to be translated to proteins to show their biological effects [<xref ref-type="bibr" rid="CR314">314</xref>].</p>
          <p>For a more detail review on the role of miRNAs and mRNA, see [<xref ref-type="bibr" rid="CR315">315</xref>].</p>
          <p>Table <xref rid="Tab10" ref-type="table">10</xref> reports a synthesis of the considered miRNAs biomarkers in BC as obtained by the integration of miRNA and mRNA.<table-wrap id="Tab10"><label>Table 10</label><caption><p>miRNA deregulated by integration miRNA and mRNA</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Biomarker</th><th>Biological effect</th><th>References</th></tr></thead><tbody><tr><td><italic>miR-16, 155, 125b, 374a</italic></td><td>predictive of overall survival (<italic>P</italic> = 0.05)</td><td>[<xref ref-type="bibr" rid="CR307">307</xref>]</td></tr><tr><td><italic>miR-16, 125b, 374a, 374b, 421, 655, 497</italic></td><td>predictive of distant-disease free survival (<italic>P</italic> = 0.009)</td><td>[<xref ref-type="bibr" rid="CR307">307</xref>]</td></tr><tr><td><italic>miR-1307, 103, 328, 83, 874, 484, 148b</italic></td><td>associated with overall survival across different clinical and molecular subclasses</td><td>[<xref ref-type="bibr" rid="CR308">308</xref>]</td></tr><tr><td><italic>miR-767-3p, 128a, 769–3, 135a, and miR-27b, 144, 210, 42, 150, 30c</italic></td><td>associated with DRFS in estrogen receptor</td><td>[<xref ref-type="bibr" rid="CR309">309</xref>]</td></tr><tr><td><italic>miR-335, 337-5p, 451, 486-3p, 520a-5p, 548d-5p, 15a, 24, 29a, 30b, 320, 342-5p, 342-3p</italic></td><td>associated with inflammatory breast cancer</td><td>[<xref ref-type="bibr" rid="CR310">310</xref>]</td></tr><tr><td><italic>miR-150, 155, 142</italic></td><td>have strong positive correlation to the immune response module</td><td>[<xref ref-type="bibr" rid="CR311">311</xref>]</td></tr><tr><td><italic>miR-130b, 19a, 449a, 299, 154, 145</italic></td><td>association with proliferation</td><td>[<xref ref-type="bibr" rid="CR311">311</xref>]</td></tr><tr><td><italic>miR-29c</italic></td><td>associated with cell adhesion/extra cellular matrix</td><td>[<xref ref-type="bibr" rid="CR311">311</xref>]</td></tr><tr><td><italic>miR-125b, miR-182 and miR-183</italic></td><td>highly overexpressed in ductal carcinoma <italic>in situ</italic>
</td><td>[<xref ref-type="bibr" rid="CR312">312</xref>]</td></tr><tr><td><italic>miR-200c, miR-205, and miR-375</italic></td><td>down-regulated miRNAs in invasive cell lines</td><td>[<xref ref-type="bibr" rid="CR313">313</xref>]</td></tr></tbody></table></table-wrap></p>
        </sec>
        <sec id="FPar2">
          <title>Networks</title>
          <p>Each miRNA can potentially regulate the expression of hundreds of genes, and a single gene can be targeted by multiple miRNAs [<xref ref-type="bibr" rid="CR316">316</xref>].</p>
          <p>Specific miRNAs has been identified as regulator of metastatic progression through miRNA regulatory networks. Yan et al. [<xref ref-type="bibr" rid="CR317">317</xref>] found <italic>miR-21</italic> as the most significantly up-regulated miRNA in BC when compared with normal adjacent tumour tissues (NAT). Its target prediction revealed the putative target genes by creating a small miRNA regulatory networks.</p>
          <p>Figure <xref rid="Fig6" ref-type="fig">6</xref> shows mTOR and STAT3 signalling acting on <italic>miR-21</italic> up-regulation in cancer [<xref ref-type="bibr" rid="CR318">318</xref>] and <italic>miR-21</italic> promoting cancer cell invasion and metastasis through suppression of <italic>BCL-2</italic>, PTEN, PDCD4,TPM1, maspin [<xref ref-type="bibr" rid="CR319">319</xref>]. The introduction of anti-<italic>miR-21</italic> to MCF-7 BC cells and in mouse model resulted in decreased cell growth (via increased apoptosis) and in reduced cell proliferation [<xref ref-type="bibr" rid="CR319">319</xref>].<fig id="Fig6"><label>Fig. 6</label><caption><p>Example of miRNA regulatory networks</p></caption><graphic xlink:href="12918_2015_211_Fig6_HTML" id="MO6"/></fig></p>
          <p><italic>miR-10b</italic> was found highly expressed in BC metastatic cancer cells. <italic>In vivo</italic> studies demonstrated that <italic>miR-10b</italic> promotes cell migration and invasion [<xref ref-type="bibr" rid="CR320">320</xref>, <xref ref-type="bibr" rid="CR321">321</xref>] and initiates tumour metastasis [<xref ref-type="bibr" rid="CR320">320</xref>, <xref ref-type="bibr" rid="CR321">321</xref>]. <italic>miR-10b</italic> is induced by the transcription factor Twist. In turn, miR-10b inhibits HOXD10 and, through a cascade of cellular alterations, inhibits the expression of the prometastatic gene RHOC [<xref ref-type="bibr" rid="CR320">320</xref>, <xref ref-type="bibr" rid="CR321">321</xref>].</p>
          <p><italic>let-7</italic> has been found poorly expressed or deleted in many cancers. Known oncogenic targets of <italic>let-7</italic> are <italic>H-RAS, HMGA2</italic>, and <italic>BACH1</italic>. These genes result down-regulated by <italic>let-7</italic> over-expression [<xref ref-type="bibr" rid="CR322">322</xref>]. <italic>HMGA2</italic>, and <italic>BACH1</italic> promote the transcription of pro-invasive genes, suppress cell invasion and metastasis to the bone [<xref ref-type="bibr" rid="CR323">323</xref>]. <italic>let-7</italic> is regulated by LIN-28, MEK signalling, and RKIP [<xref ref-type="bibr" rid="CR323">323</xref>].</p>
          <p><italic>miR-200</italic> family is important in maintaining the tumour epithelial phenotype and in inhibiting the epithelial-to-mesenchymal transition (EMT). <italic>miR-200</italic> family was found to inhibit cell migration by acting on the transcription factors ZEB1 and ZEB2, which suppress E-cadherin [<xref ref-type="bibr" rid="CR324">324</xref>]. Furthermore, <italic>miR-200</italic> was found silencing Sec-23a and promoting metastases by inhibiting <italic>TINAGL1</italic> and <italic>IGFBP4</italic> [<xref ref-type="bibr" rid="CR325">325</xref>].</p>
          <p>Table <xref rid="Tab11" ref-type="table">11</xref> reports a synthesis of the considered mRNA-miRNA networks.<table-wrap id="Tab11"><label>Table 11</label><caption><p>Example of network between miRNA and their targets in BC</p></caption><table frame="hsides" rules="groups"><thead><tr><th>miRNA</th><th>Targets</th><th>Phenotype</th><th>Ref.</th></tr></thead><tbody><tr><td><italic>miR-21</italic></td><td>BCL-2,PTEN, PDCD4,TPM1, maspin</td><td>Migration, invasion</td><td>[<xref ref-type="bibr" rid="CR318">318</xref>, <xref ref-type="bibr" rid="CR319">319</xref>]</td></tr><tr><td><italic>miR-335</italic></td><td>SOX4, Tenascin-C</td><td>Migration, invasion</td><td>[<xref ref-type="bibr" rid="CR326">326</xref>–<xref ref-type="bibr" rid="CR328">328</xref>]</td></tr><tr><td><italic>miR-10b</italic></td><td>HOXD10, RhoC</td><td>Migration, invasion</td><td>[<xref ref-type="bibr" rid="CR320">320</xref>, <xref ref-type="bibr" rid="CR321">321</xref>]</td></tr><tr><td><italic>let-7</italic></td><td>H-RAS, HMGA2, LIN28, PEBP1</td><td>Proliferation, differentiation</td><td>[<xref ref-type="bibr" rid="CR322">322</xref>, <xref ref-type="bibr" rid="CR323">323</xref>]</td></tr><tr><td><italic>miR-200</italic></td><td>BMI2, ZEB1, ZEB2, Sec-23a</td><td>Migration</td><td>[<xref ref-type="bibr" rid="CR324">324</xref>]</td></tr></tbody></table></table-wrap></p>
        </sec>
      </sec>
      <sec id="Sec29">
        <title>Experimental methods</title>
        <p>The most used experimental technique for determining miRNA targets is the transfection of mimic miRNAs or of miRNA inhibitors [<xref ref-type="bibr" rid="CR329">329</xref>]. The consequences of the modulation of miRNAs on the expression levels are measured by using different tools, including RT-PCR or microarrays. The most important disadvantage of these techniques is that they are not able to discriminate between indirect and direct interactions [<xref ref-type="bibr" rid="CR329">329</xref>]. Labelled miRNA pull-down (LAMP) assay system or luciferase report assays add reporters or labels to miRNAs on the 3'-UTR of transcripts of interest, allowing the identification and the analysis of direct interaction regions among miRNA and its target gene [<xref ref-type="bibr" rid="CR7">7</xref>]. The disadvantage of reporter assays is that they are laborious, sensitive upon the region chosen for cloning, and that they require hard and complex work for trasfection [<xref ref-type="bibr" rid="CR330">330</xref>].</p>
      </sec>
      <sec id="Sec30">
        <title>Computational methods</title>
        <p>There are different approaches to examine both miRNA and mRNA expression profiles. In this paragraph we examine miRNA and mRNA regulatory pairs together [<xref ref-type="bibr" rid="CR183">183</xref>, <xref ref-type="bibr" rid="CR185">185</xref>, <xref ref-type="bibr" rid="CR187">187</xref>, <xref ref-type="bibr" rid="CR188">188</xref>]. Several studies showed that the miRNA-mRNA interactions varies with the development of disease [<xref ref-type="bibr" rid="CR331">331</xref>, <xref ref-type="bibr" rid="CR332">332</xref>].</p>
        <p>Recently, <italic>in silico</italic> studies used expression profiles to decrease the number of false positives and to enhance the number of biologically relevant targets [<xref ref-type="bibr" rid="CR333">333</xref>, <xref ref-type="bibr" rid="CR334">334</xref>].</p>
        <p>The integrative methods employ a three-step procedure: 1) Identification of DE miRNAs and mRNAs in the biological condition of interest. It can be done as reported in section 2 c); 2) Selection of putative miRNA-mRNA pairs (for instance, a prediction algorithm can be used to obtain the DE miRNA from DE mRNA. It can be done as reported in section 3 c); and 3) Identification of statistically significant miRNA-mRNA pairs. This last step needs the selection of an appropriate association measure, and the determination of its significance. The common assumption is based on the idea that regulatory relationship between any miRNA and its target mRNAs is an inverse correlation [<xref ref-type="bibr" rid="CR335">335</xref>].</p>
        <p>The mathematic tools consider simple correlation analyses (Pearson, Spearman) [<xref ref-type="bibr" rid="CR336">336</xref>, <xref ref-type="bibr" rid="CR337">337</xref>], mutual information [<xref ref-type="bibr" rid="CR337">337</xref>], linear regression [<xref ref-type="bibr" rid="CR338">338</xref>–<xref ref-type="bibr" rid="CR340">340</xref>], regularized least squares [<xref ref-type="bibr" rid="CR341">341</xref>, <xref ref-type="bibr" rid="CR342">342</xref>] and bayesian inference [<xref ref-type="bibr" rid="CR343">343</xref>, <xref ref-type="bibr" rid="CR344">344</xref>]. These methods give a score for each interaction mRNA-miRNA.</p>
        <p>van Iterson et al. [<xref ref-type="bibr" rid="CR305">305</xref>] used the global test [<xref ref-type="bibr" rid="CR345">345</xref>] to associate each miRNA with the expression levels of a set of predicted mRNA targets. They suggest global tests to be better suited for integrated analysis of miRNA and mRNA expression data, compared with either Pearson correlation or lasso-based approaches.</p>
        <p>Pearson Correlation is a measure of linear-dependency, widely used to show miRNA-mRNA showing a statistically significant correlation [<xref ref-type="bibr" rid="CR346">346</xref>]. There are several web-tools that employ Pearson correlation for miRNA-mRNA target research (e.g. [<xref ref-type="bibr" rid="CR349">349</xref>–<xref ref-type="bibr" rid="CR353">353</xref>]).</p>
        <p>Non-parametric (Spearman) correlation coefficient can be used as alternative measure of correlation. Usually it is chosen in case of outliers or with small number of measures. Contrary to Spearman correlations, Pearson coefficients require that both variables derive from a bi-variate normal distribution [<xref ref-type="bibr" rid="CR348">348</xref>].</p>
        <p>Mutual information is analogous to the Pearson Correlation but it is sensitive not just to linear dependencies, and can define whether two given variables are independent [<xref ref-type="bibr" rid="CR348">348</xref>].</p>
        <p>Multiple linear regression can evaluate the interactions between a set of miRNAs and a target mRNA, contrary to correlation measures which focuses on particular pairs interaction.</p>
        <p>R-squared statistics is used for measuring the goodness of the fit of the data . When the number of samples with GE profiles is smaller than the number of covariates (e.g. miRNA), partial least squares can be applied [<xref ref-type="bibr" rid="CR351">351</xref>]. This model gives those miRNAs explaining the maximum variance in GE profiles by ensuring a good fit of the model.</p>
        <p>Lasso-based approaches are used to deal with undetermined linear system [<xref ref-type="bibr" rid="CR342">342</xref>].</p>
        <p>Bayesian inference use a priori information to estimate parameters and predict values in a probability framework. Several studies use this method for scoring putative miRNA-mRNA targets based on miRNA and mRNA expression data [<xref ref-type="bibr" rid="CR352">352</xref>–<xref ref-type="bibr" rid="CR354">354</xref>].</p>
        <p>Table <xref rid="Tab12" ref-type="table">12</xref> reports a synthesis of methods considered for the integration analysis mRNA-miRNA.<table-wrap id="Tab12"><label>Table 12</label><caption><p>Methods for mRNA-miRNAs analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Method</th><th>Ref.</th></tr></thead><tbody><tr><td>global test</td><td>[<xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR282">282</xref>]</td></tr><tr><td>Pearson correlation</td><td>[<xref ref-type="bibr" rid="CR346">346</xref>–<xref ref-type="bibr" rid="CR350">350</xref>]</td></tr><tr><td>Spearman correlation</td><td>[<xref ref-type="bibr" rid="CR348">348</xref>]</td></tr><tr><td>lasso-based approaches</td><td>[<xref ref-type="bibr" rid="CR342">342</xref>]</td></tr><tr><td>Mutual information</td><td>[<xref ref-type="bibr" rid="CR348">348</xref>]</td></tr><tr><td>Multiple linear regression</td><td>[<xref ref-type="bibr" rid="CR338">338</xref>–<xref ref-type="bibr" rid="CR340">340</xref>]</td></tr><tr><td>Partial least squares</td><td>[<xref ref-type="bibr" rid="CR351">351</xref>]</td></tr><tr><td>Bayesian inference</td><td>[<xref ref-type="bibr" rid="CR352">352</xref>–<xref ref-type="bibr" rid="CR354">354</xref>]</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec31">
        <title>Therapeutic approach</title>
        <p>In the context of a network, miRNAs are able to regulate distinct biological cell processes like apoptosis, proliferation or receptor driven pathways, thus suggesting their possible use also as therapeutic targets or tools [<xref ref-type="bibr" rid="CR147">147</xref>]. The most important advantage, with respect to other approaches targeting single genes, is their ability to target multiple molecules.</p>
        <p>There are two main approaches to target miRNA expression in cancer. Direct approaches involve the use of oligonucleotides or virus‐based vectors to either block the expression of an oncogenic miRNA or to reintroduce a TS miRNA lost in cancer. Indirect approaches involve the use of drugs to modulate miRNA expression by targeting their transcription and their processing.</p>
        <p>We think that the miRNAs described in the following sections could be interesting for the development of possible therapies in BC.<list list-type="bullet"><list-item><p>Ma et al. [<xref ref-type="bibr" rid="CR321">321</xref>] found <italic>miR-10b</italic> up-regulated in BC and explored a possible therapeutic application in an animal model of BC-bearing mice. The silencing of <italic>miR-10b</italic> with antagomiRs reduces miR-10b levels and increases <italic>miR-10b</italic> target, <italic>HOXD10</italic>. The therapy decreases metastases and was well tolerated by mice.</p></list-item><list-item><p>Multiple studies have also shown a significant association between <italic>miR-206</italic> and <italic>ER</italic> in BC (e.g. [<xref ref-type="bibr" rid="CR157">157</xref>]). In mouse models, the overexpression of <italic>miR-206</italic> was found significantly decreasing metastatic activity for 2 BC cell lines: BOM1 (highly metastatic to bone) and LM2 (highly metastatic to lung) [<xref ref-type="bibr" rid="CR355">355</xref>].</p></list-item><list-item><p><italic>miR-125</italic> was found to be significantly down regulated in BC patients [<xref ref-type="bibr" rid="CR356">356</xref>]. Experimentally, over-expression of miR-125 reduces ERBB2 and ERBB3 cell motility, and also reduces invasiveness of other numerous cancers [<xref ref-type="bibr" rid="CR357">357</xref>, <xref ref-type="bibr" rid="CR358">358</xref>]</p></list-item><list-item><p><italic>miR-34</italic> is down regulated in BC cell lines and tissues, compared with normal cell lines and adjacent non-tumor tissues [<xref ref-type="bibr" rid="CR359">359</xref>]. Expression of <italic>miR-34</italic> was found correlated with p53 status. In fact, silencing of p53 in human tumour cell lines decreases in <italic>miR-34</italic> level [<xref ref-type="bibr" rid="CR360">360</xref>]. Moreover, as reported by Weidhaas et al. [<xref ref-type="bibr" rid="CR361">361</xref>] <italic>miR-34</italic> levels change levels significantly after irradiation. A potential use for <italic>miR-34</italic> as radiosensitizing agent could be envisaged.</p></list-item><list-item><p><italic>miR-155</italic> is also linked to key cancer pathways as the gene is up-regulated by mutant p53 in BC, thus facilitating tumour cell invasion [<xref ref-type="bibr" rid="CR362">362</xref>]. <italic>miR-155</italic> has also attracted considerable interest as a putative therapeutic target [<xref ref-type="bibr" rid="CR363">363</xref>].</p></list-item></list></p>
        <p>Table <xref rid="Tab13" ref-type="table">13</xref> reports a synthesis of the considered miRNAs, their potential target and function.<table-wrap id="Tab13"><label>Table 13</label><caption><p>Potential therapeutic miRNAs</p></caption><table frame="hsides" rules="groups"><thead><tr><th>miRNA</th><th>Potential Target</th><th>Function</th><th>References</th></tr></thead><tbody><tr><td><italic>miR-10b</italic></td><td>RHOC</td><td>Invasion and metastasis</td><td>[<xref ref-type="bibr" rid="CR321">321</xref>]</td></tr><tr><td><italic>miR-206</italic></td><td>ER</td><td>Metastasis</td><td>[<xref ref-type="bibr" rid="CR155">155</xref>]</td></tr><tr><td><italic>miR-125</italic></td><td>ERBB2, ERBB3</td><td>Coordinate suppression</td><td>[<xref ref-type="bibr" rid="CR356">356</xref>–<xref ref-type="bibr" rid="CR358">358</xref>]</td></tr><tr><td><italic>miR-34</italic></td><td><italic>p53, CCND1</italic>, <italic>CDK4</italic> and <italic>CDK6,</italic>
</td><td>cell cycle</td><td>[<xref ref-type="bibr" rid="CR359">359</xref>–<xref ref-type="bibr" rid="CR361">361</xref>]</td></tr><tr><td><italic>miR-155</italic></td><td><italic>p53</italic></td><td>cell cycle</td><td>[<xref ref-type="bibr" rid="CR362">362</xref>, <xref ref-type="bibr" rid="CR363">363</xref>]</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec32">
      <title>Integrated analysis of CNA and miRNA in BC</title>
      <sec id="Sec33">
        <title>Biological insights</title>
        <p>Many miRNAs are frequently located at fragile sites of the genome, which are usually either amplified or deleted in human cancer [<xref ref-type="bibr" rid="CR364">364</xref>]. The aberrant miRNA expression in BC, in part, is due to these genomic alternations.</p>
        <p>Zhang and colleagues studied 283 known human miRNAs in BC and showed that 72.8 % of miRNAs are located in regions that reveal CNAs [<xref ref-type="bibr" rid="CR365">365</xref>]. In a recent study, miRNAs were shown to be up-regulated in gain regions compared to copy-neutral regions in BC, although the effect on miRNA expression was not incisive [<xref ref-type="bibr" rid="CR366">366</xref>]. Iorio et al. [<xref ref-type="bibr" rid="CR129">129</xref>] compared BC CGH data with independent miRNA expression by miRNA microarrays, and demonstrated that 81.8 % of miRNAs increased expression level and showed high DNA CN, and that 60 % of miRNAs exhibit decreased expression level with loss of DNA CN.</p>
        <p>Several miRNAs have been associated with cancers due to CNA, suggesting that miRNAs can act either as oncomiRs or oncosuppressor miRNA [<xref ref-type="bibr" rid="CR213">213</xref>]. Figure <xref rid="Fig7" ref-type="fig">7</xref> shows amplification of chromosomal regions of miRNAs encoding oncomiRs and leading to their up-regulation. OncomiRs can act silencing TSG thus making possible the development of cancer.<fig id="Fig7"><label>Fig. 7</label><caption><p>Amplifications of chromosomal regions of oncomiR lead to their up-regulation. These oncomiRs would then silence the TSG leading to the development of cancer</p></caption><graphic xlink:href="12918_2015_211_Fig7_HTML" id="MO7"/></fig></p>
        <sec id="FPar3">
          <title>Biomarkers</title>
          <p>The first miRNA found to act as a mammalian oncogene is polycistron <italic>miR-17-92</italic>, also known as OncomiR-1 because it was the first identified oncomiR [<xref ref-type="bibr" rid="CR367">367</xref>]. It is located in chromosome 13 and has been found amplified in human BC [<xref ref-type="bibr" rid="CR368">368</xref>]. It acts as an anti-apoptotic miR cluster by targeting intrinsic apoptotic protein Bim in B-cell lymphoma subtypes [<xref ref-type="bibr" rid="CR369">369</xref>].</p>
          <p>Other oncomiRs have been described since the first discovery. <italic>miR-21</italic> is located in 3'UTR of VMP1 (vacuole membrane protein 1) gene at chromosome 17q23.2, a region amplified in BC and also in neuroblastomas, colon and lung cancers [<xref ref-type="bibr" rid="CR370">370</xref>]. <italic>miR-151a-5p</italic> is located on 8q24.3, a genomic site frequently associated with gain in BC [<xref ref-type="bibr" rid="CR371">371</xref>]. High expression of <italic>miR-151a-5p</italic> has been associated with gain, and functional experiments showed that over-expression induce cell proliferation and also increase the levels of p-AKT [<xref ref-type="bibr" rid="CR372">372</xref>].</p>
          <p>As for oncomiRs, also several miRNAs with oncosuppressor functions have been described. Figure <xref rid="Fig8" ref-type="fig">8</xref> shows deletion of chromosome region of oncosuppressor miRNAs leading to their down-regulation. Down-regulation of oncosuppressor miRNAs results in up-expression of target oncogenes.<fig id="Fig8"><label>Fig. 8</label><caption><p>Deletions of chromosomal regions of oncosuppressor miRNAs lead to their down-regulation. Down-regulation of oncosuppressor miRNAs results in up-regulation of oncogenes and thus proliferation of cancer cells</p></caption><graphic xlink:href="12918_2015_211_Fig8_HTML" id="MO8"/></fig></p>
          <p>Chromosome 11 is frequently altered in BC and <italic>mirR-125b,</italic> that is located at 11q23-24, results one of the most frequently deleted regions [<xref ref-type="bibr" rid="CR373">373</xref>]. In a study of Muller et al. [<xref ref-type="bibr" rid="CR374">374</xref>], <italic>mir-320</italic> has been found to be located in regions with DNA CN loss in BC. The predicted target of <italic>miR-320</italic> is <italic>MECP2</italic> which is up-regulated in BC and serves as an oncogene promoting cell proliferation. Genetic deletion could contribute to <italic>miR-100</italic> down-regulation [<xref ref-type="bibr" rid="CR375">375</xref>] inducing epithelial-mesenchymal transition.</p>
          <p>In several cancer types, including BC, genomic deletion or loss of heterozygosis of the region of the <italic>miR-34a</italic> have been described [<xref ref-type="bibr" rid="CR376">376</xref>]. <italic>miR-34a</italic> is highly expressed in normal tissues. Its expression level is under the control of the TS gene product p53 and it acts as a TS inducing cell cycle arrest in G1-phase, senescence and apoptosis [<xref ref-type="bibr" rid="CR377">377</xref>].</p>
          <p>Wang et al. [<xref ref-type="bibr" rid="CR378">378</xref>] showed that CN deletion is an important mechanism leading to the down-regulation of expression of specific <italic>let-7</italic> family members in BC. Also miR-33 expression was found to be strongly associated with the genomic alteration [<xref ref-type="bibr" rid="CR128">128</xref>]. Furthermore, the expression of the cluster <italic>miR-145/miR-143</italic> family, miRNA located on a region involved in several types of translocations and deletions, has been found reduced or absent in various types of cancers, including BC [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR368">368</xref>].</p>
          <p>Table <xref rid="Tab14" ref-type="table">14</xref> shows the principal oncomiRs and oncogenes with their alterations considered in this section.<table-wrap id="Tab14"><label>Table 14</label><caption><p>miRNAs altered obtained by the integration miRNA and CNA</p></caption><table frame="hsides" rules="groups"><thead><tr><th>miRNA</th><th>Genetic alterations</th><th>Ref.</th></tr></thead><tbody><tr><td><italic>miR-125b</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR373">373</xref>]</td></tr><tr><td><italic>mir-320d</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR374">374</xref>]</td></tr><tr><td><italic>let-7 g</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR378">378</xref>]</td></tr><tr><td><italic>miR-34a</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR376">376</xref>]</td></tr><tr><td><italic>miR-100</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR375">375</xref>]</td></tr><tr><td><italic>miR-145</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td><italic>miR-143</italic></td><td>Deletions</td><td>[<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td><italic>OncomiR-1</italic></td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR367">367</xref>]</td></tr><tr><td><italic>miR-21</italic></td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR369">369</xref>]</td></tr><tr><td><italic>miR-155</italic></td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR368">368</xref>]</td></tr><tr><td><italic>miR-151a-5p</italic></td><td>Amplifications</td><td>[<xref ref-type="bibr" rid="CR370">370</xref>, <xref ref-type="bibr" rid="CR371">371</xref>]</td></tr></tbody></table></table-wrap></p>
        </sec>
        <sec id="FPar4">
          <title>Networks</title>
          <p>miRNAs that are silenced or amplified from CNA can have a cascade effect on the expression of different genes regulating entire pathways.</p>
          <p>In the following paragraph, we give examples of important miRNAs that are altered in BC and of the consequences of their downregulation in the functional pathway.</p>
          <p>Figure <xref rid="Fig9" ref-type="fig">9a</xref> shows <italic>miR-335</italic> that suppresses BC metastasis by targeting <italic>SOX4</italic> and <italic>Tenascin-C</italic> which promote cancer cell migration, invasion and ultimately metastasis [<xref ref-type="bibr" rid="CR326">326</xref>–<xref ref-type="bibr" rid="CR328">328</xref>]. <italic>miR-335</italic> is silenced through CN deletions [<xref ref-type="bibr" rid="CR328">328</xref>].<fig id="Fig9"><label>Fig. 9</label><caption><p>Examples of CNAs regulatory network. <bold>a</bold>) Deletions of <italic>miR-335</italic> produces effect that appear as promoting migration, invasion, and metastasis. In particular, it has been shown to be an important negative regulator of SOX4, and TENASCIN-C <bold>b</bold>) Amplifications of <italic>miR-33</italic> produce effects that appear as dyseregulation of PTEN pathway</p></caption><graphic xlink:href="12918_2015_211_Fig9_HTML" id="MO9"/></fig></p>
          <p><italic>mir-320</italic> is found to be located in regions with CN loss in BC. The predicted target of <italic>miR-320</italic> is methyl CpG-binding protein 2 (<italic>MECP2</italic>), which is up-regulated in BC and is an oncogene promoting cell proliferation [<xref ref-type="bibr" rid="CR374">374</xref>].</p>
          <p>In a study of Volinia <italic>et al.</italic> [<xref ref-type="bibr" rid="CR368">368</xref>] <italic>miR-21</italic> was found as the only miRNA up-regulated in all six types of solid cancers (BC, colon, lung, prostate, stomach carcinomas and pancreas exocrine tumours). Figure <xref rid="Fig9" ref-type="fig">9b</xref> shows <italic>miR-21</italic> network: it modulates gemcitabine-induced apoptosis by <italic>PTEN-</italic>dependent activation of PI 3-kinase and by activation of AKT/mTOR signalling [<xref ref-type="bibr" rid="CR379">379</xref>]. Inhibition of this miRNA should result in cell death [<xref ref-type="bibr" rid="CR370">370</xref>].</p>
        </sec>
      </sec>
      <sec id="Sec34">
        <title>Computational methods</title>
        <p>Several studies showed that miRNA levels are influenced by CNAs.</p>
        <p>No-experimental methods are usually used for their integration. Individual studies from miRNA and CNA are combined with statistically and/or computational analysis.</p>
        <p>de rinaldis et al. [<xref ref-type="bibr" rid="CR380">380</xref>] analysed association between miRNA expression and CNAs in a large triple-negative BC data set. This association was evaluated using Spearman correlation. In addition, for each miRNA-encoding DNA locus identified as altered in any of the samples, a separate non-parametric Wilcoxon rank sum test was applied to measure differences in expression between samples with deletions and amplifications, compared to samples with no CNAs. 64 miRNAs were found with statistically significant miRNA-CNA correlation, showing an overall influence of genetic alterations (amplifications and deletions) on the expression of the miRNAs.</p>
        <p>Aure et al. [<xref ref-type="bibr" rid="CR372">372</xref>] investigated individual and combined effects of CN and methylation on miRNA expression in BC. They identified 70 miRNAs whose expression was associated with CNAs or methylation, or with both conditions. 24 miRNAs were associated mainly with CNAs, 22 miRNAs with methylation aberrations and 24 miRNAs with a combination of CN and methylation aberrations. In order to identify miRNAs associated with hypomethylation or amplification, each miRNA in each patient was allocated to one of the two groups ‘altered’ or ‘non-altered’ based on CNA and DNA methylation. A Wilcoxon rank-sum test was used for each miRNA to underlie whether the miRNA expression was significantly different in the two groups.</p>
        <p>Srivastava et al. [<xref ref-type="bibr" rid="CR381">381</xref>] showed that <italic>H2AX</italic> was negatively correlated with <italic>miR-24-2</italic> and not in accordance with the CNA status, both in cell lines and in sporadic BC tissues. The authors tried to explain the possible mechanisms of such non concordant relationship between expression and number of gene copies based on specific miR regulation of expression. They discussed a role of miR-24-2 in guiding <italic>H2AFX</italic> GE in the background of the differential status of CNA.</p>
      </sec>
    </sec>
    <sec id="Sec35">
      <title>Combination of gene expression, genetic alterations and miRNAs in BC</title>
      <p>Fearon and Vogelstein [<xref ref-type="bibr" rid="CR382">382</xref>] proposed that accumulation of genetic alterations could determine a malignant phenotype and accompany cancer progression. However, this theory does not explain the great heterogeneity of observed genetic alterations, even within homogeneous histological groups [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
      <p>Normal cells evolve progressively to a neoplastic state, based on a multistep process to acquire the traits that enable them to become tumorigenic and ultimately malignant. Tumors are not only masses of proliferating cancer cells, but complex tissues composed of multiple distinct molecular types that participate in an interaction with one another [<xref ref-type="bibr" rid="CR383">383</xref>, <xref ref-type="bibr" rid="CR384">384</xref>].</p>
      <p>The transitions in the malignant cancer progression are dynamic and reversible steps between multiple phenotypic states (e.g. epithelial and mesenchymal phenotype) [<xref ref-type="bibr" rid="CR385">385</xref>]. These reversible transitions are based on complex epigenetic regulatory mechanisms (e.g. the induction of changes in the modifications of chromatin-associated histones) during epithelial-mesenchymal transitions [<xref ref-type="bibr" rid="CR385">385</xref>, <xref ref-type="bibr" rid="CR386">386</xref>].</p>
      <p>Sarkar et al. [<xref ref-type="bibr" rid="CR387">387</xref>] reported a review based on the role of epigenetic regulation in the steps from normal cell to cancer progenitor cells that, after growing, undergo an epithelial-mesenchymal transition. Epigenetic drugs could potentiate traditional therapeutics by inhibiting both the formation and growth of cancer progenitor cells [<xref ref-type="bibr" rid="CR387">387</xref>].</p>
      <p>We argue that tumour heterogeneity is due not only to a simple accumulation of genetic alterations but can be the cause of the combined effect of genetic and epigenetic alterations. Furthermore, Alfred Knudson [<xref ref-type="bibr" rid="CR388">388</xref>] hypothesized that hereditary retinoblastoma involves two mutations, the first one in the germ line. Thus, non-hereditary retinoblastoma should be due to two somatic mutations, an hypothesis known as Knudson “two-hit” hypothesis. The two-hit hypothesis proposes that loss of a single functional allele, which may potentially results in expression of a truncated or mutated product, is insufficient to involve cellular functions.</p>
      <p>Several studies support the validity of the "two hit theory" in BC. Meric-Bernstam et al. [<xref ref-type="bibr" rid="CR389">389</xref>] applied this hypothesis in BC, and suggested that the second hit does not need to be a point of mutation or somatic loss, but it may be the epigenetic silencing of a gene.</p>
      <p>Konishi et al. [<xref ref-type="bibr" rid="CR390">390</xref>] showed that cell lines carrying one mutant and one normal copy of <italic>BRCA1</italic> have a normal cell phenotype, and they are normal until the second allele is lost through somatic mutation or epigenetic silencing.</p>
      <p>Genetic and epigenetic events are two complementary mechanisms that are involved in carcinogenesis. It is not clear at all how these mechanisms influence GE during tumorigenesis.</p>
      <p>In BC, integration analysis of GE, genomic changes and miRNA expression was adopted in a limited number of studies (e.g. [<xref ref-type="bibr" rid="CR397">397</xref>–<xref ref-type="bibr" rid="CR399">399</xref>]). Eo et al. [<xref ref-type="bibr" rid="CR391">391</xref>] proposed a pathway-based classification of BC which integrates data on DE genes, CNA and miRNA. Pathway information was incorporated in a condition-specific manner. A 215-gene signature was found from 327 tumours. By using an independent data set, this gene signature was validated.</p>
      <p>Cancer Genome Atlas Network [<xref ref-type="bibr" rid="CR392">392</xref>] analysed BC by genomic DNA CN arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. They found biomarkers for gene expression subtypes and the presence of four main BC classes.</p>
      <p>Kristensen et al. [<xref ref-type="bibr" rid="CR393">393</xref>] used an integrated approach to identify and classify BC according to the most deregulated pathways that provide the best predictive value with respect to prognosis, and identified key molecular and stromal signatures.</p>
      <p>In a combined analysis of miRNA and mRNA expression data, Blenkiron et al. [<xref ref-type="bibr" rid="CR128">128</xref>] found a number of miRNAs DE among molecular tumour subtypes. Furthermore, they found that changes in miRNA expression correlate with genomic loss or gain.</p>
      <p>PARADIGM was tested using CN and mRNA expression data [<xref ref-type="bibr" rid="CR394">394</xref>], as well as with the addition of methylation and miRNA expression data [<xref ref-type="bibr" rid="CR393">393</xref>].</p>
      <p>Cava et al. [<xref ref-type="bibr" rid="CR5">5</xref>] assessed the potential of a new triple approach by integrating mRNA expression profile, CNAs, and miRNA expression levels to select a limited number of genomic BC biomarkers and to obtain a more accurate classification of BC grade.</p>
      <p>CNAs have been demonstrated to be able also to identify genes DE between drug-sensitive and -resistant BC cells when integrated to GE and microRNA expression profiles.</p>
      <p>Yamamoto et al. [<xref ref-type="bibr" rid="CR395">395</xref>] focused on miRNAs and genes located on the genome-amplified and -deleted regions. These genes showed also an altered expression in GE profiles. The authors analysed MCF7 and a parental BC cell line drug-resistance MCF7-ADR. <italic>miR-505</italic> was identified as a tumour suppressor, whose genomic region was found to be deleted in doxorubicin-resistant cells. Furthermore, <italic>miR-505</italic> seems to be regulated by its predicted target <italic>Akt3</italic> (an anti-apoptotic gene), by mRNA profiling coupled with downstream validation studies.</p>
    </sec>
  </sec>
  <sec id="Sec36">
    <title>Discussion</title>
    <p>Despite promising initial results about the possible clinical implications of GE profiling, a more recent source of concern has been that gene signatures derived from the various studies show little overlap and poor reproducibility. This can be explained, from one side, by the complexity of the human genome which provides that different genes can be indices of the same message with identical outcomes. From the other side, one explanation can be the use of different types of arrays (of different sample quality) and the different parameters considered for the data analysis. However, GE analysis measures mRNA expression, which, by the central dogma of molecular biology, results from the transcription of DNA. Specifically, GE analysis give information on DE genes among different conditions, but do not consider primary alterations of DNA from secondary effects of disease, such as, in the case of cancer, proliferation and differentiation state. On the other hand, studies of DNA CNA allow important indices to be derived as drivers of cancer. Therefore, integrating DNA and RNA data has been proposed to clarify genetic some regulatory relationships in cancer cells.</p>
    <p>Since 2001, a new term "microRNA" was introduced into the scientific literature, challenging the central dogma of molecular biology. miRNAs are segments of RNA that are transcribed from DNA in a way similar to mRNA but they are not translated into proteins. In short, instead of producing a protein, miRNA can block mRNA directly. Evidences demonstrated that their deregulation is associated to several steps of cancer initiation and progression. However, we think that the association of miRNAs and their mRNA targets is a more favourable approach to study cell differentiation and cancer progression when compared with GE expression or miRNA profile alone. It is therefore of great concern for researchers to investigate how miRNA expression is linked to known BC markers. Several advantages can be envisaged by miRNA analysis: i) miRNAs are certainly more stable due to their small size when compared to long mRNAs [<xref ref-type="bibr" rid="CR127">127</xref>], ii) miRNA expression levels can characterize the functional activity of the target gene while genes have to be translated to proteins to be biologically functional iii) miRNA-based therapeutics have the ability to target multiple genes.</p>
    <p>Misregulation of genes with consequence disruption of the gene function is often induced by epigenetic and genetics events. The epigenetic silencing of one allele may act in concert with an inactivating genetic alteration in the opposite allele, thus resulting in a total allelic loss of the gene [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. From this viewpoint a gene subjected to a different possible alterations (such as CNAs and target of miRNAs) and that presents DE levels between two conditions is a "weak" point of DNA and could be a key element for cancer development. In our opinion each cancer should have a signature with the description of a specific set of alterations. Based on these observations, targeting specifically and simultaneously multiple pathways subjected to different alterations may confer a greater therapeutic efficacy.</p>
    <p>We argue that useful information has been revealed by analysing GE profiles alone, CNA data alone but or miRNAs, however, in order to have complimentary information in gene characterization, an integrative analysis of CNA and GE data and miRNA is necessary.</p>
    <p>However, integrative analyses have some limitations: the most fundamental challenge is dimensionally, considering that more levels in the analysis increase the computational time and the dimension of unknown parameters [<xref ref-type="bibr" rid="CR396">396</xref>]. In addition, at every step, there are problems of compatibility of the data, such as normalization to the same scale, batch effects, and use of different platforms.</p>
    <p>Large-scale integration is possible only for few projects worldwide, given the high cost for all analyses to be carried out simultaneously and on the entire data set.</p>
    <p>In referring to current studies of genetic changes associated with BC, we focused in particular on the processes controlled by CNA. However, DNA changes include other genomic rearrangements, such as somatic point mutations.</p>
    <p>The analysis of the genomes of 100 tumours revealed more than 7400 somatic point mutations in 21416 protein-coding genes [<xref ref-type="bibr" rid="CR397">397</xref>]. These mutations affect many of the well-established cancer related genes, such as BRCA1, RB1, TP53, PTEN, AKT1, CDH1, GATA3, PI3KCA. These genes control apoptosis, proliferation and cell cycle, and transcription. Other somatic mutations affect genes involved in signal transduction (APC, KRAS, MAPK2K4, SMAD4, CASP8, CDKN1B…). Somatic mutation in three main genes (TP53, PI3KCA, and GATA3) shows more than 10 % incidence across all BC [<xref ref-type="bibr" rid="CR397">397</xref>]. One of the most commonly mutated TSG in BC is <italic>P53</italic> [<xref ref-type="bibr" rid="CR398">398</xref>]. It is localized to chromosome 17p13 and its inactivation is important also in other cancer diseases. Several studies have investigated the predictive power of <italic>P53</italic> for response to treatments and outcome of BC patients [<xref ref-type="bibr" rid="CR399">399</xref>–<xref ref-type="bibr" rid="CR401">401</xref>]. Bertheau et al. [<xref ref-type="bibr" rid="CR401">401</xref>] reported that <italic>P53</italic> base-pair substitutions are highly linked to specific BC molecular subtypes, being found in 26 % of luminal tumours (17 % of luminal A, 41 % of luminal B), in 50 % of HER2 amplified tumours, and in 88 % of basal-like carcinomas. The type of mutations changes according to the tumour subtype. Basal-like tumours present higher frequency of deletions. Furthermore, the authors found that non inflammatory locally advanced BC with mutated <italic>P53</italic> has a higher rate of response to dose-dense doxorubicin–cyclophosphamide chemotherapy than <italic>TP53</italic>-WT tumours. As recently reported [<xref ref-type="bibr" rid="CR402">402</xref>], <italic>P53</italic> is at the centre of the hallmarks of cancer, supporting genomic stability, exerting anti-angiogenic effects, controlling tumour inflammation and immune response, and repressing metastases. In BC, mutations in <italic>BRCA1</italic> and <italic>BRCA2</italic> result in protein truncations as consequence of small insertions, deletions or nonsense mutations. Although <italic>BRCA1</italic> and <italic>BCRA2</italic> mutations are hereditary, these genes would also be involved in the development of sporadic BC. Compared with normal breast epithelium, many BCs have shown low levels of the <italic>BRCA1</italic> mRNA [<xref ref-type="bibr" rid="CR403">403</xref>, <xref ref-type="bibr" rid="CR404">404</xref>], while <italic>BRCA2</italic> has been found the target of frequent loss of heterozygosity (LOH) in BC [<xref ref-type="bibr" rid="CR405">405</xref>, <xref ref-type="bibr" rid="CR406">406</xref>].</p>
    <p>Other omics data could be further integrated for a more inclusive analysis. Considering that proteins translate effects of CNAs into the biological functions of the cell, further studies could integrate protein-protein interactions networks with gene-gene co-expression networks. For example, by dissecting the protein-protein interaction network into disjoint sub networks, van den Akkerb et al. [<xref ref-type="bibr" rid="CR407">407</xref>] found sub-population of genes by using pair wise GE correlation measures. The obtained genes were consistently found across different studies.</p>
    <p>Also the DNA methylation could be integrated in a pathway analysis and could be combined with other biological data. Andrews et al. [<xref ref-type="bibr" rid="CR408">408</xref>] integrated results from CNAs, GE profiling and methylation to identify differentially regulated pathways between a highly metastatic BC cell line and low metastatic parental cell line. Validation experiments confirmed that hypermethylated genes correlated with decreased expression in the metastatic, compared to the parental cell line.</p>
    <p>Results generated from whole-genome analyses have been submitted in The Cancer Genome Atlas (TCGA) database, which includes CNAs, DNA methylation and GE profiles [<xref ref-type="bibr" rid="CR409">409</xref>, <xref ref-type="bibr" rid="CR410">410</xref>]. These data might be used for integrative analyses of results generated from a single technology platform [<xref ref-type="bibr" rid="CR411">411</xref>].</p>
  </sec>
  <sec id="Sec37">
    <title>Conclusions</title>
    <p>Integrating genetics and epigenetics in BC may offer a powerful approach for the identification of biomarkers with diagnostic, prognostic and therapeutic potential. The experimental and computational methods presented in this review can be used to guide researchers for these integration studies.</p>
  </sec>
</body>
<back>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>BC</term>
        <def>
          <p>Breast Cancer</p>
        </def>
      </def-item>
      <def-item>
        <term>CNA</term>
        <def>
          <p>Copy number alteration</p>
        </def>
      </def-item>
      <def-item>
        <term>GE</term>
        <def>
          <p>Gene expression</p>
        </def>
      </def-item>
      <def-item>
        <term>miRNA</term>
        <def>
          <p>microRNA</p>
        </def>
      </def-item>
      <def-item>
        <term>ER</term>
        <def>
          <p>Estrogen receptors</p>
        </def>
      </def-item>
      <def-item>
        <term>PR</term>
        <def>
          <p>Progesterone receptors</p>
        </def>
      </def-item>
      <def-item>
        <term>HER2</term>
        <def>
          <p>Human epidermal growth factor receptor-2</p>
        </def>
      </def-item>
      <def-item>
        <term>CN</term>
        <def>
          <p>Copy number</p>
        </def>
      </def-item>
      <def-item>
        <term>WT</term>
        <def>
          <p>Wild type</p>
        </def>
      </def-item>
      <def-item>
        <term>TSGs</term>
        <def>
          <p>Tumor suppressor genes</p>
        </def>
      </def-item>
      <def-item>
        <term>OGs</term>
        <def>
          <p>Oncogenes</p>
        </def>
      </def-item>
      <def-item>
        <term>LOH</term>
        <def>
          <p>Loss of heterozygosity</p>
        </def>
      </def-item>
      <def-item>
        <term>FISH</term>
        <def>
          <p>Fluorescence <italic>in situ</italic> hybridization technique</p>
        </def>
      </def-item>
      <def-item>
        <term>SNP</term>
        <def>
          <p>Single nucleotide polymorphism</p>
        </def>
      </def-item>
      <def-item>
        <term>NGS</term>
        <def>
          <p>Next generation sequencing</p>
        </def>
      </def-item>
      <def-item>
        <term>dChip</term>
        <def>
          <p>DNA-Chip analyzer</p>
        </def>
      </def-item>
      <def-item>
        <term>HMM</term>
        <def>
          <p>Hidden Markov model</p>
        </def>
      </def-item>
      <def-item>
        <term>CNAG</term>
        <def>
          <p>Copy number analyser for GeneChip arrays</p>
        </def>
      </def-item>
      <def-item>
        <term>RMA</term>
        <def>
          <p>Robust multichip average</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <italic>EGFR</italic>
        </term>
        <def>
          <p>Epidermal growth factor receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>DE</term>
        <def>
          <p>Differentially expressed</p>
        </def>
      </def-item>
      <def-item>
        <term>RT-PCR</term>
        <def>
          <p>Real-time quantitative reverse transcription PCR</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <fn-group>
    <fn>
      <p>
        <bold>Competing interests</bold>
      </p>
      <p>The authors declare that they have no competing interests.</p>
    </fn>
    <fn>
      <p>
        <bold>Authors’ contributions</bold>
      </p>
      <p>Conceived and designed the paper: CC, GB, IC. Performed the experiments: CC GB. Wrote the paper: CC, GB, IC. All authors read and approved the final manuscript.</p>
    </fn>
    <fn>
      <p>
        <bold>Authors’ information</bold>
      </p>
      <p>Not applicable.</p>
      <p>
        <bold>Funding</bold>
      </p>
      <p>This study was partially supported by INTEROMICS flagship project (<ext-link ext-link-type="uri" xlink:href="http://www.interomics.eu/it/home">http://www.interomics.eu/it/home</ext-link>), National Research Council CUP grant B91J12000190001.</p>
    </fn>
    <fn>
      <p>
        <bold>Availability of data and materials</bold>
      </p>
      <p>Not applicable.</p>
    </fn>
  </fn-group>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Polyak</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Heterogeneity in breast cancer</article-title>
        <source>J Clin Invest</source>
        <year>2011</year>
        <volume>10</volume>
        <fpage>3786</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1172/JCI60534</pub-id>
        <pub-id pub-id-type="pmid">21965334</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Viale</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>The current state of breast cancer classification</article-title>
        <source>Ann Oncol</source>
        <year>2012</year>
        <volume>23</volume>
        <issue>Suppl 10</issue>
        <fpage>207</fpage>
        <lpage>10</lpage>
        <pub-id pub-id-type="doi">10.1093/annonc/mds326</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hsiao</surname>
            <given-names>YH</given-names>
          </name>
          <name>
            <surname>Chou</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Fowler</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Mason</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Man</surname>
            <given-names>YG</given-names>
          </name>
        </person-group>
        <article-title>Breast cancer heterogeneity: mechanisms, proofs, and implications</article-title>
        <source>J Cancer</source>
        <year>2010</year>
        <volume>1</volume>
        <issue>1</issue>
        <fpage>6</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.7150/jca.1.6</pub-id>
        <?supplied-pmid 20842218?>
        <pub-id pub-id-type="pmid">20842218</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sotiriou</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wirapati</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Loi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fox</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Smeds</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis</article-title>
        <source>J Natl Cancer Inst</source>
        <year>2006</year>
        <volume>98</volume>
        <issue>4</issue>
        <fpage>262</fpage>
        <lpage>72</lpage>
        <pub-id pub-id-type="doi">10.1093/jnci/djj052</pub-id>
        <?supplied-pmid 16478745?>
        <pub-id pub-id-type="pmid">16478745</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cava</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bertoli</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ripamonti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mauri</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Zoppis</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Della Rosa</surname>
            <given-names>PA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integration of mRNA Expression Profile, Copy Number Alterations, and microRNA Expression Levels in Breast Cancer to Improve Grade Definition</article-title>
        <source>PLoS One</source>
        <year>2014</year>
        <volume>9</volume>
        <issue>5</issue>
        <fpage>e97681</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0097681</pub-id>
        <?supplied-pmid 24866763?>
        <pub-id pub-id-type="pmid">24866763</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ivshina</surname>
            <given-names>AV</given-names>
          </name>
          <name>
            <surname>George</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Senko</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Mow</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Putti</surname>
            <given-names>TC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer</article-title>
        <source>Cancer Res</source>
        <year>2006</year>
        <volume>66</volume>
        <issue>21</issue>
        <fpage>10292</fpage>
        <lpage>10301</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4414</pub-id>
        <?supplied-pmid 17079448?>
        <pub-id pub-id-type="pmid">17079448</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>De Summa</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Petriella</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tudoran</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Danza</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tommasi</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>The value of new high-throughput technologies for diagnosis and prognosis in solid tumors</article-title>
        <source>Cancer Biomark</source>
        <year>2014</year>
        <volume>14</volume>
        <issue>2–3</issue>
        <fpage>103</fpage>
        <lpage>17</lpage>
        <?supplied-pmid 24878811?>
        <pub-id pub-id-type="pmid">24878811</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <mixed-citation publication-type="other">Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10(26):3001–7.</mixed-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Birgisdottir</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Stefansson</surname>
            <given-names>OA</given-names>
          </name>
          <name>
            <surname>Bodvarsdottir</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Hilmarsdottir</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Jonasson</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Eyfjord</surname>
            <given-names>JE</given-names>
          </name>
        </person-group>
        <article-title>Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer</article-title>
        <source>Breast Cancer Res</source>
        <year>2006</year>
        <volume>4</volume>
        <fpage>R38</fpage>
        <pub-id pub-id-type="doi">10.1186/bcr1522</pub-id>
        <pub-id pub-id-type="pmid">16846527</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Jin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Xia</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors</article-title>
        <source>BMC Cancer</source>
        <year>2010</year>
        <volume>10</volume>
        <fpage>98</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2407-10-98</pub-id>
        <?supplied-pmid 20230646?>
        <pub-id pub-id-type="pmid">20230646</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <mixed-citation publication-type="other">Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, et al. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res. 2002;9:2890–3.</mixed-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Feinberg</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Ohlsson</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Henikoff</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>The epigenetic progenitor origin of human cancer</article-title>
        <source>Nat Rev Genet</source>
        <year>2006</year>
        <volume>7</volume>
        <issue>1</issue>
        <fpage>21</fpage>
        <lpage>33</lpage>
        <pub-id pub-id-type="doi">10.1038/nrg1748</pub-id>
        <?supplied-pmid 16369569?>
        <pub-id pub-id-type="pmid">16369569</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gonzalez-Angulo</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Hennessy</surname>
            <given-names>BT</given-names>
          </name>
          <name>
            <surname>Mills</surname>
            <given-names>GB</given-names>
          </name>
        </person-group>
        <article-title>Future of personalized medicine in oncology: a systems biology approach</article-title>
        <source>J Clin Oncol</source>
        <year>2010</year>
        <volume>28</volume>
        <issue>16</issue>
        <fpage>2777</fpage>
        <lpage>83</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2009.27.0777</pub-id>
        <?supplied-pmid 20406928?>
        <pub-id pub-id-type="pmid">20406928</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Beroukhim</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Mermel</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Porter</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Raychaudhuri</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Donovan</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The landscape of somatic copy-number alteration across human cancers</article-title>
        <source>Nature</source>
        <year>2010</year>
        <volume>463</volume>
        <issue>7283</issue>
        <fpage>899</fpage>
        <lpage>905</lpage>
        <pub-id pub-id-type="doi">10.1038/nature08822</pub-id>
        <?supplied-pmid 20164920?>
        <pub-id pub-id-type="pmid">20164920</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Poplawski</surname>
            <given-names>AB</given-names>
          </name>
          <name>
            <surname>Jankowski</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Erickson</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Diaz de Stahl</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Partridge</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Crasto</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression</article-title>
        <source>Eur J Human Genet</source>
        <year>2010</year>
        <volume>18</volume>
        <fpage>560</fpage>
        <lpage>568</lpage>
        <pub-id pub-id-type="doi">10.1038/ejhg.2009.230</pub-id>
        <pub-id pub-id-type="pmid">20051991</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Slamon</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>SG</given-names>
          </name>
          <name>
            <surname>Levin</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Ullrich</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>McGuire</surname>
            <given-names>WL</given-names>
          </name>
        </person-group>
        <article-title>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title>
        <source>Science</source>
        <year>1987</year>
        <volume>235</volume>
        <fpage>177</fpage>
        <lpage>182</lpage>
        <pub-id pub-id-type="doi">10.1126/science.3798106</pub-id>
        <?supplied-pmid 3798106?>
        <pub-id pub-id-type="pmid">3798106</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Staaf</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Jönsson</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ringnér</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Vallon-Christersson</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Grabau</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Arason</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Research article High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer</article-title>
        <source>Breast Cancer Res</source>
        <year>2010</year>
        <volume>12</volume>
        <fpage>R25</fpage>
        <pub-id pub-id-type="doi">10.1186/bcr2568</pub-id>
        <?supplied-pmid 20459607?>
        <pub-id pub-id-type="pmid">20459607</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rizzolo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Silvestri</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Falchetti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ottini</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Inherited and acquired alterations in development of breast cancer</article-title>
        <source>Appl Clin Genet</source>
        <year>2011</year>
        <volume>4</volume>
        <fpage>145</fpage>
        <?supplied-pmid 23776375?>
        <pub-id pub-id-type="pmid">23776375</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Faivre</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Lange</surname>
            <given-names>CA</given-names>
          </name>
        </person-group>
        <article-title>Progesterone receptors upregulate Wnt-1 to induceepidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells</article-title>
        <source>Mol Cell Biol</source>
        <year>2007</year>
        <volume>27</volume>
        <issue>2</issue>
        <fpage>466</fpage>
        <lpage>80</lpage>
        <pub-id pub-id-type="doi">10.1128/MCB.01539-06</pub-id>
        <?supplied-pmid 17074804?>
        <pub-id pub-id-type="pmid">17074804</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tsutsui</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ohno</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Murakami</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hachitanda</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Oda</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer</article-title>
        <source>Breast Cancer Res Treat</source>
        <year>2002</year>
        <volume>71</volume>
        <fpage>67</fpage>
        <lpage>75</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1013397232011</pub-id>
        <?supplied-pmid 11859875?>
        <pub-id pub-id-type="pmid">11859875</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Knoop</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Knudsen</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Balslev</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group</article-title>
        <source>J Clin Oncol</source>
        <year>2005</year>
        <volume>23</volume>
        <fpage>7483</fpage>
        <lpage>7490</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2005.11.007</pub-id>
        <?supplied-pmid 16234514?>
        <pub-id pub-id-type="pmid">16234514</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>O'Malley</surname>
            <given-names>FP</given-names>
          </name>
          <name>
            <surname>Chia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tu</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Topoisomerase II α and responsiveness of breast cancer to adjuvant chemotherapy</article-title>
        <source>J Natl Cancer Inst</source>
        <year>2009</year>
        <volume>101</volume>
        <fpage>644</fpage>
        <lpage>650</lpage>
        <pub-id pub-id-type="doi">10.1093/jnci/djp067</pub-id>
        <?supplied-pmid 19401546?>
        <pub-id pub-id-type="pmid">19401546</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tanner</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Isola</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wiklund</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu–amplified breast cancer: Scandinavian Breast Group Trial 9401</article-title>
        <source>J Clin Oncol</source>
        <year>2006</year>
        <volume>24</volume>
        <fpage>2428</fpage>
        <lpage>2436</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2005.02.9264</pub-id>
        <?supplied-pmid 16682728?>
        <pub-id pub-id-type="pmid">16682728</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gonzalez‐Angulo</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Karuturi</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Chavez‐MacGregor</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tsavachidis</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Meric‐Bernstam</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Frequency of mesenchymal‐epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide‐3‐kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer</article-title>
        <source>Cancer</source>
        <year>2013</year>
        <volume>119</volume>
        <issue>1</issue>
        <fpage>7</fpage>
        <lpage>15</lpage>
        <pub-id pub-id-type="doi">10.1002/cncr.27608</pub-id>
        <?supplied-pmid 22736407?>
        <pub-id pub-id-type="pmid">22736407</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Olopade</surname>
            <given-names>OI</given-names>
          </name>
        </person-group>
        <article-title>MYC and breast cancer</article-title>
        <source>Gene Canc</source>
        <year>2010</year>
        <volume>1</volume>
        <issue>6</issue>
        <fpage>629</fpage>
        <lpage>640</lpage>
        <pub-id pub-id-type="doi">10.1177/1947601910378691</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aulmann</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bentz</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sinn</surname>
            <given-names>HP</given-names>
          </name>
        </person-group>
        <article-title>C-myc oncogene amplification in ductal carcinoma in situ of the breast</article-title>
        <source>Breast Cancer Res Treat</source>
        <year>2002</year>
        <volume>74</volume>
        <fpage>25</fpage>
        <lpage>31</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1016061327812</pub-id>
        <?supplied-pmid 12150449?>
        <pub-id pub-id-type="pmid">12150449</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Robanus-Maandag</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Bosch</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Kristel</surname>
            <given-names>PM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas</article-title>
        <source>J Pathol</source>
        <year>2003</year>
        <volume>201</volume>
        <fpage>75</fpage>
        <lpage>82</lpage>
        <pub-id pub-id-type="doi">10.1002/path.1385</pub-id>
        <?supplied-pmid 12950019?>
        <pub-id pub-id-type="pmid">12950019</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aulmann</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Adler</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Rom</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Helmchen</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Schirmacher</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Sinn</surname>
            <given-names>HP</given-names>
          </name>
        </person-group>
        <article-title>c-myc amplifications in primary breast carcinomas and their local recurrences</article-title>
        <source>J Clin Pathol</source>
        <year>2006</year>
        <volume>59</volume>
        <fpage>424</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1136/jcp.2005.029264</pub-id>
        <?supplied-pmid 16497871?>
        <pub-id pub-id-type="pmid">16497871</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Corzo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Corominas</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Tusquets</surname>
            <given-names>I</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma</article-title>
        <source>Cancer Genet Cytogenet</source>
        <year>2006</year>
        <volume>165</volume>
        <fpage>151</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cancergencyto.2005.08.013</pub-id>
        <?supplied-pmid 16527609?>
        <pub-id pub-id-type="pmid">16527609</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lundgren</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pineda</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Cuzick</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Salter</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zabaglo</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study</article-title>
        <source>Breast Cancer Res</source>
        <year>2012</year>
        <volume>14</volume>
        <issue>2</issue>
        <fpage>R57</fpage>
        <pub-id pub-id-type="doi">10.1186/bcr3161</pub-id>
        <?supplied-pmid 22475046?>
        <pub-id pub-id-type="pmid">22475046</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sherr</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>JM</given-names>
          </name>
        </person-group>
        <article-title>CDK inhibitors: positive and negative regulators of G<sub>1</sub>-phase progression</article-title>
        <source>Genes Dev</source>
        <year>1999</year>
        <volume>13</volume>
        <fpage>1501</fpage>
        <lpage>1512</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.13.12.1501</pub-id>
        <?supplied-pmid 10385618?>
        <pub-id pub-id-type="pmid">10385618</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Holst</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Stahl</surname>
            <given-names>PR</given-names>
          </name>
          <name>
            <surname>Ruiz</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer</article-title>
        <source>Nat Genet</source>
        <year>2007</year>
        <volume>39</volume>
        <fpage>655</fpage>
        <lpage>660</lpage>
        <pub-id pub-id-type="doi">10.1038/ng2006</pub-id>
        <?supplied-pmid 17417639?>
        <pub-id pub-id-type="pmid">17417639</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Desouki</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Liao</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Conroy</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nowak</surname>
            <given-names>NJ</given-names>
          </name>
          <name>
            <surname>Shepherd</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach</article-title>
        <source>J Cancer Res Clin Oncol</source>
        <year>2011</year>
        <volume>137</volume>
        <fpage>795</fpage>
        <lpage>809</lpage>
        <pub-id pub-id-type="doi">10.1007/s00432-010-0937-1</pub-id>
        <?supplied-pmid 20680643?>
        <pub-id pub-id-type="pmid">20680643</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rodriguez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hughes-Davies</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Vallès</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome</article-title>
        <source>Clin Cancer Res</source>
        <year>2004</year>
        <volume>10</volume>
        <fpage>5785</fpage>
        <lpage>5791</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0410</pub-id>
        <?supplied-pmid 15355907?>
        <pub-id pub-id-type="pmid">15355907</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Iakovlev</surname>
            <given-names>VV</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Warren</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Iakovleva</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study</article-title>
        <source>Gene Chromosome Canc</source>
        <year>2009</year>
        <volume>48</volume>
        <fpage>1091</fpage>
        <lpage>1101</lpage>
        <pub-id pub-id-type="doi">10.1002/gcc.20711</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Trapé</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Gonzalez-Angulo</surname>
            <given-names>AM</given-names>
          </name>
        </person-group>
        <article-title>Breast cancer and metastasis: on the way toward individualized therapy</article-title>
        <source>Cancer Genomics-Proteomics</source>
        <year>2012</year>
        <volume>9</volume>
        <issue>5</issue>
        <fpage>297</fpage>
        <lpage>310</lpage>
        <?supplied-pmid 22990109?>
        <pub-id pub-id-type="pmid">22990109</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Imataka</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Arisaka</surname>
            <given-names>O</given-names>
          </name>
        </person-group>
        <article-title>Chromosome analysis using spectral karyotyping (SKY)</article-title>
        <source>Cell Biochem Biophys</source>
        <year>2012</year>
        <volume>62</volume>
        <issue>1</issue>
        <fpage>13</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="doi">10.1007/s12013-011-9285-2</pub-id>
        <?supplied-pmid 21948110?>
        <pub-id pub-id-type="pmid">21948110</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Salman</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jhanwar</surname>
            <given-names>SC</given-names>
          </name>
          <name>
            <surname>Ostrer</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Will the new cytogenetics replace the old cytogenetics?</article-title>
        <source>Clin Genet</source>
        <year>2004</year>
        <volume>66</volume>
        <fpage>265</fpage>
        <lpage>275</lpage>
        <pub-id pub-id-type="doi">10.1111/j.1399-0004.2004.00316.x</pub-id>
        <?supplied-pmid 15355426?>
        <pub-id pub-id-type="pmid">15355426</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Alkan</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Coe</surname>
            <given-names>BP</given-names>
          </name>
          <name>
            <surname>Eichler</surname>
            <given-names>EE</given-names>
          </name>
        </person-group>
        <article-title>Genome structural variation discovery and genotyping</article-title>
        <source>Nat Rev Genet</source>
        <year>2011</year>
        <volume>12</volume>
        <issue>5</issue>
        <fpage>363</fpage>
        <lpage>376</lpage>
        <pub-id pub-id-type="doi">10.1038/nrg2958</pub-id>
        <?supplied-pmid 21358748?>
        <pub-id pub-id-type="pmid">21358748</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Park</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Discovery of common Asian copy number variants using integrated high-resolution array CGH and massively parallel DNA sequencing</article-title>
        <source>Nat Genet</source>
        <year>2010</year>
        <volume>42</volume>
        <fpage>400</fpage>
        <lpage>405</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.555</pub-id>
        <?supplied-pmid 20364138?>
        <pub-id pub-id-type="pmid">20364138</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Olivier</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Current analysis platforms and methods for detecting copy number variation</article-title>
        <source>Physiol Genomics</source>
        <year>2013</year>
        <volume>45</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1152/physiolgenomics.00082.2012</pub-id>
        <?supplied-pmid 23132758?>
        <pub-id pub-id-type="pmid">23132758</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <mixed-citation publication-type="other">Clevert DA, Mitterecker A, Mayr A, Klambauer G, Tuefferd M, De Bondt A, et al. cn. FARMS: a latent variable model to detect copy number variations in microarray data with a low false discovery rate. Nucleic Acids Res. 2011;39(12):e79–9.</mixed-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bignell</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Stratton</surname>
            <given-names>MR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Whole genome DNA copy number changes identified by high density oligonucleotide arrays</article-title>
        <source>Hum Genomics</source>
        <year>2004</year>
        <volume>1</volume>
        <fpage>287</fpage>
        <lpage>299</lpage>
        <pub-id pub-id-type="doi">10.1186/1479-7364-1-4-287</pub-id>
        <?supplied-pmid 15588488?>
        <pub-id pub-id-type="pmid">15588488</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Paez</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Chin</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Janne</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>TH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays</article-title>
        <source>Cancer Res</source>
        <year>2004</year>
        <volume>64</volume>
        <issue>9</issue>
        <fpage>3060</fpage>
        <lpage>3071</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3308</pub-id>
        <?supplied-pmid 15126342?>
        <pub-id pub-id-type="pmid">15126342</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nannya</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sanada</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nakazaki</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hosoya</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Hangaishi</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays</article-title>
        <source>Cancer Res</source>
        <year>2005</year>
        <volume>65</volume>
        <issue>14</issue>
        <fpage>6071</fpage>
        <lpage>6079</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0465</pub-id>
        <?supplied-pmid 16024607?>
        <pub-id pub-id-type="pmid">16024607</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Korn</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Kuruvilla</surname>
            <given-names>FG</given-names>
          </name>
          <name>
            <surname>McCarroll</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Wysoker</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nemesh</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cawley</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs</article-title>
        <source>Nat Genet</source>
        <year>2008</year>
        <volume>40</volume>
        <fpage>1253</fpage>
        <lpage>1260</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.237</pub-id>
        <?supplied-pmid 18776909?>
        <pub-id pub-id-type="pmid">18776909</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bengtsson</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Irizarry</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Carvalho</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Speed</surname>
            <given-names>TP</given-names>
          </name>
        </person-group>
        <article-title>Estimation and assessment of raw copy numbers at the single locus level</article-title>
        <source>Bioinformatics</source>
        <year>2008</year>
        <volume>24</volume>
        <fpage>759</fpage>
        <lpage>767</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btn016</pub-id>
        <?supplied-pmid 18204055?>
        <pub-id pub-id-type="pmid">18204055</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gai</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Perin</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Murphy</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>O'Hara</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>D'arcy</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wenocur</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CNV Workshop: an integrated platform for high-throughput copy number variation discovery and clinical diagnostics</article-title>
        <source>BMC Bioinformatics</source>
        <year>2010</year>
        <volume>11</volume>
        <issue>1</issue>
        <fpage>74</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-11-74</pub-id>
        <?supplied-pmid 20132550?>
        <pub-id pub-id-type="pmid">20132550</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <mixed-citation publication-type="other">Baross A, Delaney AD, Li HI, Nayar T, Flibotte S, Qian H, et al. Assessment of algorithms for high throughput detection of genomic copy number variation in oligonucleotide microarray data. BMC Bioinformatics. 2007;8:368.</mixed-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eckel-Passow</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Atkinson</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Maharjan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kardia</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>de Andrade</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Software comparison for evaluating genomic copy number variation for Affymetrix 6.0 SNP array platform</article-title>
        <source>BMC Bioinformatics</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>220</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-12-220</pub-id>
        <?supplied-pmid 21627824?>
        <pub-id pub-id-type="pmid">21627824</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <mixed-citation publication-type="other">Zhang D, Qian Y, Akula N, Alliey-Rodriguez N, Tang J, Gershon ES, et al. Accuracy of CNV detection from GWAS data. PLoS One. 2011;6:e14511.</mixed-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gordon</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Resio</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Pellman</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Causes and consequences of aneuploidy in cancer</article-title>
        <source>Nat Rev Genet</source>
        <year>2012</year>
        <volume>13</volume>
        <fpage>189</fpage>
        <lpage>203</lpage>
        <?supplied-pmid 22269907?>
        <pub-id pub-id-type="pmid">22269907</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Carling</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>The AMP-activated protein kinase cascade—a unifying system for energy control</article-title>
        <source>Trends Biochem Sci</source>
        <year>2004</year>
        <volume>29</volume>
        <fpage>18</fpage>
        <lpage>24</lpage>
        <pub-id pub-id-type="doi">10.1016/j.tibs.2003.11.005</pub-id>
        <?supplied-pmid 14729328?>
        <pub-id pub-id-type="pmid">14729328</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Paez</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Ja¨nne</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Tracy</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Greulich</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Gabriel</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title>
        <source>Science</source>
        <year>2004</year>
        <volume>304</volume>
        <fpage>1497</fpage>
        <lpage>1500</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1099314</pub-id>
        <?supplied-pmid 15118125?>
        <pub-id pub-id-type="pmid">15118125</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <mixed-citation publication-type="other">Shih J, Bashir B, Gustafson KS, Andrake M, Dunbrack RL, Goldstein LJ, et al. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. J Natl Compr Canc Netw. 2015;13(8):947–52.</mixed-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Baselga</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Norton</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Albanell</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>YM</given-names>
          </name>
          <name>
            <surname>Mendelsohn</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts</article-title>
        <source>Cancer Res</source>
        <year>1998</year>
        <volume>58</volume>
        <fpage>2825</fpage>
        <lpage>2831</lpage>
        <?supplied-pmid 9661897?>
        <pub-id pub-id-type="pmid">9661897</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Baselga</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cortés</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Im</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Hegg</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Im</surname>
            <given-names>YH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</article-title>
        <source>N Engl J Med</source>
        <year>2012</year>
        <volume>366</volume>
        <issue>2</issue>
        <fpage>109</fpage>
        <lpage>119</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa1113216</pub-id>
        <?supplied-pmid 22149875?>
        <pub-id pub-id-type="pmid">22149875</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Scheuer</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Friess</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Burtscher</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Bossenmaier</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Endl</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hasmann</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models</article-title>
        <source>Cancer Res</source>
        <year>2009</year>
        <volume>69</volume>
        <fpage>9330</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4597</pub-id>
        <?supplied-pmid 19934333?>
        <pub-id pub-id-type="pmid">19934333</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bird</surname>
            <given-names>AP</given-names>
          </name>
        </person-group>
        <article-title>CpG-rich islands and the function of DNA methylation</article-title>
        <source>Nature</source>
        <year>1986</year>
        <volume>321</volume>
        <fpage>209</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.1038/321209a0</pub-id>
        <?supplied-pmid 2423876?>
        <pub-id pub-id-type="pmid">2423876</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ehrlich</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gama-Sosa</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>LH</given-names>
          </name>
          <name>
            <surname>Midgett</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Kuo</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>McCune</surname>
            <given-names>RA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells</article-title>
        <source>Nucleic Acids Res</source>
        <year>1982</year>
        <volume>10</volume>
        <fpage>2709</fpage>
        <lpage>21</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/10.8.2709</pub-id>
        <?supplied-pmid 7079182?>
        <pub-id pub-id-type="pmid">7079182</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fullgrabe</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kavanagh</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Joseph</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Histone onco-modifications</article-title>
        <source>Oncogene</source>
        <year>2011</year>
        <volume>30</volume>
        <fpage>3391</fpage>
        <lpage>3403</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2011.121</pub-id>
        <?supplied-pmid 21516126?>
        <pub-id pub-id-type="pmid">21516126</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jones</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Baylin</surname>
            <given-names>SB</given-names>
          </name>
        </person-group>
        <article-title>The epigenomics of cancer</article-title>
        <source>Cell</source>
        <year>2007</year>
        <volume>128</volume>
        <fpage>683</fpage>
        <lpage>692</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2007.01.029</pub-id>
        <?supplied-pmid 17320506?>
        <pub-id pub-id-type="pmid">17320506</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stearns</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Davidson</surname>
            <given-names>NE</given-names>
          </name>
        </person-group>
        <article-title>Epigenetic regulation as a new target for breast cancer therapy</article-title>
        <source>Cancer Invest</source>
        <year>2007</year>
        <volume>25</volume>
        <fpage>659</fpage>
        <lpage>665</lpage>
        <pub-id pub-id-type="doi">10.1080/07357900701719234</pub-id>
        <?supplied-pmid 18058459?>
        <pub-id pub-id-type="pmid">18058459</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <mixed-citation publication-type="other">Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315–22.</mixed-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <mixed-citation publication-type="other">Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 2004;13:4442–52.</mixed-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <mixed-citation publication-type="other">Jeronimo C, Monteiro P, Henrique R, Dinis-Ribeiro M, Costa I, Costa VL, et al. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat. 2008;1:27–34.</mixed-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Radpour</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kohler</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Haghighi</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>AX</given-names>
          </name>
          <name>
            <surname>Holzgreve</surname>
            <given-names>W</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array</article-title>
        <source>Oncogene</source>
        <year>2009</year>
        <volume>28</volume>
        <fpage>2969</fpage>
        <lpage>2978</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2009.149</pub-id>
        <?supplied-pmid 19503099?>
        <pub-id pub-id-type="pmid">19503099</pub-id>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <mixed-citation publication-type="other">Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat. 2008;3:429–37.</mixed-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <mixed-citation publication-type="other">Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res. 2008;3:R46.</mixed-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <mixed-citation publication-type="other">Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004;64:3807–13.</mixed-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <mixed-citation publication-type="other">Li L, Lee KM, Han W, Choi JY, Lee JY, Kang GH, et al. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet. 2010;21:4273–7.</mixed-citation>
    </ref>
    <ref id="CR72">
      <label>72.</label>
      <mixed-citation publication-type="other">Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011;3:75ra25.</mixed-citation>
    </ref>
    <ref id="CR73">
      <label>73.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leon</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Shapiro</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Sklaroff</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Yaros</surname>
            <given-names>MJ</given-names>
          </name>
        </person-group>
        <article-title>Free DNA in the serum of cancer patients and the effect of therapy</article-title>
        <source>Cancer Res</source>
        <year>1977</year>
        <volume>37</volume>
        <fpage>646</fpage>
        <lpage>650</lpage>
        <?supplied-pmid 837366?>
        <pub-id pub-id-type="pmid">837366</pub-id>
      </element-citation>
    </ref>
    <ref id="CR74">
      <label>74.</label>
      <mixed-citation publication-type="other">Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013;1:R4.</mixed-citation>
    </ref>
    <ref id="CR75">
      <label>75.</label>
      <mixed-citation publication-type="other">Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, et al. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin Biochem. 2013;3:235–40.</mixed-citation>
    </ref>
    <ref id="CR76">
      <label>76.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chimonidou</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Strati</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Malamos</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Georgoulias</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Lianidou</surname>
            <given-names>ES</given-names>
          </name>
        </person-group>
        <article-title>SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer</article-title>
        <source>Clin Chem</source>
        <year>2013</year>
        <volume>1</volume>
        <fpage>270</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1373/clinchem.2012.191551</pub-id>
        <pub-id pub-id-type="pmid">23136251</pub-id>
      </element-citation>
    </ref>
    <ref id="CR77">
      <label>77.</label>
      <mixed-citation publication-type="other">Guerrero-Preston R, Hadar T, Ostrow KL, Soudry E, Echenique M, Ili-Gangas C, et al. Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol Rep. 2014;32:505–12.</mixed-citation>
    </ref>
    <ref id="CR78">
      <label>78.</label>
      <mixed-citation publication-type="other">Yang R, Pfütze K, Zucknick M, Sutter C, Wappenschmidt B, Marme F, et al. DNA methylation array analyses identified breast cancer associated HYAL2 methylation in peripheral blood. Int J Cancer. 2015;136:1845–55.</mixed-citation>
    </ref>
    <ref id="CR79">
      <label>79.</label>
      <mixed-citation publication-type="other">Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009;9:3802–9.</mixed-citation>
    </ref>
    <ref id="CR80">
      <label>80.</label>
      <mixed-citation publication-type="other">Yokoyama Y, Matsumoto A, Hieda M, Shinchi Y, Ogihara E, Hamada M, et al. Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Res. 2014;3:R66.</mixed-citation>
    </ref>
    <ref id="CR81">
      <label>81.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dhingra</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Mittal</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sarma</surname>
            <given-names>GS</given-names>
          </name>
        </person-group>
        <article-title>Analytical Techniques for DNA Methylation–An Overview</article-title>
        <source>Curr Pharm Anal</source>
        <year>2014</year>
        <volume>1</volume>
        <fpage>71</fpage>
        <lpage>85</lpage>
        <pub-id pub-id-type="doi">10.2174/157341291001140102111956</pub-id>
      </element-citation>
    </ref>
    <ref id="CR82">
      <label>82.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szyf</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>DNA methylation signatures for breast cancer classification and prognosis</article-title>
        <source>Genome Med</source>
        <year>2012</year>
        <volume>3</volume>
        <fpage>26</fpage>
        <pub-id pub-id-type="doi">10.1186/gm325</pub-id>
        <pub-id pub-id-type="pmid">22494847</pub-id>
      </element-citation>
    </ref>
    <ref id="CR83">
      <label>83.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gitan</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>PS</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>TH</given-names>
          </name>
        </person-group>
        <article-title>Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis</article-title>
        <source>Genome Res</source>
        <year>2002</year>
        <volume>1</volume>
        <fpage>158</fpage>
        <lpage>164</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.202801</pub-id>
        <pub-id pub-id-type="pmid">11779841</pub-id>
      </element-citation>
    </ref>
    <ref id="CR84">
      <label>84.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Pastor</surname>
            <given-names>WA</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tahiliani</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Rao</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing</article-title>
        <source>PLoS ONE</source>
        <year>2010</year>
        <volume>5</volume>
        <fpage>e8888</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0008888</pub-id>
        <?supplied-pmid 20126651?>
        <pub-id pub-id-type="pmid">20126651</pub-id>
      </element-citation>
    </ref>
    <ref id="CR85">
      <label>85.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Perry</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Laux</surname>
            <given-names>DE</given-names>
          </name>
        </person-group>
        <article-title>Methylation profiling of CpG islands in human breast cancer cells</article-title>
        <source>Hum Mol Genet</source>
        <year>1999</year>
        <volume>3</volume>
        <fpage>459</fpage>
        <lpage>470</lpage>
        <pub-id pub-id-type="doi">10.1093/hmg/8.3.459</pub-id>
        <pub-id pub-id-type="pmid">9949205</pub-id>
      </element-citation>
    </ref>
    <ref id="CR86">
      <label>86.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yan</surname>
            <given-names>PS</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Rahmatpanah</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>TH</given-names>
          </name>
        </person-group>
        <article-title>Applications of CpG island microarrays for high-throughput analysis of DNA methylation</article-title>
        <source>J Nutr</source>
        <year>2002</year>
        <volume>132</volume>
        <issue>8 Suppl</issue>
        <fpage>S2430</fpage>
        <lpage>S2434</lpage>
      </element-citation>
    </ref>
    <ref id="CR87">
      <label>87.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schumacher</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kapranov</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kaminsky</surname>
            <given-names>Z</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Microarray-based DNA methylation profiling: technology and applications</article-title>
        <source>Nucleic Acids Res</source>
        <year>2006</year>
        <volume>2</volume>
        <fpage>528</fpage>
        <lpage>542</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkj461</pub-id>
        <pub-id pub-id-type="pmid">16428248</pub-id>
      </element-citation>
    </ref>
    <ref id="CR88">
      <label>88.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mohn</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Weber</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Schübeler</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Roloff</surname>
            <given-names>TC</given-names>
          </name>
        </person-group>
        <article-title>Methylated DNA immunoprecipitation (MeDIP)</article-title>
        <source>Methods Mol Biol</source>
        <year>2009</year>
        <volume>507</volume>
        <fpage>55</fpage>
        <lpage>64</lpage>
        <pub-id pub-id-type="doi">10.1007/978-1-59745-522-0_5</pub-id>
        <?supplied-pmid 18987806?>
        <pub-id pub-id-type="pmid">18987806</pub-id>
      </element-citation>
    </ref>
    <ref id="CR89">
      <label>89.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Lowdon</surname>
            <given-names>RF</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Nagarajan</surname>
            <given-names>RP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&amp;M algorithm</article-title>
        <source>Genome Res</source>
        <year>2013</year>
        <volume>23</volume>
        <fpage>1522</fpage>
        <lpage>1540</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.156539.113</pub-id>
        <?supplied-pmid 23804400?>
        <pub-id pub-id-type="pmid">23804400</pub-id>
      </element-citation>
    </ref>
    <ref id="CR90">
      <label>90.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Challenges in understanding genome-wide DNA methylation</article-title>
        <source>J Comput Sci Technol</source>
        <year>2010</year>
        <volume>1</volume>
        <fpage>26</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="doi">10.1007/s11390-010-9302-8</pub-id>
      </element-citation>
    </ref>
    <ref id="CR91">
      <label>91.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bhasin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Reinherz</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Reche</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Prediction of methylated CpGs in DNA sequences using a support vector machine</article-title>
        <source>FEBS Lett</source>
        <year>2005</year>
        <volume>579</volume>
        <fpage>4302</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1016/j.febslet.2005.07.002</pub-id>
        <?supplied-pmid 16051225?>
        <pub-id pub-id-type="pmid">16051225</pub-id>
      </element-citation>
    </ref>
    <ref id="CR92">
      <label>92.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Qian</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Predicting DNA methylation status using word composition</article-title>
        <source>J Biomedical Science and Engineering</source>
        <year>2010</year>
        <volume>3</volume>
        <fpage>672</fpage>
        <lpage>676</lpage>
        <pub-id pub-id-type="doi">10.4236/jbise.2010.37091</pub-id>
      </element-citation>
    </ref>
    <ref id="CR93">
      <label>93.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Ali</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Seker</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Detailed methylation prediction of CpG islands on human chromosome 21. 10th WSEAS International Conference on Mathematics and Computers</article-title>
        <source>Biology and Chemistry</source>
        <year>2009</year>
        <fpage>147</fpage>
        <lpage>152</lpage>
      </element-citation>
    </ref>
    <ref id="CR94">
      <label>94.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Histone methylation marks play important roles in predicting the methylation status of CpG islands</article-title>
        <source>Biochem Biophys Res Commun</source>
        <year>2008</year>
        <volume>374</volume>
        <fpage>559</fpage>
        <lpage>564</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bbrc.2008.07.077</pub-id>
        <?supplied-pmid 18656446?>
        <pub-id pub-id-type="pmid">18656446</pub-id>
      </element-citation>
    </ref>
    <ref id="CR95">
      <label>95.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Previti</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Harari</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Zwir</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>del Val</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Profile analysis and prediction of tissue-specific CpG island methylation classes</article-title>
        <source>BMC Bioinformatics</source>
        <year>2009</year>
        <volume>10</volume>
        <fpage>116</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-10-116</pub-id>
        <?supplied-pmid 19383127?>
        <pub-id pub-id-type="pmid">19383127</pub-id>
      </element-citation>
    </ref>
    <ref id="CR96">
      <label>96.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bell</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Pai</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Pickrell</surname>
            <given-names>JK</given-names>
          </name>
          <name>
            <surname>Gaffney</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Pique-Regi</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Degner</surname>
            <given-names>JF</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines</article-title>
        <source>Genome Biol</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>R10</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2011-12-1-r10</pub-id>
        <?supplied-pmid 21251332?>
        <pub-id pub-id-type="pmid">21251332</pub-id>
      </element-citation>
    </ref>
    <ref id="CR97">
      <label>97.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eckhardt</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Lewin</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cortese</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Rakyan</surname>
            <given-names>VK</given-names>
          </name>
          <name>
            <surname>Attwood</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Burger</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DNA methylation profiling of human chromosomes 6, 20 and 22</article-title>
        <source>Nat Genet</source>
        <year>2006</year>
        <volume>38</volume>
        <fpage>1378</fpage>
        <lpage>85</lpage>
        <pub-id pub-id-type="doi">10.1038/ng1909</pub-id>
        <?supplied-pmid 17072317?>
        <pub-id pub-id-type="pmid">17072317</pub-id>
      </element-citation>
    </ref>
    <ref id="CR98">
      <label>98.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Spector</surname>
            <given-names>TD</given-names>
          </name>
          <name>
            <surname>Deloukas</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bell</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Engelhardt</surname>
            <given-names>BE</given-names>
          </name>
        </person-group>
        <article-title>Predicting genome-wide DNA methylation using methylation marks, genomic position, and DNA regulatory elements</article-title>
        <source>Genome Biol</source>
        <year>2015</year>
        <volume>16</volume>
        <fpage>14</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-015-0581-9</pub-id>
        <?supplied-pmid 25616342?>
        <pub-id pub-id-type="pmid">25616342</pub-id>
      </element-citation>
    </ref>
    <ref id="CR99">
      <label>99.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Du</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bourgon</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <source>methyAnalysis: DNA methylation data analysis and visualization. R package version 1.10.0</source>
        <year>2014</year>
      </element-citation>
    </ref>
    <ref id="CR100">
      <label>100.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barfield</surname>
            <given-names>RT</given-names>
          </name>
          <name>
            <surname>Kilaru</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Conneely</surname>
            <given-names>KN</given-names>
          </name>
        </person-group>
        <article-title>CpGassoc: an R function for analysis of DNA methylation microarray data</article-title>
        <source>Bioinformatics</source>
        <year>2012</year>
        <volume>9</volume>
        <fpage>1280</fpage>
        <lpage>1</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bts124</pub-id>
        <pub-id pub-id-type="pmid">22451269</pub-id>
      </element-citation>
    </ref>
    <ref id="CR101">
      <label>101.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Assenov</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Mueller</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Lutsik</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Walter</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lengauer</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Bock</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Compehensive Analysis of DNA Methylation Data with RnBeads</article-title>
        <source>Nat Methods</source>
        <year>2014</year>
        <volume>11</volume>
        <fpage>1138</fpage>
        <lpage>1140</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth.3115</pub-id>
        <?supplied-pmid 25262207?>
        <pub-id pub-id-type="pmid">25262207</pub-id>
      </element-citation>
    </ref>
    <ref id="CR102">
      <label>102.</label>
      <mixed-citation publication-type="other">Wang D, Yan L, Hu Q, Sucheston LE, Higgins MJ, Ambrosone CB, et al. IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics. 2012;5:729–30.</mixed-citation>
    </ref>
    <ref id="CR103">
      <label>103.</label>
      <mixed-citation publication-type="other">Price EM, Cotton AM, Lam LL, Farré P, Emberly E, Brown CJ, et al. Additional annotation enhances potential for biologically-relevant analysis of the illumina infinium humanmethylation450 beadchip array. Epigenetics Chromatin. 2013;1:4.</mixed-citation>
    </ref>
    <ref id="CR104">
      <label>104.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aryee</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Jaffe</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Corrada-Bravo</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ladd-Acosta</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Feinberg</surname>
            <given-names>AP</given-names>
          </name>
        </person-group>
        <article-title>Hansen KD and Irizarry RA Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA Methylation microarrays</article-title>
        <source>Bioinformatics</source>
        <year>2014</year>
        <volume>10</volume>
        <fpage>1363</fpage>
        <lpage>1369</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu049</pub-id>
        <pub-id pub-id-type="pmid">24478339</pub-id>
      </element-citation>
    </ref>
    <ref id="CR105">
      <label>105.</label>
      <mixed-citation publication-type="other">Jaffe AE, Murakami P, Lee H, Leek JT, Fallin DM, Feinberg AP, et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol. 2012;1:200–9.</mixed-citation>
    </ref>
    <ref id="CR106">
      <label>106.</label>
      <mixed-citation publication-type="other">Kanduri M, Cahill N, Göransson H, Enström C, Ryan F, Isaksson A, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;2:296–305.</mixed-citation>
    </ref>
    <ref id="CR107">
      <label>107.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wessely</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Emes</surname>
            <given-names>RD</given-names>
          </name>
        </person-group>
        <article-title>Identification of DNA methylation biomarkers from Infinium arrays</article-title>
        <source>Front Genet</source>
        <year>2012</year>
        <volume>3</volume>
        <fpage>161</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2012.00161</pub-id>
        <?supplied-pmid 22936948?>
        <pub-id pub-id-type="pmid">22936948</pub-id>
      </element-citation>
    </ref>
    <ref id="CR108">
      <label>108.</label>
      <mixed-citation publication-type="other">Wilhelm-Benartzi CS, Koestler DC, Karagas MR, Flanagan JM, Christensen BC, Kelsey KT, et al. Review of processing and analysis methods for DNA methylation array data. Br J Cancer. 2013;6:1394–402.</mixed-citation>
    </ref>
    <ref id="CR109">
      <label>109.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Phipson</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Oshlack</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>DiffVar: a new method for detecting differential variability with application to methylation in cancer and aging</article-title>
        <source>Genome Biol</source>
        <year>2014</year>
        <volume>9</volume>
        <fpage>465</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-014-0465-4</pub-id>
        <pub-id pub-id-type="pmid">25245051</pub-id>
      </element-citation>
    </ref>
    <ref id="CR110">
      <label>110.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Goeman</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Bühlmann</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Analyzing gene expression data in terms of gene sets: methodological issues</article-title>
        <source>Bioinformatics</source>
        <year>2007</year>
        <volume>23</volume>
        <issue>8</issue>
        <fpage>980</fpage>
        <lpage>987</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btm051</pub-id>
        <?supplied-pmid 17303618?>
        <pub-id pub-id-type="pmid">17303618</pub-id>
      </element-citation>
    </ref>
    <ref id="CR111">
      <label>111.</label>
      <mixed-citation publication-type="other">Zhao N, Bell DA, Maity A, Staicu AM, Joubert BR, London SJ, et al. Global analysis of methylation profiles from high resolution CpG data. Genet Epidemiol. 2012;2:53–64.</mixed-citation>
    </ref>
    <ref id="CR112">
      <label>112.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Westfall</surname>
            <given-names>PH</given-names>
          </name>
          <name>
            <surname>Stanley Young</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <source>Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment</source>
        <year>1993</year>
        <publisher-loc>New York</publisher-loc>
        <publisher-name>Wiley-Interscience</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR113">
      <label>113.</label>
      <mixed-citation publication-type="other">Teng M, Wang Y, Kim S, Li L, Shen C, Wang G, et al. Empirical bayes model comparisons for differential methylation analysis. Comp Funct Genomics. 2012;2012:376706.</mixed-citation>
    </ref>
    <ref id="CR114">
      <label>114.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Pape</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Dye</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>An evaluation of statistical methods for DNA methylation microarray data analysis</article-title>
        <source>BMC Bioinformatics</source>
        <year>2015</year>
        <volume>16</volume>
        <fpage>217</fpage>
        <pub-id pub-id-type="doi">10.1186/s12859-015-0641-x</pub-id>
        <?supplied-pmid 26156501?>
        <pub-id pub-id-type="pmid">26156501</pub-id>
      </element-citation>
    </ref>
    <ref id="CR115">
      <label>115.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Subramaniam</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Thombre</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Dhar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Anant</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>DNA methyltransferases: a novel target for prevention and therapy</article-title>
        <source>Front Oncol</source>
        <year>2014</year>
        <volume>4</volume>
        <fpage>80</fpage>
        <pub-id pub-id-type="doi">10.3389/fonc.2014.00080</pub-id>
        <?supplied-pmid 24822169?>
        <pub-id pub-id-type="pmid">24822169</pub-id>
      </element-citation>
    </ref>
    <ref id="CR116">
      <label>116.</label>
      <mixed-citation publication-type="other">Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007;25:4603–9.</mixed-citation>
    </ref>
    <ref id="CR117">
      <label>117.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pouliot</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Labrie</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Diorio</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Durocher</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>The Role of Methylation in Breast Cancer Susceptibility and Treatment</article-title>
        <source>Anticancer Res</source>
        <year>2015</year>
        <volume>9</volume>
        <fpage>4569</fpage>
        <lpage>74</lpage>
        <pub-id pub-id-type="pmid">26254344</pub-id>
      </element-citation>
    </ref>
    <ref id="CR118">
      <label>118.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shabashvili</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Nawab</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>SX</given-names>
          </name>
          <name>
            <surname>Dyer</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>KD</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer</article-title>
        <source>Mol Cancer Ther</source>
        <year>2012</year>
        <volume>11</volume>
        <fpage>370</fpage>
        <lpage>382</lpage>
        <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0458</pub-id>
        <?supplied-pmid 22203734?>
        <pub-id pub-id-type="pmid">22203734</pub-id>
      </element-citation>
    </ref>
    <ref id="CR119">
      <label>119.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Billam</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sobolewski</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Davidson</surname>
            <given-names>NE</given-names>
          </name>
        </person-group>
        <article-title>Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells</article-title>
        <source>Breast Cancer Res Treat</source>
        <year>2010</year>
        <volume>120</volume>
        <fpage>581</fpage>
        <lpage>592</lpage>
        <pub-id pub-id-type="doi">10.1007/s10549-009-0420-3</pub-id>
        <?supplied-pmid 19459041?>
        <pub-id pub-id-type="pmid">19459041</pub-id>
      </element-citation>
    </ref>
    <ref id="CR120">
      <label>120.</label>
      <mixed-citation publication-type="other">Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, et al. Delivery of 5-aza-2’-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007;67:6400–8.</mixed-citation>
    </ref>
    <ref id="CR121">
      <label>121.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nie</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors</article-title>
        <source>Cancer Lett</source>
        <year>2014</year>
        <volume>354</volume>
        <fpage>12</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="doi">10.1016/j.canlet.2014.08.010</pub-id>
        <?supplied-pmid 25130173?>
        <pub-id pub-id-type="pmid">25130173</pub-id>
      </element-citation>
    </ref>
    <ref id="CR122">
      <label>122.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Marson</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer</article-title>
        <source>Anticancer Agents Med Chem</source>
        <year>2009</year>
        <volume>9</volume>
        <fpage>661</fpage>
        <lpage>692</lpage>
        <pub-id pub-id-type="doi">10.2174/187152009788679976</pub-id>
        <?supplied-pmid 19601748?>
        <pub-id pub-id-type="pmid">19601748</pub-id>
      </element-citation>
    </ref>
    <ref id="CR123">
      <label>123.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Munster</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>Thurn</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Raha</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Lacevic</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</article-title>
        <source>Br J Cancer</source>
        <year>2011</year>
        <volume>104</volume>
        <fpage>1828</fpage>
        <lpage>1835</lpage>
        <pub-id pub-id-type="doi">10.1038/bjc.2011.156</pub-id>
        <?supplied-pmid 21559012?>
        <pub-id pub-id-type="pmid">21559012</pub-id>
      </element-citation>
    </ref>
    <ref id="CR124">
      <label>124.</label>
      <mixed-citation publication-type="other">Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;17:2128–35.</mixed-citation>
    </ref>
    <ref id="CR125">
      <label>125.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bartel</surname>
            <given-names>DP</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title>
        <source>Cell</source>
        <year>2004</year>
        <volume>116</volume>
        <fpage>281</fpage>
        <lpage>297</lpage>
        <pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id>
        <?supplied-pmid 14744438?>
        <pub-id pub-id-type="pmid">14744438</pub-id>
      </element-citation>
    </ref>
    <ref id="CR126">
      <label>126.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pasquinelli</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bracht</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs: a developing story</article-title>
        <source>Curr Opin Genet Dev</source>
        <year>2005</year>
        <volume>15</volume>
        <fpage>200</fpage>
        <lpage>205</lpage>
        <pub-id pub-id-type="doi">10.1016/j.gde.2005.01.002</pub-id>
        <?supplied-pmid 15797203?>
        <pub-id pub-id-type="pmid">15797203</pub-id>
      </element-citation>
    </ref>
    <ref id="CR127">
      <label>127.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Iorio</surname>
            <given-names>MV</given-names>
          </name>
          <name>
            <surname>Croce</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review</article-title>
        <source>EMBO Mol Med</source>
        <year>2012</year>
        <volume>4</volume>
        <issue>3</issue>
        <fpage>143</fpage>
        <lpage>159</lpage>
        <pub-id pub-id-type="doi">10.1002/emmm.201100209</pub-id>
        <?supplied-pmid 22351564?>
        <pub-id pub-id-type="pmid">22351564</pub-id>
      </element-citation>
    </ref>
    <ref id="CR128">
      <label>128.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Blenkiron</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Goldstein</surname>
            <given-names>LD</given-names>
          </name>
          <name>
            <surname>Thorne</surname>
            <given-names>NP</given-names>
          </name>
          <name>
            <surname>Spiteri</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Chin</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Dunning</surname>
            <given-names>MJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype</article-title>
        <source>Genome Biol</source>
        <year>2007</year>
        <volume>8</volume>
        <fpage>R214</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2007-8-10-r214</pub-id>
        <?supplied-pmid 17922911?>
        <pub-id pub-id-type="pmid">17922911</pub-id>
      </element-citation>
    </ref>
    <ref id="CR129">
      <label>129.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Iorio</surname>
            <given-names>MV</given-names>
          </name>
          <name>
            <surname>Ferracin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Veronese</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Spizzo</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Sabbioni</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA gene expression deregulation in human breast cancer</article-title>
        <source>Cancer Res</source>
        <year>2005</year>
        <volume>65</volume>
        <fpage>7065</fpage>
        <lpage>7070</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1783</pub-id>
        <?supplied-pmid 16103053?>
        <pub-id pub-id-type="pmid">16103053</pub-id>
      </element-citation>
    </ref>
    <ref id="CR130">
      <label>130.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lowery</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Devaney</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>McNeill</surname>
            <given-names>RE</given-names>
          </name>
          <name>
            <surname>Davoren</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Lemetre</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer</article-title>
        <source>Breast Cancer Res</source>
        <year>2009</year>
        <volume>11</volume>
        <fpage>R27</fpage>
        <pub-id pub-id-type="doi">10.1186/bcr2257</pub-id>
        <?supplied-pmid 19432961?>
        <pub-id pub-id-type="pmid">19432961</pub-id>
      </element-citation>
    </ref>
    <ref id="CR131">
      <label>131.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mattie</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Benz</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Bowers</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Sensinger</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>GK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies</article-title>
        <source>Mol Cancer</source>
        <year>2006</year>
        <volume>5</volume>
        <fpage>24</fpage>
        <pub-id pub-id-type="doi">10.1186/1476-4598-5-24</pub-id>
        <?supplied-pmid 16784538?>
        <pub-id pub-id-type="pmid">16784538</pub-id>
      </element-citation>
    </ref>
    <ref id="CR132">
      <label>132.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gregory</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Bracken</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Bert</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Goodall</surname>
            <given-names>GJ</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs as regulators of epithelial–mesenchymal transition</article-title>
        <source>Cell Cycle</source>
        <year>2008</year>
        <volume>7</volume>
        <fpage>3112</fpage>
        <lpage>3118</lpage>
        <pub-id pub-id-type="doi">10.4161/cc.7.20.6851</pub-id>
        <?supplied-pmid 18927505?>
        <pub-id pub-id-type="pmid">18927505</pub-id>
      </element-citation>
    </ref>
    <ref id="CR133">
      <label>133.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sempere</surname>
            <given-names>LF</given-names>
          </name>
          <name>
            <surname>Christensen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Silahtaroglu</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bak</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Heath</surname>
            <given-names>CV</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer</article-title>
        <source>Cancer Res</source>
        <year>2007</year>
        <volume>67</volume>
        <fpage>11612</fpage>
        <lpage>11620</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5019</pub-id>
        <?supplied-pmid 18089790?>
        <pub-id pub-id-type="pmid">18089790</pub-id>
      </element-citation>
    </ref>
    <ref id="CR134">
      <label>134.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Xi</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression</article-title>
        <source>J Biol Chem</source>
        <year>2010</year>
        <volume>285</volume>
        <fpage>21496</fpage>
        <lpage>22507</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M109.083337</pub-id>
        <?supplied-pmid 20460378?>
        <pub-id pub-id-type="pmid">20460378</pub-id>
      </element-citation>
    </ref>
    <ref id="CR135">
      <label>135.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Taylor</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Sossey-Alaoui</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Danielpour</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Schiemann</surname>
            <given-names>WP</given-names>
          </name>
        </person-group>
        <article-title>TGF-beta upregulates miR-181a expression to promote breast cancer metastasis</article-title>
        <source>J Clin Invest</source>
        <year>2013</year>
        <volume>123</volume>
        <fpage>150</fpage>
        <lpage>163</lpage>
        <pub-id pub-id-type="doi">10.1172/JCI64946</pub-id>
        <?supplied-pmid 23241956?>
        <pub-id pub-id-type="pmid">23241956</pub-id>
      </element-citation>
    </ref>
    <ref id="CR136">
      <label>136.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Iwanaga</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Drasin</surname>
            <given-names>DJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer</article-title>
        <source>Oncogene</source>
        <year>2012</year>
        <volume>31</volume>
        <fpage>5162</fpage>
        <lpage>5171</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2012.11</pub-id>
        <?supplied-pmid 22286770?>
        <pub-id pub-id-type="pmid">22286770</pub-id>
      </element-citation>
    </ref>
    <ref id="CR137">
      <label>137.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>de Souza Rocha Simonini</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Breiling</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gupta</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells</article-title>
        <source>Cancer Res</source>
        <year>2010</year>
        <volume>70</volume>
        <fpage>9175</fpage>
        <lpage>9184</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1318</pub-id>
        <?supplied-pmid 20978187?>
        <pub-id pub-id-type="pmid">20978187</pub-id>
      </element-citation>
    </ref>
    <ref id="CR138">
      <label>138.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Reddy</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Ohshiro</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Rayala</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions</article-title>
        <source>Cancer Res</source>
        <year>2008</year>
        <volume>68</volume>
        <fpage>8195</fpage>
        <lpage>200</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2103</pub-id>
        <?supplied-pmid 18922890?>
        <pub-id pub-id-type="pmid">18922890</pub-id>
      </element-citation>
    </ref>
    <ref id="CR139">
      <label>139.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Webster</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Giles</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Price</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Mattick</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Leedman</surname>
            <given-names>PJ</given-names>
          </name>
        </person-group>
        <article-title>Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7</article-title>
        <source>J Biol Chem</source>
        <year>2009</year>
        <volume>284</volume>
        <fpage>5731</fpage>
        <lpage>41</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M804280200</pub-id>
        <?supplied-pmid 19073608?>
        <pub-id pub-id-type="pmid">19073608</pub-id>
      </element-citation>
    </ref>
    <ref id="CR140">
      <label>140.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Willmarth</surname>
            <given-names>NE</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Katiyar</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2010</year>
        <volume>107</volume>
        <fpage>8231</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1002080107</pub-id>
        <?supplied-pmid 20406904?>
        <pub-id pub-id-type="pmid">20406904</pub-id>
      </element-citation>
    </ref>
    <ref id="CR141">
      <label>141.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Casimiro</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A cyclin D1/microRNA 17/20 regulatory feed-back loop in control of breast cancer cell proliferation</article-title>
        <source>J Cell Biol</source>
        <year>2008</year>
        <volume>182</volume>
        <fpage>509</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="doi">10.1083/jcb.200801079</pub-id>
        <?supplied-pmid 18695042?>
        <pub-id pub-id-type="pmid">18695042</pub-id>
      </element-citation>
    </ref>
    <ref id="CR142">
      <label>142.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Takeshita</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Hino</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Fukunaga</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kudo</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tamaki</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miR-22 represses cancer progres-sion by inducing cellular senescence</article-title>
        <source>J Cell Biol</source>
        <year>2011</year>
        <volume>193</volume>
        <fpage>409</fpage>
        <lpage>24</lpage>
        <pub-id pub-id-type="doi">10.1083/jcb.201010100</pub-id>
        <?supplied-pmid 21502362?>
        <pub-id pub-id-type="pmid">21502362</pub-id>
      </element-citation>
    </ref>
    <ref id="CR143">
      <label>143.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Patel</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Appaiah</surname>
            <given-names>HN</given-names>
          </name>
          <name>
            <surname>Burnett</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Bhat-Nakshatri</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Mehta</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22</article-title>
        <source>Oncogene</source>
        <year>2011</year>
        <volume>30</volume>
        <fpage>1290</fpage>
        <lpage>301</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2010.510</pub-id>
        <?supplied-pmid 21057539?>
        <pub-id pub-id-type="pmid">21057539</pub-id>
      </element-citation>
    </ref>
    <ref id="CR144">
      <label>144.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pandey</surname>
            <given-names>DP</given-names>
          </name>
          <name>
            <surname>Picard</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA</article-title>
        <source>Mol Cell Biol</source>
        <year>2009</year>
        <volume>29</volume>
        <fpage>3783</fpage>
        <lpage>90</lpage>
        <pub-id pub-id-type="doi">10.1128/MCB.01875-08</pub-id>
        <?supplied-pmid 19414598?>
        <pub-id pub-id-type="pmid">19414598</pub-id>
      </element-citation>
    </ref>
    <ref id="CR145">
      <label>145.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Beck</surname>
            <given-names>WT</given-names>
          </name>
          <name>
            <surname>Mo</surname>
            <given-names>YY</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA- mediated regulation of Ubc9 expression in cancer cells</article-title>
        <source>Clin Cancer Res</source>
        <year>2009</year>
        <volume>15</volume>
        <fpage>1550</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0820</pub-id>
        <?supplied-pmid 19223510?>
        <pub-id pub-id-type="pmid">19223510</pub-id>
      </element-citation>
    </ref>
    <ref id="CR146">
      <label>146.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells</article-title>
        <source>Oncogene</source>
        <year>2010</year>
        <volume>29</volume>
        <fpage>4194</fpage>
        <lpage>204</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2010.167</pub-id>
        <?supplied-pmid 20498642?>
        <pub-id pub-id-type="pmid">20498642</pub-id>
      </element-citation>
    </ref>
    <ref id="CR147">
      <label>147.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Valastyan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Reinhardt</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Benaich</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Calogrias</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Szász</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>ZC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis</article-title>
        <source>Cell</source>
        <year>2009</year>
        <volume>137</volume>
        <fpage>1032</fpage>
        <lpage>46</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2009.03.047</pub-id>
        <?supplied-pmid 19524507?>
        <pub-id pub-id-type="pmid">19524507</pub-id>
      </element-citation>
    </ref>
    <ref id="CR148">
      <label>148.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Valastyan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Benaich</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Reinhardt</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis</article-title>
        <source>Cancer Res</source>
        <year>2010</year>
        <volume>70</volume>
        <fpage>5147</fpage>
        <lpage>54</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0410</pub-id>
        <?supplied-pmid 20530680?>
        <pub-id pub-id-type="pmid">20530680</pub-id>
      </element-citation>
    </ref>
    <ref id="CR149">
      <label>149.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Valastyan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Benaich</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Reinhardt</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis</article-title>
        <source>Genes Dev</source>
        <year>2009</year>
        <volume>23</volume>
        <fpage>2592</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.1832709</pub-id>
        <?supplied-pmid 19875476?>
        <pub-id pub-id-type="pmid">19875476</pub-id>
      </element-citation>
    </ref>
    <ref id="CR150">
      <label>150.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Harris</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Yamakuchi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ferlito</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mendell</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Lowenstein</surname>
            <given-names>CJ</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2008</year>
        <volume>105</volume>
        <fpage>1516</fpage>
        <lpage>21</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0707493105</pub-id>
        <?supplied-pmid 18227515?>
        <pub-id pub-id-type="pmid">18227515</pub-id>
      </element-citation>
    </ref>
    <ref id="CR151">
      <label>151.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sachdeva</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Walia</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>p53 represses c-Myc through induction of the tumor suppressor miR-145</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2009</year>
        <volume>106</volume>
        <fpage>3207</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0808042106</pub-id>
        <?supplied-pmid 19202062?>
        <pub-id pub-id-type="pmid">19202062</pub-id>
      </element-citation>
    </ref>
    <ref id="CR152">
      <label>152.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hurst</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Edmonds</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Scott</surname>
            <given-names>GK</given-names>
          </name>
          <name>
            <surname>Benz</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Vaidya</surname>
            <given-names>KS</given-names>
          </name>
          <name>
            <surname>Welch</surname>
            <given-names>DR</given-names>
          </name>
        </person-group>
        <article-title>Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis</article-title>
        <source>Cancer Res</source>
        <year>2009</year>
        <volume>69</volume>
        <fpage>1279</fpage>
        <lpage>83</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3559</pub-id>
        <?supplied-pmid 19190326?>
        <pub-id pub-id-type="pmid">19190326</pub-id>
      </element-citation>
    </ref>
    <ref id="CR153">
      <label>153.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>XF</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Shao</surname>
            <given-names>ZM</given-names>
          </name>
        </person-group>
        <article-title>Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer</article-title>
        <source>Oncogene</source>
        <year>2009</year>
        <volume>28</volume>
        <fpage>3937</fpage>
        <lpage>48</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2009.245</pub-id>
        <?supplied-pmid 19701247?>
        <pub-id pub-id-type="pmid">19701247</pub-id>
      </element-citation>
    </ref>
    <ref id="CR154">
      <label>154.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mo</surname>
            <given-names>YY</given-names>
          </name>
        </person-group>
        <article-title>Suppression of cell growth and invasion by miR-205 in breast cancer</article-title>
        <source>Cell Res</source>
        <year>2009</year>
        <volume>19</volume>
        <fpage>439</fpage>
        <lpage>48</lpage>
        <pub-id pub-id-type="doi">10.1038/cr.2009.18</pub-id>
        <?supplied-pmid 19238171?>
        <pub-id pub-id-type="pmid">19238171</pub-id>
      </element-citation>
    </ref>
    <ref id="CR155">
      <label>155.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Song</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation</article-title>
        <source>J Biol Chem</source>
        <year>2009</year>
        <volume>284</volume>
        <fpage>31921</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M109.046862</pub-id>
        <?supplied-pmid 19723635?>
        <pub-id pub-id-type="pmid">19723635</pub-id>
      </element-citation>
    </ref>
    <ref id="CR156">
      <label>156.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Edmonds</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Hurst</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Vaidya</surname>
            <given-names>KS</given-names>
          </name>
          <name>
            <surname>Stafford</surname>
            <given-names>LJ</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Welch</surname>
            <given-names>DR</given-names>
          </name>
        </person-group>
        <article-title>Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression</article-title>
        <source>Int J Cancer</source>
        <year>2009</year>
        <volume>125</volume>
        <fpage>1778</fpage>
        <lpage>85</lpage>
        <pub-id pub-id-type="doi">10.1002/ijc.24616</pub-id>
        <?supplied-pmid 19585508?>
        <pub-id pub-id-type="pmid">19585508</pub-id>
      </element-citation>
    </ref>
    <ref id="CR157">
      <label>157.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>QQ</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>ZQ</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>XX</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>YY</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells</article-title>
        <source>Cell Death Differ</source>
        <year>2011</year>
        <volume>18</volume>
        <fpage>16</fpage>
        <lpage>25</lpage>
        <pub-id pub-id-type="doi">10.1038/cdd.2010.103</pub-id>
        <?supplied-pmid 20798686?>
        <pub-id pub-id-type="pmid">20798686</pub-id>
      </element-citation>
    </ref>
    <ref id="CR158">
      <label>158.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Reddy</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Pakala</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Ohshiro</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Rayala</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions</article-title>
        <source>Cancer Res</source>
        <year>2009</year>
        <volume>69</volume>
        <fpage>5639</fpage>
        <lpage>42</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0898</pub-id>
        <?supplied-pmid 19584269?>
        <pub-id pub-id-type="pmid">19584269</pub-id>
      </element-citation>
    </ref>
    <ref id="CR159">
      <label>159.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>let-7 regulates self renewal and tumorigenicity of breast cancer cells</article-title>
        <source>Cell</source>
        <year>2007</year>
        <volume>131</volume>
        <fpage>1109</fpage>
        <lpage>23</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2007.10.054</pub-id>
        <?supplied-pmid 18083101?>
        <pub-id pub-id-type="pmid">18083101</pub-id>
      </element-citation>
    </ref>
    <ref id="CR160">
      <label>160.</label>
      <mixed-citation publication-type="other">Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.</mixed-citation>
    </ref>
    <ref id="CR161">
      <label>161.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Taylor</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Gercel-Taylor</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer</article-title>
        <source>Gynecol Oncol</source>
        <year>2008</year>
        <volume>110</volume>
        <fpage>13</fpage>
        <lpage>21</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ygyno.2008.04.033</pub-id>
        <?supplied-pmid 18589210?>
        <pub-id pub-id-type="pmid">18589210</pub-id>
      </element-citation>
    </ref>
    <ref id="CR162">
      <label>162.</label>
      <mixed-citation publication-type="other">Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010;16:34–8.</mixed-citation>
    </ref>
    <ref id="CR163">
      <label>163.</label>
      <mixed-citation publication-type="other">Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15:5473–7.</mixed-citation>
    </ref>
    <ref id="CR164">
      <label>164.</label>
      <mixed-citation publication-type="other">Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. Altered miRNA expression in sputum for diagnosis of nonsmall cell lung cancer. Lung Cancer. 2010;67:170–6.</mixed-citation>
    </ref>
    <ref id="CR165">
      <label>165.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Todd</surname>
            <given-names>NW</given-names>
          </name>
          <name>
            <surname>Xing</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers</article-title>
        <source>Int J Cancer</source>
        <year>2010</year>
        <volume>127</volume>
        <fpage>2870</fpage>
        <lpage>2878</lpage>
        <pub-id pub-id-type="doi">10.1002/ijc.25289</pub-id>
        <?supplied-pmid 21351266?>
        <pub-id pub-id-type="pmid">21351266</pub-id>
      </element-citation>
    </ref>
    <ref id="CR166">
      <label>166.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lodes</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Caraballo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Suciu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Munro</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Detection of cancer with serum miRNAs on an oligonucleotide microarray</article-title>
        <source>PLoS One</source>
        <year>2009</year>
        <volume>4</volume>
        <fpage>e6229</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0006229</pub-id>
        <?supplied-pmid 19597549?>
        <pub-id pub-id-type="pmid">19597549</pub-id>
      </element-citation>
    </ref>
    <ref id="CR167">
      <label>167.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Madhavan</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Cuk</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Burwinkel</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures</article-title>
        <source>Front Genet</source>
        <year>2013</year>
        <volume>4</volume>
        <fpage>116</fpage>
        <?supplied-pmid 23802013?>
        <pub-id pub-id-type="pmid">23802013</pub-id>
      </element-citation>
    </ref>
    <ref id="CR168">
      <label>168.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Si</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer</article-title>
        <source>J Cancer Res Clin Oncol</source>
        <year>2013</year>
        <volume>139</volume>
        <fpage>223</fpage>
        <lpage>229</lpage>
        <pub-id pub-id-type="doi">10.1007/s00432-012-1315-y</pub-id>
        <?supplied-pmid 23052693?>
        <pub-id pub-id-type="pmid">23052693</pub-id>
      </element-citation>
    </ref>
    <ref id="CR169">
      <label>169.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mar-Aguilar</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Mendoza-Ramirez</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Malagon-Santiago</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Espino-Silva</surname>
            <given-names>PK</given-names>
          </name>
          <name>
            <surname>Santuario-Facio</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Ruiz-Flores</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Serum circulating microRNA profiling for identification of potential breast cancer biomarkers</article-title>
        <source>Dis Markers</source>
        <year>2013</year>
        <volume>34</volume>
        <fpage>163</fpage>
        <lpage>169</lpage>
        <pub-id pub-id-type="doi">10.1155/2013/259454</pub-id>
        <?supplied-pmid 23334650?>
        <pub-id pub-id-type="pmid">23334650</pub-id>
      </element-citation>
    </ref>
    <ref id="CR170">
      <label>170.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zeng</surname>
            <given-names>RC</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>XQ</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>ZQ</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>ED</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>DP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer</article-title>
        <source>Med Oncol</source>
        <year>2013</year>
        <volume>30</volume>
        <fpage>477</fpage>
        <pub-id pub-id-type="doi">10.1007/s12032-013-0477-z</pub-id>
        <?supplied-pmid 23389917?>
        <pub-id pub-id-type="pmid">23389917</pub-id>
      </element-citation>
    </ref>
    <ref id="CR171">
      <label>171.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Madhavan</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zucknick</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wallwiener</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cuk</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Modugno</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Scharpff</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer</article-title>
        <source>Clin Cancer Res</source>
        <year>2012</year>
        <volume>18</volume>
        <fpage>5972</fpage>
        <lpage>5982</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1407</pub-id>
        <?supplied-pmid 22952344?>
        <pub-id pub-id-type="pmid">22952344</pub-id>
      </element-citation>
    </ref>
    <ref id="CR172">
      <label>172.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Barekati</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Zhong</surname>
            <given-names>XY</given-names>
          </name>
        </person-group>
        <article-title>The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers</article-title>
        <source>Tumour Biol</source>
        <year>2012</year>
        <volume>34</volume>
        <fpage>455</fpage>
        <lpage>462</lpage>
        <pub-id pub-id-type="doi">10.1007/s13277-012-0570-5</pub-id>
        <?supplied-pmid 23238818?>
        <pub-id pub-id-type="pmid">23238818</pub-id>
      </element-citation>
    </ref>
    <ref id="CR173">
      <label>173.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Z</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Circulating MiR-125b as a marker predicting chemoresistance in breast cancer</article-title>
        <source>PLoS ONE</source>
        <year>2012</year>
        <volume>7</volume>
        <fpage>e34210</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0034210</pub-id>
        <?supplied-pmid 22523546?>
        <pub-id pub-id-type="pmid">22523546</pub-id>
      </element-citation>
    </ref>
    <ref id="CR174">
      <label>174.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Qi</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Serum microRNA-155 as a potential biomarker to track disease in breast cancer</article-title>
        <source>PLoS ONE</source>
        <year>2012</year>
        <volume>7</volume>
        <fpage>e47003</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0047003</pub-id>
        <?supplied-pmid 23071695?>
        <pub-id pub-id-type="pmid">23071695</pub-id>
      </element-citation>
    </ref>
    <ref id="CR175">
      <label>175.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Thompson</surname>
            <given-names>RC</given-names>
          </name>
          <name>
            <surname>Deo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Turner</surname>
            <given-names>DL</given-names>
          </name>
        </person-group>
        <article-title>Analysis of microRNA expression by in situ hybridization with RNA oligonucleotide probes</article-title>
        <source>Methods</source>
        <year>2007</year>
        <volume>43</volume>
        <issue>2</issue>
        <fpage>153</fpage>
        <lpage>161</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ymeth.2007.04.008</pub-id>
        <?supplied-pmid 17889803?>
        <pub-id pub-id-type="pmid">17889803</pub-id>
      </element-citation>
    </ref>
    <ref id="CR176">
      <label>176.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stark</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Tyagi</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Nancarrow</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Boyle</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Cook</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Whiteman</surname>
            <given-names>PG</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Characterization of the Melanoma miRNAome by Deep Sequencing</article-title>
        <source>PLoS One</source>
        <year>2010</year>
        <volume>5</volume>
        <issue>3</issue>
        <fpage>e9685</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0009685</pub-id>
        <?supplied-pmid 20300190?>
        <pub-id pub-id-type="pmid">20300190</pub-id>
      </element-citation>
    </ref>
    <ref id="CR177">
      <label>177.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Farazi</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Horlings</surname>
            <given-names>HM</given-names>
          </name>
          <name>
            <surname>Ten Hoeve</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Mihailovic</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Halfwerk</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Morozov</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA sequence and expression analysis in breast tumors by deep sequencing</article-title>
        <source>Cancer Res</source>
        <year>2011</year>
        <volume>71</volume>
        <fpage>4443</fpage>
        <lpage>53</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0608</pub-id>
        <?supplied-pmid 21586611?>
        <pub-id pub-id-type="pmid">21586611</pub-id>
      </element-citation>
    </ref>
    <ref id="CR178">
      <label>178.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Ge</surname>
            <given-names>Q</given-names>
          </name>
        </person-group>
        <article-title>Next-generation sequencing of microRNAs for breast cancer detection</article-title>
        <source>J Biomed Biotechnol</source>
        <year>2011</year>
        <volume>2011</volume>
        <fpage>597145</fpage>
        <?supplied-pmid 21716661?>
        <pub-id pub-id-type="pmid">21716661</pub-id>
      </element-citation>
    </ref>
    <ref id="CR179">
      <label>179.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Jin</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Shu</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer</article-title>
        <source>J Clin Oncol Off J Am Soc Clin Oncol</source>
        <year>2010</year>
        <volume>28</volume>
        <fpage>1721</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2009.24.9342</pub-id>
      </element-citation>
    </ref>
    <ref id="CR180">
      <label>180.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>JZ</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>CW</given-names>
          </name>
        </person-group>
        <article-title>Hunting for robust gene signature from cancer profiling data: sources of variability, different interpretations, and recent methodological developments</article-title>
        <source>Cancer Lett</source>
        <year>2010</year>
        <volume>296</volume>
        <fpage>9</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1016/j.canlet.2010.05.008</pub-id>
        <?supplied-pmid 20579805?>
        <pub-id pub-id-type="pmid">20579805</pub-id>
      </element-citation>
    </ref>
    <ref id="CR181">
      <label>181.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Peltier</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Latham</surname>
            <given-names>GJ</given-names>
          </name>
        </person-group>
        <article-title>Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues</article-title>
        <source>RNA</source>
        <year>2008</year>
        <volume>14</volume>
        <fpage>844</fpage>
        <lpage>852</lpage>
        <pub-id pub-id-type="doi">10.1261/rna.939908</pub-id>
        <?supplied-pmid 18375788?>
        <pub-id pub-id-type="pmid">18375788</pub-id>
      </element-citation>
    </ref>
    <ref id="CR182">
      <label>182.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Maire</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Yoshimoto</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Chilton-MacNeill</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zielenska</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Squire</surname>
            <given-names>JA</given-names>
          </name>
        </person-group>
        <article-title>Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma</article-title>
        <source>Cancer Genetics</source>
        <year>2011</year>
        <volume>204</volume>
        <issue>3</issue>
        <fpage>138</fpage>
        <lpage>146</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cancergen.2010.12.012</pub-id>
        <?supplied-pmid 21504713?>
        <pub-id pub-id-type="pmid">21504713</pub-id>
      </element-citation>
    </ref>
    <ref id="CR183">
      <label>183.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Sanai</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment</article-title>
        <source>Oncol Rep</source>
        <year>2012</year>
        <volume>27</volume>
        <issue>5</issue>
        <fpage>1312</fpage>
        <lpage>1320</lpage>
        <?supplied-pmid 22366961?>
        <pub-id pub-id-type="pmid">22366961</pub-id>
      </element-citation>
    </ref>
    <ref id="CR184">
      <label>184.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lai</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Wiel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rubin</surname>
            <given-names>GM</given-names>
          </name>
        </person-group>
        <article-title>Complementary miRNA pairs suggest a regulatory role for miRNA:miRNA duplexes</article-title>
        <source>RNA</source>
        <year>2004</year>
        <volume>10</volume>
        <issue>2</issue>
        <fpage>171</fpage>
        <lpage>175</lpage>
        <pub-id pub-id-type="doi">10.1261/rna.5191904</pub-id>
        <?supplied-pmid 14730015?>
        <pub-id pub-id-type="pmid">14730015</pub-id>
      </element-citation>
    </ref>
    <ref id="CR185">
      <label>185.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrating miRNA and mRNA expression profiles in response to heat stress-induced injury in rat small intestine</article-title>
        <source>Funct Integr Genomics</source>
        <year>2011</year>
        <volume>11</volume>
        <issue>2</issue>
        <fpage>203</fpage>
        <lpage>213</lpage>
        <pub-id pub-id-type="doi">10.1007/s10142-010-0198-8</pub-id>
        <?supplied-pmid 21057845?>
        <pub-id pub-id-type="pmid">21057845</pub-id>
      </element-citation>
    </ref>
    <ref id="CR186">
      <label>186.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Tsykin</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identifying functional miRNA mRNA regulatory modules with correspondence latent dirichlet allocation</article-title>
        <source>Bioinformatics</source>
        <year>2010</year>
        <volume>26</volume>
        <issue>24</issue>
        <fpage>3105</fpage>
        <lpage>3111</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btq576</pub-id>
        <?supplied-pmid 20956247?>
        <pub-id pub-id-type="pmid">20956247</pub-id>
      </element-citation>
    </ref>
    <ref id="CR187">
      <label>187.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nielsen</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Lau</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Maric</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Barker</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Hudson</surname>
            <given-names>LD</given-names>
          </name>
        </person-group>
        <article-title>Integrating microRNA and mRNA expression profiles of neuronal progenitors to identify regulatory networks underlying the onset of cortical neurogenesis</article-title>
        <source>BMC Neurosci</source>
        <year>2009</year>
        <volume>10</volume>
        <fpage>98</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2202-10-98</pub-id>
        <?supplied-pmid 19689821?>
        <pub-id pub-id-type="pmid">19689821</pub-id>
      </element-citation>
    </ref>
    <ref id="CR188">
      <label>188.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Computational approaches for microRNA studies: a review</article-title>
        <source>Mamm Genome</source>
        <year>2010</year>
        <volume>21</volume>
        <issue>1–2</issue>
        <fpage>1</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="doi">10.1007/s00335-009-9241-2</pub-id>
        <?supplied-pmid 20012966?>
        <pub-id pub-id-type="pmid">20012966</pub-id>
      </element-citation>
    </ref>
    <ref id="CR189">
      <label>189.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Grad</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Aach</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hayes</surname>
            <given-names>GD</given-names>
          </name>
          <name>
            <surname>Reinhart</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Church</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Ruvkun</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Computational and experimental identification of C. elegans microRNAs. Mol</article-title>
        <source>Cell</source>
        <year>2003</year>
        <volume>11</volume>
        <fpage>1253</fpage>
        <lpage>1263</lpage>
      </element-citation>
    </ref>
    <ref id="CR190">
      <label>190.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lim</surname>
            <given-names>LP</given-names>
          </name>
          <name>
            <surname>Lau</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Weinstein</surname>
            <given-names>EG</given-names>
          </name>
          <name>
            <surname>Abdelhakim</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Yekta</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rhoades</surname>
            <given-names>MW</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The microRNAs of <italic>Caenorhabditis elegans</italic></article-title>
        <source>Genes Dev</source>
        <year>2003</year>
        <volume>17</volume>
        <fpage>991</fpage>
        <lpage>1008</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.1074403</pub-id>
        <?supplied-pmid 12672692?>
        <pub-id pub-id-type="pmid">12672692</pub-id>
      </element-citation>
    </ref>
    <ref id="CR191">
      <label>191.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lai</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Tomancak</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Rubin</surname>
            <given-names>GM</given-names>
          </name>
        </person-group>
        <article-title>Computational identification of <italic>Drosophila</italic> microRNA genes</article-title>
        <source>Genome Biol</source>
        <year>2003</year>
        <volume>4</volume>
        <fpage>R42</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2003-4-7-r42</pub-id>
        <?supplied-pmid 12844358?>
        <pub-id pub-id-type="pmid">12844358</pub-id>
      </element-citation>
    </ref>
    <ref id="CR192">
      <label>192.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>RC</given-names>
          </name>
          <name>
            <surname>Ambros</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <article-title>An extensive class of small RNAs in Caenorhabditis elegans</article-title>
        <source>Science</source>
        <year>2001</year>
        <volume>294</volume>
        <fpage>862</fpage>
        <lpage>864</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1065329</pub-id>
        <?supplied-pmid 11679672?>
        <pub-id pub-id-type="pmid">11679672</pub-id>
      </element-citation>
    </ref>
    <ref id="CR193">
      <label>193.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berezikov</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Guryev</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Van</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Belt</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wienholds</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Plasterk</surname>
            <given-names>RH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Phylogenetic shadowing and computational identification of human microRNA genes</article-title>
        <source>Cell</source>
        <year>2005</year>
        <volume>120</volume>
        <fpage>21</fpage>
        <lpage>24</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2004.12.031</pub-id>
        <?supplied-pmid 15652478?>
        <pub-id pub-id-type="pmid">15652478</pub-id>
      </element-citation>
    </ref>
    <ref id="CR194">
      <label>194.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bentwich</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Avniel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Karov</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Aharonov</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gilad</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of hundreds of conserved and nonconserved human microRNAs</article-title>
        <source>Nat Genet</source>
        <year>2005</year>
        <volume>37</volume>
        <fpage>766</fpage>
        <lpage>770</lpage>
        <pub-id pub-id-type="doi">10.1038/ng1590</pub-id>
        <?supplied-pmid 15965474?>
        <pub-id pub-id-type="pmid">15965474</pub-id>
      </element-citation>
    </ref>
    <ref id="CR195">
      <label>195.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hofacker</surname>
            <given-names>IL</given-names>
          </name>
          <name>
            <surname>Fontana</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Stadler</surname>
            <given-names>PF</given-names>
          </name>
          <name>
            <surname>Bonhoeffer</surname>
            <given-names>LS</given-names>
          </name>
          <name>
            <surname>Tacker</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Schus-Ter</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Fast folding and comparison of RNA secondary structures</article-title>
        <source>Monatshefte fÄur Chemie/Chemial Monthly</source>
        <year>1994</year>
        <volume>125</volume>
        <issue>2</issue>
        <fpage>167</fpage>
        <lpage>188</lpage>
        <pub-id pub-id-type="doi">10.1007/BF00818163</pub-id>
      </element-citation>
    </ref>
    <ref id="CR196">
      <label>196.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lindow</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gorodkin</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Principles and limitations of computational microRNA gene and target finding</article-title>
        <source>DNA Cell Biol</source>
        <year>2007</year>
        <volume>26</volume>
        <fpage>339</fpage>
        <lpage>351</lpage>
        <pub-id pub-id-type="doi">10.1089/dna.2006.0551</pub-id>
        <?supplied-pmid 17504029?>
        <pub-id pub-id-type="pmid">17504029</pub-id>
      </element-citation>
    </ref>
    <ref id="CR197">
      <label>197.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Allmer</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yousef</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Computational methods for ab initio detection of microRNAs</article-title>
        <source>Front Genet</source>
        <year>2012</year>
        <volume>3</volume>
        <fpage>209</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2012.00209</pub-id>
        <?supplied-pmid 23087705?>
        <pub-id pub-id-type="pmid">23087705</pub-id>
      </element-citation>
    </ref>
    <ref id="CR198">
      <label>198.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Meraz</surname>
            <given-names>RF</given-names>
          </name>
          <name>
            <surname>Holbrook</surname>
            <given-names>SR</given-names>
          </name>
        </person-group>
        <article-title>PSoL: a positive sample only learning algorithm for finding non-coding RNA genes</article-title>
        <source>Bioinformatics</source>
        <year>2006</year>
        <volume>22</volume>
        <fpage>2590</fpage>
        <lpage>2596</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btl441</pub-id>
        <?supplied-pmid 16945945?>
        <pub-id pub-id-type="pmid">16945945</pub-id>
      </element-citation>
    </ref>
    <ref id="CR199">
      <label>199.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yousef</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jung</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Showe</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Showe</surname>
            <given-names>MK</given-names>
          </name>
        </person-group>
        <article-title>Learning from positive examples when the negative class is undetermined – microRNA gene identification</article-title>
        <source>Algorithms Mol Biol</source>
        <year>2008</year>
        <volume>3</volume>
        <fpage>2</fpage>
        <pub-id pub-id-type="doi">10.1186/1748-7188-3-2</pub-id>
        <?supplied-pmid 18226233?>
        <pub-id pub-id-type="pmid">18226233</pub-id>
      </element-citation>
    </ref>
    <ref id="CR200">
      <label>200.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hertel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Stadler</surname>
            <given-names>PF</given-names>
          </name>
        </person-group>
        <article-title>Hairpins in a Haystack: recognizing microRNA precursors in comparative genomics data</article-title>
        <source>Bioinformatics</source>
        <year>2006</year>
        <volume>22</volume>
        <fpage>e197</fpage>
        <lpage>202</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btl257</pub-id>
        <?supplied-pmid 16873472?>
        <pub-id pub-id-type="pmid">16873472</pub-id>
      </element-citation>
    </ref>
    <ref id="CR201">
      <label>201.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Rothschild</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>ZL</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>SH</given-names>
          </name>
        </person-group>
        <article-title>MiRFinder: an improved approach and software implementation for genome-wide fast microRNA precursor scans</article-title>
        <source>BMC Bioinformatics</source>
        <year>2007</year>
        <volume>8</volume>
        <fpage>341</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-8-341</pub-id>
        <?supplied-pmid 17868480?>
        <pub-id pub-id-type="pmid">17868480</pub-id>
      </element-citation>
    </ref>
    <ref id="CR202">
      <label>202.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nam</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Shin</surname>
            <given-names>KR</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>VN</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>BT</given-names>
          </name>
        </person-group>
        <article-title>Human microRNA prediction through a probabilistic co-learning model of sequence and structure</article-title>
        <source>Nucleic Acids Res</source>
        <year>2005</year>
        <volume>33</volume>
        <fpage>3570</fpage>
        <lpage>3581</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gki668</pub-id>
        <?supplied-pmid 15987789?>
        <pub-id pub-id-type="pmid">15987789</pub-id>
      </element-citation>
    </ref>
    <ref id="CR203">
      <label>203.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Terai</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Komori</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Asai</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kin</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>miRRim: a novel system to find conserved miRNAs with high sensitivity and specificity</article-title>
        <source>RNA</source>
        <year>2007</year>
        <volume>13</volume>
        <fpage>2081</fpage>
        <lpage>2090</lpage>
        <pub-id pub-id-type="doi">10.1261/rna.655107</pub-id>
        <?supplied-pmid 17959929?>
        <pub-id pub-id-type="pmid">17959929</pub-id>
      </element-citation>
    </ref>
    <ref id="CR204">
      <label>204.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oulas</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Boutla</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gkirtzou</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Reczko</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kalantidis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Poirazi</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Prediction of novel microRNA genes in cancer-associated genomic regions – a combined computational and experimental approach</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>3276</fpage>
        <lpage>3287</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkp120</pub-id>
        <?supplied-pmid 19324892?>
        <pub-id pub-id-type="pmid">19324892</pub-id>
      </element-citation>
    </ref>
    <ref id="CR205">
      <label>205.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kadri</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hinman</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Benos</surname>
            <given-names>PV</given-names>
          </name>
        </person-group>
        <article-title>HHMMiR: efficient de novo prediction of microRNAs using hierarchical hidden Markov models</article-title>
        <source>BMC Bioinformatics</source>
        <year>2009</year>
        <volume>10</volume>
        <issue>Suppl. 1</issue>
        <fpage>S35</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-10-S1-S35</pub-id>
        <?supplied-pmid 19208136?>
        <pub-id pub-id-type="pmid">19208136</pub-id>
      </element-citation>
    </ref>
    <ref id="CR206">
      <label>206.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yousef</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nebozhyn</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shatkay</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kanterakis</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Showe</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Showe</surname>
            <given-names>MK</given-names>
          </name>
        </person-group>
        <article-title>Combining multi-species genomic data for microRNA identification using a Naive Bayes classifier</article-title>
        <source>Bioinformatics</source>
        <year>2006</year>
        <volume>22</volume>
        <fpage>1325</fpage>
        <lpage>1334</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btl094</pub-id>
        <?supplied-pmid 16543277?>
        <pub-id pub-id-type="pmid">16543277</pub-id>
      </element-citation>
    </ref>
    <ref id="CR207">
      <label>207.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bentwich</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>Prediction and validation of microRNAs and their targets</article-title>
        <source>FEBS Lett</source>
        <year>2005</year>
        <volume>579</volume>
        <fpage>5904</fpage>
        <lpage>5910</lpage>
        <pub-id pub-id-type="doi">10.1016/j.febslet.2005.09.040</pub-id>
        <?supplied-pmid 16214134?>
        <pub-id pub-id-type="pmid">16214134</pub-id>
      </element-citation>
    </ref>
    <ref id="CR208">
      <label>208.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xue</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>GP</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Classification of real and pseudo microRNA precursors using local structure-sequence features and support vector machine</article-title>
        <source>BMC Bioinformatics</source>
        <year>2005</year>
        <volume>6</volume>
        <fpage>310</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-6-310</pub-id>
        <?supplied-pmid 16381612?>
        <pub-id pub-id-type="pmid">16381612</pub-id>
      </element-citation>
    </ref>
    <ref id="CR209">
      <label>209.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ng</surname>
            <given-names>KL</given-names>
          </name>
          <name>
            <surname>Mishra</surname>
            <given-names>SK</given-names>
          </name>
        </person-group>
        <article-title>De novo SVM classification of precursor microRNAs from genomic pseudo hairpins using global and intrinsic folding measures</article-title>
        <source>Bioinformatics</source>
        <year>2007</year>
        <volume>23</volume>
        <fpage>1321</fpage>
        <lpage>1330</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btm026</pub-id>
        <?supplied-pmid 17267435?>
        <pub-id pub-id-type="pmid">17267435</pub-id>
      </element-citation>
    </ref>
    <ref id="CR210">
      <label>210.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sewer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Paul</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Landgraf</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Aravin</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pfeffer</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Brownstein</surname>
            <given-names>MJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of clustered microRNAs using an ab initio prediction method</article-title>
        <source>BMC Bioinformatics</source>
        <year>2005</year>
        <volume>6</volume>
        <fpage>267</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-6-267</pub-id>
        <?supplied-pmid 16274478?>
        <pub-id pub-id-type="pmid">16274478</pub-id>
      </element-citation>
    </ref>
    <ref id="CR211">
      <label>211.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Holt</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>JR</given-names>
          </name>
        </person-group>
        <article-title>Controlled delivery of antisense oligonucleotides: a brief review of current strategies</article-title>
        <source>Expert Opin Drug Deliv</source>
        <year>2009</year>
        <volume>6</volume>
        <fpage>673</fpage>
        <lpage>686</lpage>
        <pub-id pub-id-type="doi">10.1517/17425240902992894</pub-id>
        <?supplied-pmid 19552611?>
        <pub-id pub-id-type="pmid">19552611</pub-id>
      </element-citation>
    </ref>
    <ref id="CR212">
      <label>212.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Stein</surname>
            <given-names>CA</given-names>
          </name>
        </person-group>
        <article-title>Antisense oligonucleotides: basic concepts and mechanisms</article-title>
        <source>Mol Cancer Ther</source>
        <year>2002</year>
        <volume>1</volume>
        <fpage>347</fpage>
        <lpage>355</lpage>
        <pub-id pub-id-type="doi">10.4161/cbt.1.4.4</pub-id>
        <?supplied-pmid 12489851?>
        <pub-id pub-id-type="pmid">12489851</pub-id>
      </element-citation>
    </ref>
    <ref id="CR213">
      <label>213.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Samantarrai</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Dash</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chhetri</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Mallick</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Genomic and epigenomic cross-talks in the regulatory landscape of miRNAs in breast cancer</article-title>
        <source>Mol Cancer Res</source>
        <year>2013</year>
        <volume>11</volume>
        <issue>4</issue>
        <fpage>315</fpage>
        <lpage>328</lpage>
        <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-12-0649</pub-id>
        <?supplied-pmid 23360796?>
        <pub-id pub-id-type="pmid">23360796</pub-id>
      </element-citation>
    </ref>
    <ref id="CR214">
      <label>214.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zoon</surname>
            <given-names>CK</given-names>
          </name>
          <name>
            <surname>Starker</surname>
            <given-names>EQ</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Emmert-Buck</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Libutti</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Tangrea</surname>
            <given-names>MA</given-names>
          </name>
        </person-group>
        <article-title>Current molecular diagnostics of breast cancer and the potential incorporation of microRNA</article-title>
        <source>Expert Rev Mol Diagn</source>
        <year>2009</year>
        <volume>9</volume>
        <issue>5</issue>
        <fpage>455</fpage>
        <lpage>67</lpage>
        <pub-id pub-id-type="doi">10.1586/erm.09.25</pub-id>
        <?supplied-pmid 19580430?>
        <pub-id pub-id-type="pmid">19580430</pub-id>
      </element-citation>
    </ref>
    <ref id="CR215">
      <label>215.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>van 't Veer</surname>
            <given-names>LJ</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>van de Vijver</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>YD</given-names>
          </name>
          <name>
            <surname>Hart</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Mao</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title>
        <source>Nature</source>
        <year>2002</year>
        <volume>415</volume>
        <issue>6871</issue>
        <fpage>530</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1038/415530a</pub-id>
        <?supplied-pmid 11823860?>
        <pub-id pub-id-type="pmid">11823860</pub-id>
      </element-citation>
    </ref>
    <ref id="CR216">
      <label>216.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>van de Vijver</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>YD</given-names>
          </name>
          <name>
            <surname>van't Veer</surname>
            <given-names>LJ</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Hart</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Voskuil</surname>
            <given-names>DW</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A gene-expression signature as a predictor of survival in breast cancer</article-title>
        <source>N Engl J Med</source>
        <year>2002</year>
        <volume>347</volume>
        <issue>25</issue>
        <fpage>1999</fpage>
        <lpage>2009</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa021967</pub-id>
        <?supplied-pmid 12490681?>
        <pub-id pub-id-type="pmid">12490681</pub-id>
      </element-citation>
    </ref>
    <ref id="CR217">
      <label>217.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Buyse</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Loi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>van't Veer</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Viale</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Delorenzi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Glas</surname>
            <given-names>AM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer</article-title>
        <source>J Natl Cancer Inst</source>
        <year>2006</year>
        <volume>98</volume>
        <issue>17</issue>
        <fpage>1183</fpage>
        <lpage>92</lpage>
        <pub-id pub-id-type="doi">10.1093/jnci/djj329</pub-id>
        <?supplied-pmid 16954471?>
        <pub-id pub-id-type="pmid">16954471</pub-id>
      </element-citation>
    </ref>
    <ref id="CR218">
      <label>218.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bueno-de-Mesquita</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>van Harten</surname>
            <given-names>WH</given-names>
          </name>
          <name>
            <surname>Retel</surname>
            <given-names>VP</given-names>
          </name>
          <name>
            <surname>van't Veer</surname>
            <given-names>LJ</given-names>
          </name>
          <name>
            <surname>van Dam</surname>
            <given-names>FS</given-names>
          </name>
          <name>
            <surname>Karsenberg</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)</article-title>
        <source>Lancet Oncol</source>
        <year>2007</year>
        <volume>8</volume>
        <issue>12</issue>
        <fpage>1079</fpage>
        <lpage>87</lpage>
        <pub-id pub-id-type="doi">10.1016/S1470-2045(07)70346-7</pub-id>
        <?supplied-pmid 18042430?>
        <pub-id pub-id-type="pmid">18042430</pub-id>
      </element-citation>
    </ref>
    <ref id="CR219">
      <label>219.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bueno-de-Mesquita</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Linn</surname>
            <given-names>SC</given-names>
          </name>
          <name>
            <surname>Keijzer</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wesseling</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nuyten</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>van Krimpen</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Validation of 70-gene prognosis signature in node-negative breast cancer</article-title>
        <source>Breast Cancer Res Treat</source>
        <year>2009</year>
        <volume>117</volume>
        <issue>3</issue>
        <fpage>483</fpage>
        <lpage>95</lpage>
        <pub-id pub-id-type="doi">10.1007/s10549-008-0191-2</pub-id>
        <?supplied-pmid 18819002?>
        <pub-id pub-id-type="pmid">18819002</pub-id>
      </element-citation>
    </ref>
    <ref id="CR220">
      <label>220.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wittner</surname>
            <given-names>BS</given-names>
          </name>
          <name>
            <surname>Sgroi</surname>
            <given-names>DC</given-names>
          </name>
          <name>
            <surname>Ryan</surname>
            <given-names>PD</given-names>
          </name>
          <name>
            <surname>Bruinsma</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Glas</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Male</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort</article-title>
        <source>Clin Cancer Res</source>
        <year>2008</year>
        <volume>14</volume>
        <issue>10</issue>
        <fpage>2988</fpage>
        <lpage>93</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4723</pub-id>
        <?supplied-pmid 18483364?>
        <pub-id pub-id-type="pmid">18483364</pub-id>
      </element-citation>
    </ref>
    <ref id="CR221">
      <label>221.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Paik</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Shak</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cronin</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</article-title>
        <source>N Engl J Med</source>
        <year>2004</year>
        <volume>351</volume>
        <issue>27</issue>
        <fpage>2817</fpage>
        <lpage>26</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa041588</pub-id>
        <?supplied-pmid 15591335?>
        <pub-id pub-id-type="pmid">15591335</pub-id>
      </element-citation>
    </ref>
    <ref id="CR222">
      <label>222.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Paik</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Shak</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cronin</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients — NSABP studies B-20 and B-14</article-title>
        <source>Breast Cancer Res Treat</source>
        <year>2003</year>
        <volume>82</volume>
        <fpage>A16</fpage>
      </element-citation>
    </ref>
    <ref id="CR223">
      <label>223.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Parker</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Mullins</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cheang</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Voduc</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Vickery</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Supervised risk predictor of breast cancer based on intrinsic subtypes</article-title>
        <source>J Clin Oncol</source>
        <year>2009</year>
        <volume>27</volume>
        <issue>8</issue>
        <fpage>1160</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2008.18.1370</pub-id>
        <?supplied-pmid 19204204?>
        <pub-id pub-id-type="pmid">19204204</pub-id>
      </element-citation>
    </ref>
    <ref id="CR224">
      <label>224.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Desmedt</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Giobbie-Hurder</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Neven</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Paridaens</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Christiaens</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Smeets</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial</article-title>
        <source>BMC Med Genomics</source>
        <year>2009</year>
        <volume>2</volume>
        <fpage>40</fpage>
        <pub-id pub-id-type="doi">10.1186/1755-8794-2-40</pub-id>
        <?supplied-pmid 19573224?>
        <pub-id pub-id-type="pmid">19573224</pub-id>
      </element-citation>
    </ref>
    <ref id="CR225">
      <label>225.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bartlett</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ross</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Seitz</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Ring</surname>
            <given-names>BZ</given-names>
          </name>
          <name>
            <surname>Beck</surname>
            <given-names>RA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy</article-title>
        <source>Breast Cancer Res</source>
        <year>2010</year>
        <volume>12</volume>
        <issue>4</issue>
        <fpage>R47</fpage>
        <pub-id pub-id-type="doi">10.1186/bcr2604</pub-id>
        <?supplied-pmid 20615243?>
        <pub-id pub-id-type="pmid">20615243</pub-id>
      </element-citation>
    </ref>
    <ref id="CR226">
      <label>226.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ring</surname>
            <given-names>BZ</given-names>
          </name>
          <name>
            <surname>Seitz</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Beck</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Shasteen</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Tarr</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Cheang</surname>
            <given-names>MC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer</article-title>
        <source>J Clin Oncol</source>
        <year>2006</year>
        <volume>24</volume>
        <issue>19</issue>
        <fpage>3039</fpage>
        <lpage>47</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2006.05.6564</pub-id>
        <?supplied-pmid 16809728?>
        <pub-id pub-id-type="pmid">16809728</pub-id>
      </element-citation>
    </ref>
    <ref id="CR227">
      <label>227.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Streit</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Michalski</surname>
            <given-names>CW</given-names>
          </name>
          <name>
            <surname>Erkan</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kleeff</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Friess</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Northern blot analysis for detection and quantification of RNA in pancreatic cancer cells and tissues</article-title>
        <source>Nat Protoc</source>
        <year>2009</year>
        <volume>4</volume>
        <issue>1</issue>
        <fpage>37</fpage>
        <lpage>43</lpage>
        <pub-id pub-id-type="doi">10.1038/nprot.2008.216</pub-id>
        <?supplied-pmid 19131955?>
        <pub-id pub-id-type="pmid">19131955</pub-id>
      </element-citation>
    </ref>
    <ref id="CR228">
      <label>228.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bustin</surname>
            <given-names>SA</given-names>
          </name>
        </person-group>
        <article-title>Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays</article-title>
        <source>J Mol Endocrinol</source>
        <year>2000</year>
        <volume>25</volume>
        <issue>2</issue>
        <fpage>169</fpage>
        <lpage>93</lpage>
        <pub-id pub-id-type="doi">10.1677/jme.0.0250169</pub-id>
        <?supplied-pmid 11013345?>
        <pub-id pub-id-type="pmid">11013345</pub-id>
      </element-citation>
    </ref>
    <ref id="CR229">
      <label>229.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Valasek</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Repa</surname>
            <given-names>JJ</given-names>
          </name>
        </person-group>
        <article-title>The power of real-time PCR</article-title>
        <source>Adv Physiol Educ</source>
        <year>2005</year>
        <volume>29</volume>
        <issue>3</issue>
        <fpage>151</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1152/advan.00019.2005</pub-id>
        <?supplied-pmid 16109794?>
        <pub-id pub-id-type="pmid">16109794</pub-id>
      </element-citation>
    </ref>
    <ref id="CR230">
      <label>230.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Giménez-Capitán</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Karachaliou</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Rosell</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Comprehensive molecular screening: from the RT-PCR to the RNA-seq</article-title>
        <source>Trans Lung Cancer Res</source>
        <year>2013</year>
        <volume>2</volume>
        <issue>2</issue>
        <fpage>87</fpage>
        <lpage>91</lpage>
      </element-citation>
    </ref>
    <ref id="CR231">
      <label>231.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Taniguchi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Miura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Iwao</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Yamanaka</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Quantitative assessment of DNA microarrays—comparison with Northern blot analyses</article-title>
        <source>Genomics</source>
        <year>2001</year>
        <volume>71</volume>
        <issue>1</issue>
        <fpage>34</fpage>
        <lpage>39</lpage>
        <pub-id pub-id-type="doi">10.1006/geno.2000.6427</pub-id>
        <?supplied-pmid 11161795?>
        <pub-id pub-id-type="pmid">11161795</pub-id>
      </element-citation>
    </ref>
    <ref id="CR232">
      <label>232.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Alwine</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Kemp</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Stark</surname>
            <given-names>GR</given-names>
          </name>
        </person-group>
        <article-title>Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>1977</year>
        <volume>74</volume>
        <issue>12</issue>
        <fpage>5350</fpage>
        <lpage>4</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.74.12.5350</pub-id>
        <?supplied-pmid 414220?>
        <pub-id pub-id-type="pmid">414220</pub-id>
      </element-citation>
    </ref>
    <ref id="CR233">
      <label>233.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pollock</surname>
            <given-names>JD</given-names>
          </name>
        </person-group>
        <article-title>Gene expression profiling: methodological challenges, results, and prospects for addiction research</article-title>
        <source>Chem Phys Lipids</source>
        <year>2002</year>
        <volume>121</volume>
        <issue>1–2</issue>
        <fpage>241</fpage>
        <lpage>56</lpage>
        <pub-id pub-id-type="doi">10.1016/S0009-3084(02)00160-3</pub-id>
        <?supplied-pmid 12505704?>
        <pub-id pub-id-type="pmid">12505704</pub-id>
      </element-citation>
    </ref>
    <ref id="CR234">
      <label>234.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Gerstein</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Snyder</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>RNA-Seq: a revolutionary tool for transcriptomics</article-title>
        <source>Nat Rev Genet</source>
        <year>2009</year>
        <volume>10</volume>
        <issue>1</issue>
        <fpage>57</fpage>
        <lpage>63</lpage>
        <pub-id pub-id-type="doi">10.1038/nrg2484</pub-id>
        <?supplied-pmid 19015660?>
        <pub-id pub-id-type="pmid">19015660</pub-id>
      </element-citation>
    </ref>
    <ref id="CR235">
      <label>235.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Velculescu</surname>
            <given-names>VE</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Vogelstein</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kinzler</surname>
            <given-names>KW</given-names>
          </name>
        </person-group>
        <article-title>Serial analysis of gene expression</article-title>
        <source>Science</source>
        <year>1995</year>
        <volume>270</volume>
        <issue>5235</issue>
        <fpage>484</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1126/science.270.5235.484</pub-id>
        <?supplied-pmid 7570003?>
        <pub-id pub-id-type="pmid">7570003</pub-id>
      </element-citation>
    </ref>
    <ref id="CR236">
      <label>236.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kodzius</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kojima</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nishiyori</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fukuda</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tagami</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CAGE: cap analysis of gene expression</article-title>
        <source>Nat Methods</source>
        <year>2006</year>
        <volume>3</volume>
        <issue>3</issue>
        <fpage>211</fpage>
        <lpage>22</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth0306-211</pub-id>
        <?supplied-pmid 16489339?>
        <pub-id pub-id-type="pmid">16489339</pub-id>
      </element-citation>
    </ref>
    <ref id="CR237">
      <label>237.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brenner</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bridgham</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Golda</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Lloyd</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays</article-title>
        <source>Nat Biotechnol</source>
        <year>2000</year>
        <volume>18</volume>
        <issue>6</issue>
        <fpage>630</fpage>
        <lpage>4</lpage>
        <pub-id pub-id-type="doi">10.1038/76469</pub-id>
        <?supplied-pmid 10835600?>
        <pub-id pub-id-type="pmid">10835600</pub-id>
      </element-citation>
    </ref>
    <ref id="CR238">
      <label>238.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Medvedev</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Stanciu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Brudno</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Computational methods for discovering structural variation with next-generation sequencing</article-title>
        <source>Nat Methods</source>
        <year>2009</year>
        <volume>6</volume>
        <issue>11 Suppl</issue>
        <fpage>S13</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth.1374</pub-id>
        <?supplied-pmid 19844226?>
        <pub-id pub-id-type="pmid">19844226</pub-id>
      </element-citation>
    </ref>
    <ref id="CR239">
      <label>239.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>van de Wiel</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Picard</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>van Wieringen</surname>
            <given-names>WN</given-names>
          </name>
          <name>
            <surname>Ylstra</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Preprocessing and downstream analysis of microarray DNA copy number profiles</article-title>
        <source>Brief Bioinform</source>
        <year>2011</year>
        <volume>12</volume>
        <issue>1</issue>
        <fpage>10</fpage>
        <lpage>21</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbq004</pub-id>
        <?supplied-pmid 20172948?>
        <pub-id pub-id-type="pmid">20172948</pub-id>
      </element-citation>
    </ref>
    <ref id="CR240">
      <label>240.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Saeys</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Inza</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Larrañaga</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>A review of feature selection techniques in bioinformatics</article-title>
        <source>Bioinformatics</source>
        <year>2007</year>
        <volume>23</volume>
        <issue>19</issue>
        <fpage>2507</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btm344</pub-id>
        <?supplied-pmid 17720704?>
        <pub-id pub-id-type="pmid">17720704</pub-id>
      </element-citation>
    </ref>
    <ref id="CR241">
      <label>241.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Golub</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Slonim</surname>
            <given-names>DK</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Huard</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gaasenbeek</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mesirov</surname>
            <given-names>JP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular classification of cancer: class discovery and class prediction by gene expression monitoring</article-title>
        <source>Science</source>
        <year>1999</year>
        <volume>286</volume>
        <issue>5439</issue>
        <fpage>531</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1126/science.286.5439.531</pub-id>
        <?supplied-pmid 10521349?>
        <pub-id pub-id-type="pmid">10521349</pub-id>
      </element-citation>
    </ref>
    <ref id="CR242">
      <label>242.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bolón-Canedo</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Sánchez-Maroño</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Alonso-Betanzos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Benítez</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Herrera</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>A review of microarray datasets and applied feature selection methods</article-title>
        <source>Inf Sci</source>
        <year>2014</year>
        <volume>282</volume>
        <fpage>111</fpage>
        <lpage>135</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ins.2014.05.042</pub-id>
      </element-citation>
    </ref>
    <ref id="CR243">
      <label>243.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Valsala</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Feature Selection for high Dimensional DNA Microarray data using hybrid approaches</article-title>
        <source>Bioinformation</source>
        <year>2013</year>
        <volume>9</volume>
        <issue>16</issue>
        <fpage>824</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.6026/97320630009824</pub-id>
        <?supplied-pmid 24143053?>
        <pub-id pub-id-type="pmid">24143053</pub-id>
      </element-citation>
    </ref>
    <ref id="CR244">
      <label>244.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chuang</surname>
            <given-names>LY</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>CH</given-names>
          </name>
        </person-group>
        <article-title>Correlation-based gene selection and classification using Taguchi-BPSO</article-title>
        <source>Methods Inf Med</source>
        <year>2010</year>
        <volume>49</volume>
        <issue>3</issue>
        <fpage>254</fpage>
        <lpage>68</lpage>
        <pub-id pub-id-type="doi">10.3414/ME09-01-0010</pub-id>
        <?supplied-pmid 20135079?>
        <pub-id pub-id-type="pmid">20135079</pub-id>
      </element-citation>
    </ref>
    <ref id="CR245">
      <label>245.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jafari</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Azuaje</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>An assessment of recently published gene expression data analyses: reporting experimental design and statistical factors</article-title>
        <source>BMC Med Inform Decis Mak</source>
        <year>2006</year>
        <volume>6</volume>
        <fpage>27</fpage>
        <pub-id pub-id-type="doi">10.1186/1472-6947-6-27</pub-id>
        <?supplied-pmid 16790051?>
        <pub-id pub-id-type="pmid">16790051</pub-id>
      </element-citation>
    </ref>
    <ref id="CR246">
      <label>246.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Battiti</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Using mutual information for selecting features in supervised neural net learning</article-title>
        <source>IEEE Trans Neural Netw</source>
        <year>1994</year>
        <volume>5</volume>
        <issue>4</issue>
        <fpage>537</fpage>
        <lpage>50</lpage>
        <pub-id pub-id-type="doi">10.1109/72.298224</pub-id>
        <?supplied-pmid 18267827?>
        <pub-id pub-id-type="pmid">18267827</pub-id>
      </element-citation>
    </ref>
    <ref id="CR247">
      <label>247.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Krishnan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mondry</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>An entropy-based gene selection method for cancer classification using microarray data</article-title>
        <source>BMC Bioinformatics</source>
        <year>2005</year>
        <volume>6</volume>
        <fpage>76</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-6-76</pub-id>
        <?supplied-pmid 15790388?>
        <pub-id pub-id-type="pmid">15790388</pub-id>
      </element-citation>
    </ref>
    <ref id="CR248">
      <label>248.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tusher</surname>
            <given-names>VG</given-names>
          </name>
          <name>
            <surname>Tibshirani</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Chu</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Significance analysis of microarrays applied to the ionizing radiation response</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2001</year>
        <volume>98</volume>
        <issue>9</issue>
        <fpage>5116</fpage>
        <lpage>21</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.091062498</pub-id>
        <?supplied-pmid 11309499?>
        <pub-id pub-id-type="pmid">11309499</pub-id>
      </element-citation>
    </ref>
    <ref id="CR249">
      <label>249.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oh</surname>
            <given-names>IS</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Moon</surname>
            <given-names>BR</given-names>
          </name>
        </person-group>
        <article-title>Hybrid genetic algorithms for feature selection</article-title>
        <source>IEEE Trans Pattern Anal Mach Intell</source>
        <year>2004</year>
        <volume>26</volume>
        <issue>11</issue>
        <fpage>1424</fpage>
        <lpage>37</lpage>
        <pub-id pub-id-type="doi">10.1109/TPAMI.2004.105</pub-id>
        <?supplied-pmid 15521491?>
        <pub-id pub-id-type="pmid">15521491</pub-id>
      </element-citation>
    </ref>
    <ref id="CR250">
      <label>250.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chuang</surname>
            <given-names>LY</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HW</given-names>
          </name>
          <name>
            <surname>Tu</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>CH</given-names>
          </name>
        </person-group>
        <article-title>Improved binary PSO for feature selection using gene expression data</article-title>
        <source>Comput Biol Chem</source>
        <year>2008</year>
        <volume>32</volume>
        <issue>1</issue>
        <fpage>29</fpage>
        <lpage>37</lpage>
        <pub-id pub-id-type="doi">10.1016/j.compbiolchem.2007.09.005</pub-id>
        <?supplied-pmid 18023261?>
        <pub-id pub-id-type="pmid">18023261</pub-id>
      </element-citation>
    </ref>
    <ref id="CR251">
      <label>251.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sharma</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Imoto</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Miyano</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>A top-r feature selection algorithm for microarray gene expression data</article-title>
        <source>IEEE/ACM Trans Comput Biol Bioinform</source>
        <year>2012</year>
        <volume>9</volume>
        <issue>3</issue>
        <fpage>754</fpage>
        <lpage>64</lpage>
        <pub-id pub-id-type="doi">10.1109/TCBB.2011.151</pub-id>
        <?supplied-pmid 22084149?>
        <pub-id pub-id-type="pmid">22084149</pub-id>
      </element-citation>
    </ref>
    <ref id="CR252">
      <label>252.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Wanderley</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gardeux</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Natowicz</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Braga</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Ga-kde-bayes: an evolutionary wrapper method based on non-parametric density estimation applied to bioinformatics problems</article-title>
        <source>21st European Symposium on Artificial Neural Networks-ESANN</source>
        <year>2013</year>
        <fpage>155</fpage>
        <lpage>160</lpage>
      </element-citation>
    </ref>
    <ref id="CR253">
      <label>253.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ambroise</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>McLachlan</surname>
            <given-names>GJ</given-names>
          </name>
        </person-group>
        <article-title>Selection bias in gene extraction on the basis of microarray gene-expression data</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2002</year>
        <volume>99</volume>
        <issue>10</issue>
        <fpage>6562</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.102102699</pub-id>
        <?supplied-pmid 11983868?>
        <pub-id pub-id-type="pmid">11983868</pub-id>
      </element-citation>
    </ref>
    <ref id="CR254">
      <label>254.</label>
      <mixed-citation publication-type="other">Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther. 2005;12(2):189–211.</mixed-citation>
    </ref>
    <ref id="CR255">
      <label>255.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hallahan</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Mauceri</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Seung</surname>
            <given-names>LP</given-names>
          </name>
          <name>
            <surname>Dunphy</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Wayne</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Hanna</surname>
            <given-names>NN</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Spatial and temporal control of gene therapy using ionizing radiation</article-title>
        <source>Nat Med</source>
        <year>1995</year>
        <volume>1</volume>
        <issue>8</issue>
        <fpage>786</fpage>
        <lpage>91</lpage>
        <pub-id pub-id-type="doi">10.1038/nm0895-786</pub-id>
        <?supplied-pmid 7585181?>
        <pub-id pub-id-type="pmid">7585181</pub-id>
      </element-citation>
    </ref>
    <ref id="CR256">
      <label>256.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kan</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Griffiths</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Baban</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Iqball</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Uden</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Spearman</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer</article-title>
        <source>Cancer Gene Ther</source>
        <year>2001</year>
        <volume>8</volume>
        <issue>7</issue>
        <fpage>473</fpage>
        <lpage>82</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.cgt.7700329</pub-id>
        <?supplied-pmid 11498768?>
        <pub-id pub-id-type="pmid">11498768</pub-id>
      </element-citation>
    </ref>
    <ref id="CR257">
      <label>257.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Walther</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Siegel</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kobelt</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Knösel</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Dietel</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bembenek</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer</article-title>
        <source>Clin Cancer Res</source>
        <year>2008</year>
        <volume>14</volume>
        <issue>22</issue>
        <fpage>7545</fpage>
        <lpage>53</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0412</pub-id>
        <?supplied-pmid 19010873?>
        <pub-id pub-id-type="pmid">19010873</pub-id>
      </element-citation>
    </ref>
    <ref id="CR258">
      <label>258.</label>
      <mixed-citation publication-type="other">Henrichsen CN, Vinckenbosch N, Zöllner S, Chaignat E, Pradervand S, Schütz F, et al. Segmental copy number variation shapes tissue transcriptomes. Nat Genet. 2009;41:424–9.</mixed-citation>
    </ref>
    <ref id="CR259">
      <label>259.</label>
      <mixed-citation publication-type="other">Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007;315:848–53.</mixed-citation>
    </ref>
    <ref id="CR260">
      <label>260.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Futcher</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Carbon</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Toxic effects of excess cloned centromeres</article-title>
        <source>Mol Cell Biol</source>
        <year>1986</year>
        <volume>6</volume>
        <fpage>2213</fpage>
        <lpage>2222</lpage>
        <pub-id pub-id-type="doi">10.1128/MCB.6.6.2213</pub-id>
        <?supplied-pmid 3537715?>
        <pub-id pub-id-type="pmid">3537715</pub-id>
      </element-citation>
    </ref>
    <ref id="CR261">
      <label>261.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Veitia</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Exploring the etiology of haploinsufficiency</article-title>
        <source>Bioessays</source>
        <year>2002</year>
        <volume>24</volume>
        <fpage>175</fpage>
        <lpage>184</lpage>
        <pub-id pub-id-type="doi">10.1002/bies.10023</pub-id>
        <?supplied-pmid 11835282?>
        <pub-id pub-id-type="pmid">11835282</pub-id>
      </element-citation>
    </ref>
    <ref id="CR262">
      <label>262.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pollack</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Srlie</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Perou</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rees</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Jeffrey</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Lonning</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Microarray analysis reveals a major direct role of dna copy number alteration in the transcriptional program of human breast tumors</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2002</year>
        <volume>99</volume>
        <fpage>12963</fpage>
        <lpage>12968</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.162471999</pub-id>
        <?supplied-pmid 12297621?>
        <pub-id pub-id-type="pmid">12297621</pub-id>
      </element-citation>
    </ref>
    <ref id="CR263">
      <label>263.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>PK</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Lessons from a decade of integrating cancer copy number alterations with gene expression profiles</article-title>
        <source>Brief Bioinform</source>
        <year>2012</year>
        <volume>13</volume>
        <issue>3</issue>
        <fpage>305</fpage>
        <lpage>316</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbr056</pub-id>
        <?supplied-pmid 21949216?>
        <pub-id pub-id-type="pmid">21949216</pub-id>
      </element-citation>
    </ref>
    <ref id="CR264">
      <label>264.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Phillips</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Hayward</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis</article-title>
        <source>Cancer Res</source>
        <year>2001</year>
        <volume>61</volume>
        <fpage>8143</fpage>
        <lpage>9</lpage>
        <?supplied-pmid 11719443?>
        <pub-id pub-id-type="pmid">11719443</pub-id>
      </element-citation>
    </ref>
    <ref id="CR265">
      <label>265.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wolf</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mousses</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hautaniemi</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression</article-title>
        <source>Neoplasia</source>
        <year>2004</year>
        <volume>6</volume>
        <fpage>240</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1593/neo.03439</pub-id>
        <?supplied-pmid 15153336?>
        <pub-id pub-id-type="pmid">15153336</pub-id>
      </element-citation>
    </ref>
    <ref id="CR266">
      <label>266.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Masayesva</surname>
            <given-names>BG</given-names>
          </name>
          <name>
            <surname>Ha</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Garrett-Mayer</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2004</year>
        <volume>101</volume>
        <fpage>8715</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0400027101</pub-id>
        <?supplied-pmid 15155901?>
        <pub-id pub-id-type="pmid">15155901</pub-id>
      </element-citation>
    </ref>
    <ref id="CR267">
      <label>267.</label>
      <mixed-citation publication-type="other">National Cancer Institute. The Cancer Genome Atlas Homepage. <ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov">http://cancergenome.nih.gov</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR268">
      <label>268.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cava</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zoppis</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Gariboldi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Castiglioni</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Mauri</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Antoniotti</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Combined analysis of chromosomal instabilities and gene expression for colon cancer progression inference</article-title>
        <source>J Clinical Bioinformatics</source>
        <year>2014</year>
        <volume>4</volume>
        <fpage>2</fpage>
        <pub-id pub-id-type="doi">10.1186/2043-9113-4-2</pub-id>
      </element-citation>
    </ref>
    <ref id="CR269">
      <label>269.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Cava</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zoppis</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Mauri</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ripamonti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gallivanone</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Salvatore</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Combination of gene expression and genome copy number alteration has a prognostic value for breast cancer</article-title>
        <source>Engineering in Medicine and Biology Society (EMBC), 2013 35th Annual International Conference of the IEEE</source>
        <year>2013</year>
        <fpage>608</fpage>
        <lpage>611</lpage>
      </element-citation>
    </ref>
    <ref id="CR270">
      <label>270.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>PJ</given-names>
          </name>
        </person-group>
        <article-title>Integrative analysis reveals the direct and indirect interactions between DNA copy number aberrations and gene expression changes</article-title>
        <source>Bioinformatics</source>
        <year>2008</year>
        <volume>24</volume>
        <fpage>889</fpage>
        <lpage>96</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btn034</pub-id>
        <?supplied-pmid 18263644?>
        <pub-id pub-id-type="pmid">18263644</pub-id>
      </element-citation>
    </ref>
    <ref id="CR271">
      <label>271.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Monni</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Barlund</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mousses</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2001</year>
        <volume>98</volume>
        <fpage>5711</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.091582298</pub-id>
        <?supplied-pmid 11331760?>
        <pub-id pub-id-type="pmid">11331760</pub-id>
      </element-citation>
    </ref>
    <ref id="CR272">
      <label>272.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Salto‐Tellez</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Palanisamy</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ganesan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>LK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Targets of genome copy number reduction in primary breast cancers identified by integrative genomics</article-title>
        <source>Genes Chromosom Cancer</source>
        <year>2007</year>
        <volume>46</volume>
        <issue>3</issue>
        <fpage>288</fpage>
        <lpage>301</lpage>
        <pub-id pub-id-type="doi">10.1002/gcc.20411</pub-id>
        <?supplied-pmid 17171680?>
        <pub-id pub-id-type="pmid">17171680</pub-id>
      </element-citation>
    </ref>
    <ref id="CR273">
      <label>273.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Martens</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>JX</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Copy number alterations that predict metastatic capability of human breast cancer</article-title>
        <source>Cancer Res</source>
        <year>2009</year>
        <volume>69</volume>
        <fpage>3795</fpage>
        <lpage>801</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4596</pub-id>
        <?supplied-pmid 19336569?>
        <pub-id pub-id-type="pmid">19336569</pub-id>
      </element-citation>
    </ref>
    <ref id="CR274">
      <label>274.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Andre</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Job</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Dessen</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array</article-title>
        <source>Clin Cancer Res</source>
        <year>2009</year>
        <volume>15</volume>
        <fpage>441</fpage>
        <lpage>51</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1791</pub-id>
        <?supplied-pmid 19147748?>
        <pub-id pub-id-type="pmid">19147748</pub-id>
      </element-citation>
    </ref>
    <ref id="CR275">
      <label>275.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hyman</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Kauraniemi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hautaniemi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wolf</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mousses</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rozenblum</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Impact of DNA amplification on gene expression patterns in breast cancer</article-title>
        <source>Cancer Res</source>
        <year>2002</year>
        <volume>62</volume>
        <fpage>6240</fpage>
        <lpage>5</lpage>
        <?supplied-pmid 12414653?>
        <pub-id pub-id-type="pmid">12414653</pub-id>
      </element-citation>
    </ref>
    <ref id="CR276">
      <label>276.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Orsetti</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Nugoli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cervera</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q</article-title>
        <source>Br J Cancer</source>
        <year>2006</year>
        <volume>95</volume>
        <fpage>1439</fpage>
        <lpage>47</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.bjc.6603433</pub-id>
        <?supplied-pmid 17060936?>
        <pub-id pub-id-type="pmid">17060936</pub-id>
      </element-citation>
    </ref>
    <ref id="CR277">
      <label>277.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chin</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Devries</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Fridlyand</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</article-title>
        <source>Cancer Cell</source>
        <year>2006</year>
        <volume>10</volume>
        <fpage>529</fpage>
        <lpage>41</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.009</pub-id>
        <?supplied-pmid 17157792?>
        <pub-id pub-id-type="pmid">17157792</pub-id>
      </element-citation>
    </ref>
    <ref id="CR278">
      <label>278.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chin</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Teschendorff</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Marioni</surname>
            <given-names>JC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High-resolution array-CGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer</article-title>
        <source>Genome Biol</source>
        <year>2007</year>
        <volume>8</volume>
        <fpage>R215</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2007-8-10-r215</pub-id>
        <?supplied-pmid 17925008?>
        <pub-id pub-id-type="pmid">17925008</pub-id>
      </element-citation>
    </ref>
    <ref id="CR279">
      <label>279.</label>
      <mixed-citation publication-type="other">Lahti L, Schäfer M, Klein H U, Bicciato S, Dugas M. Cancer gene prioritization by integrative analysis of mRNA expression and DNA copy number data: a comparative review. Briefings in bioinformatics. 2012; bbs005.</mixed-citation>
    </ref>
    <ref id="CR280">
      <label>280.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Menezes</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Boetzer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sieswerda</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated analysis of DNA copy number and gene expression microarray analysis using gene sets</article-title>
        <source>BMC Bioinformatics</source>
        <year>2009</year>
        <volume>10</volume>
        <fpage>203</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-10-203</pub-id>
        <?supplied-pmid 19563656?>
        <pub-id pub-id-type="pmid">19563656</pub-id>
      </element-citation>
    </ref>
    <ref id="CR281">
      <label>281.</label>
      <mixed-citation publication-type="other">Lahti L, Schäfer M, Klein HU, Bicciato S, Dugas M. Cancer gene prioritization by integrative analysis of mRNA expression and DNA copy number data: a comparative review. Brief Bioinform. 2013;(14):27-35.</mixed-citation>
    </ref>
    <ref id="CR282">
      <label>282.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Solvang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Lingjaerde</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Frigessi</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Linear and non-linear dependencies between copy number aberrations and mRNA expression reveal distinct molecular pathways in breast cancer</article-title>
        <source>BMC Bioinformatics</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>197</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-12-197</pub-id>
        <?supplied-pmid 21609452?>
        <pub-id pub-id-type="pmid">21609452</pub-id>
      </element-citation>
    </ref>
    <ref id="CR283">
      <label>283.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mayer</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Lorent</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Horgan</surname>
            <given-names>GW</given-names>
          </name>
        </person-group>
        <article-title>Exploratory analysis of multiple omics datasets using the adjusted RV coefficient</article-title>
        <source>Stat Appl Genet Mol Biol</source>
        <year>2011</year>
        <volume>10</volume>
        <fpage>14</fpage>
      </element-citation>
    </ref>
    <ref id="CR284">
      <label>284.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tsafrir</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bacolod</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Selvanayagam</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Tsafrir</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Shia</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>Z</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Relationship of gene expression and chromosomal abnormalities in colorectal cancer</article-title>
        <source>Cancer Res</source>
        <year>2006</year>
        <volume>66</volume>
        <fpage>2129</fpage>
        <lpage>2137</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2569</pub-id>
        <?supplied-pmid 16489013?>
        <pub-id pub-id-type="pmid">16489013</pub-id>
      </element-citation>
    </ref>
    <ref id="CR285">
      <label>285.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Salari</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tibshirani</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Pollack</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>DR-Integrator: a new analytic tool for integrating DNA copy number and gene expression data</article-title>
        <source>Bioinformatics</source>
        <year>2010</year>
        <volume>26</volume>
        <fpage>414</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp702</pub-id>
        <?supplied-pmid 20031972?>
        <pub-id pub-id-type="pmid">20031972</pub-id>
      </element-citation>
    </ref>
    <ref id="CR286">
      <label>286.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ortiz-Estevez</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>De Las Rivas</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Fontanillo</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Segmentation of genomic and transcriptomic microarrays data reveals major correlation between DNA copy number aberrations and gene-loci expression</article-title>
        <source>Genomics</source>
        <year>2011</year>
        <volume>97</volume>
        <fpage>86</fpage>
        <lpage>93</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ygeno.2010.10.008</pub-id>
        <?supplied-pmid 21044881?>
        <pub-id pub-id-type="pmid">21044881</pub-id>
      </element-citation>
    </ref>
    <ref id="CR287">
      <label>287.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schäfer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Schwender</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Merk</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated analysis of copy number alterations and gene expression: a bivariate assessment of equally directed abnormalities</article-title>
        <source>Bioinformatics</source>
        <year>2009</year>
        <volume>25</volume>
        <fpage>3228</fpage>
        <lpage>35</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp592</pub-id>
        <?supplied-pmid 19828576?>
        <pub-id pub-id-type="pmid">19828576</pub-id>
      </element-citation>
    </ref>
    <ref id="CR288">
      <label>288.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Lipson</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ben-Dor</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Dehan</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <person-group person-group-type="editor">
          <name>
            <surname>Jonassen</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Joint analysis of DNA copy numbers and gene expression levels</article-title>
        <source>Proc Algorithms in Bioinformatics: 4th International Workshop WABI 2004</source>
        <year>2004</year>
        <publisher-loc>Germany</publisher-loc>
        <publisher-name>Springer</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR289">
      <label>289.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Alter</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>PO</given-names>
          </name>
          <name>
            <surname>Botstein</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Singular Value Decomposition for Genome-Wide Expression Data Processing and Modeling</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2000</year>
        <volume>97</volume>
        <fpage>10</fpage>
        <pub-id pub-id-type="doi">10.1073/pnas.97.18.10101</pub-id>
      </element-citation>
    </ref>
    <ref id="CR290">
      <label>290.</label>
      <mixed-citation publication-type="other">Hastie T, Tibshirani R, Eisen MB, Alizadeh A, Levy R, Staudt L, et al. 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol. 2000;1(3):1–20.</mixed-citation>
    </ref>
    <ref id="CR291">
      <label>291.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berger</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Hautaniemi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mitra</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Astola</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Jointly Analyzing Genes Expression and Copy Number Data in Breast Cancer using Data Reduction models</article-title>
        <source>IEEE Trans Comput Biol Bioinform</source>
        <year>2006</year>
        <volume>3</volume>
        <issue>1</issue>
        <fpage>2</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1109/TCBB.2006.10</pub-id>
      </element-citation>
    </ref>
    <ref id="CR292">
      <label>292.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Soneson</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Lilljebjorn</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Fioretos</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Fontes</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Integrative analysis of gene expression and copy number alterations using canonical correlation analysis</article-title>
        <source>BMC Bioinformatics</source>
        <year>2010</year>
        <volume>11</volume>
        <fpage>191</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-11-191</pub-id>
        <?supplied-pmid 20398334?>
        <pub-id pub-id-type="pmid">20398334</pub-id>
      </element-citation>
    </ref>
    <ref id="CR293">
      <label>293.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gonzalez</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>DeJean</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Highlighting relationships between heterogeneous biological data through graphical displays based on regularized canonical correlation analysis</article-title>
        <source>J Biol Syst</source>
        <year>2008</year>
        <volume>17</volume>
        <fpage>173</fpage>
        <lpage>99</lpage>
        <pub-id pub-id-type="doi">10.1142/S0218339009002831</pub-id>
      </element-citation>
    </ref>
    <ref id="CR294">
      <label>294.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shen</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Olshen</surname>
            <given-names>AB</given-names>
          </name>
          <name>
            <surname>Ladanyi</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis</article-title>
        <source>Bioinformatics</source>
        <year>2009</year>
        <volume>25</volume>
        <fpage>2906</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp543</pub-id>
        <?supplied-pmid 19759197?>
        <pub-id pub-id-type="pmid">19759197</pub-id>
      </element-citation>
    </ref>
    <ref id="CR295">
      <label>295.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wieringen</surname>
            <given-names>WN</given-names>
          </name>
          <name>
            <surname>Belien</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Vosse</surname>
            <given-names>SJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ACE-it: a tool for genome-wide integration of gene dosage and RNA expression data</article-title>
        <source>Bioinformatics</source>
        <year>2006</year>
        <volume>22</volume>
        <fpage>1919</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btl269</pub-id>
        <?supplied-pmid 16731696?>
        <pub-id pub-id-type="pmid">16731696</pub-id>
      </element-citation>
    </ref>
    <ref id="CR296">
      <label>296.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kingsley</surname>
            <given-names>CB</given-names>
          </name>
          <name>
            <surname>Kuo</surname>
            <given-names>WL</given-names>
          </name>
          <name>
            <surname>Polikoff</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Magellan: a web based system for the integrated analysis of heterogeneous biological data and annotations; application to DNA copy number and expression data in ovarian cancer</article-title>
        <source>Cancer Inform</source>
        <year>2007</year>
        <volume>2</volume>
        <fpage>10</fpage>
        <lpage>21</lpage>
        <?supplied-pmid 19458754?>
        <pub-id pub-id-type="pmid">19458754</pub-id>
      </element-citation>
    </ref>
    <ref id="CR297">
      <label>297.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bicciato</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Spinelli</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Zampieri</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A computational procedure to identify significant overlap of differentially expressed and genomic imbalanced regions in cancer datasets</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>5057</fpage>
        <lpage>70</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkp520</pub-id>
        <?supplied-pmid 19542187?>
        <pub-id pub-id-type="pmid">19542187</pub-id>
      </element-citation>
    </ref>
    <ref id="CR298">
      <label>298.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Louhimo</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hautaniemi</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>CNAmet: an R package for integrating copy number, methylation and expression data</article-title>
        <source>Bioinformatics</source>
        <year>2011</year>
        <volume>27</volume>
        <fpage>887</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btr019</pub-id>
        <?supplied-pmid 21228048?>
        <pub-id pub-id-type="pmid">21228048</pub-id>
      </element-citation>
    </ref>
    <ref id="CR299">
      <label>299.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Akavia</surname>
            <given-names>UD</given-names>
          </name>
          <name>
            <surname>Litvin</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An integrated approach to uncover drivers of cancer</article-title>
        <source>Cell</source>
        <year>2010</year>
        <volume>143</volume>
        <fpage>1005</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2010.11.013</pub-id>
        <?supplied-pmid 21129771?>
        <pub-id pub-id-type="pmid">21129771</pub-id>
      </element-citation>
    </ref>
    <ref id="CR300">
      <label>300.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hervouet</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Cartron</surname>
            <given-names>PF</given-names>
          </name>
          <name>
            <surname>Jouvenot</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Delage-Mourroux</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Epigenetic regulation of estrogen signaling in breast cancer</article-title>
        <source>Epigenetics</source>
        <year>2013</year>
        <volume>8</volume>
        <fpage>237</fpage>
        <lpage>245</lpage>
        <pub-id pub-id-type="doi">10.4161/epi.23790</pub-id>
        <?supplied-pmid 23364277?>
        <pub-id pub-id-type="pmid">23364277</pub-id>
      </element-citation>
    </ref>
    <ref id="CR301">
      <label>301.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sarkar</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Goldgar</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Byler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rosenthal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Heerboth</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Demethylation and reexpression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy</article-title>
        <source>Epigenomics</source>
        <year>2013</year>
        <volume>1</volume>
        <fpage>87</fpage>
        <lpage>94</lpage>
        <pub-id pub-id-type="doi">10.2217/epi.12.68</pub-id>
        <pub-id pub-id-type="pmid">23414323</pub-id>
      </element-citation>
    </ref>
    <ref id="CR302">
      <label>302.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>K-C</given-names>
          </name>
          <name>
            <surname>Liao</surname>
            <given-names>Y-C</given-names>
          </name>
          <name>
            <surname>Hsieh</surname>
            <given-names>IC</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y-S</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>C-Y</given-names>
          </name>
          <name>
            <surname>Juo</surname>
            <given-names>S-HH</given-names>
          </name>
        </person-group>
        <article-title>OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: novel mechanisms for cardiovascular diseases</article-title>
        <source>J Mol Cell Cardiol</source>
        <year>2012</year>
        <volume>52</volume>
        <fpage>587</fpage>
        <lpage>95</lpage>
        <pub-id pub-id-type="doi">10.1016/j.yjmcc.2011.12.005</pub-id>
        <?supplied-pmid 22226905?>
        <pub-id pub-id-type="pmid">22226905</pub-id>
      </element-citation>
    </ref>
    <ref id="CR303">
      <label>303.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ahmad</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bao</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Dyson</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Sarkar</surname>
            <given-names>FH</given-names>
          </name>
        </person-group>
        <article-title>Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion</article-title>
        <source>Epigenetics</source>
        <year>2012</year>
        <volume>7</volume>
        <fpage>940</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.4161/epi.21236</pub-id>
        <?supplied-pmid 22805767?>
        <pub-id pub-id-type="pmid">22805767</pub-id>
      </element-citation>
    </ref>
    <ref id="CR304">
      <label>304.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer</article-title>
        <source>Biochem Biophys Res Commun</source>
        <year>2012</year>
        <volume>424</volume>
        <fpage>28</fpage>
        <lpage>33</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bbrc.2012.06.028</pub-id>
        <?supplied-pmid 22705304?>
        <pub-id pub-id-type="pmid">22705304</pub-id>
      </element-citation>
    </ref>
    <ref id="CR305">
      <label>305.</label>
      <mixed-citation publication-type="other">van Iterson M, Bervoets S, de Meijer EJ, Buermans HP, AC’t Hoen P, Menezes RX, et al. Integrated analysis of microRNA and mRNA expression: adding biological significance to microRNA target predictions. Nucleic Acids Res. 2013;41(15):e146.</mixed-citation>
    </ref>
    <ref id="CR306">
      <label>306.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Jin</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A Systematic Analysis of miRNA-mRNA Paired Variations Reveals Widespread miRNA Misregulation in Breast Cancer</article-title>
        <source>BioMed Research International</source>
        <year>2014</year>
        <volume>2014</volume>
        <fpage>291280</fpage>
        <?supplied-pmid 24949432?>
        <pub-id pub-id-type="pmid">24949432</pub-id>
      </element-citation>
    </ref>
    <ref id="CR307">
      <label>307.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cascione</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gasparini</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Lovat</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Carasi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pulvirenti</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ferro</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer</article-title>
        <source>PLoS One</source>
        <year>2013</year>
        <volume>8</volume>
        <issue>2</issue>
        <fpage>e55910</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0055910</pub-id>
        <?supplied-pmid 23405235?>
        <pub-id pub-id-type="pmid">23405235</pub-id>
      </element-citation>
    </ref>
    <ref id="CR308">
      <label>308.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Volinia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Croce</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer</article-title>
        <source>Proc Natl Acad Sci</source>
        <year>2013</year>
        <volume>110</volume>
        <issue>18</issue>
        <fpage>7413</fpage>
        <lpage>7417</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1304977110</pub-id>
        <?supplied-pmid 23589849?>
        <pub-id pub-id-type="pmid">23589849</pub-id>
      </element-citation>
    </ref>
    <ref id="CR309">
      <label>309.</label>
      <mixed-citation publication-type="other">Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011;71(17):5635–45.</mixed-citation>
    </ref>
    <ref id="CR310">
      <label>310.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Van der Auwera</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Limame</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Van Dam</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Vermeulen</surname>
            <given-names>PB</given-names>
          </name>
          <name>
            <surname>Dirix</surname>
            <given-names>LY</given-names>
          </name>
          <name>
            <surname>Van Laere</surname>
            <given-names>SJ</given-names>
          </name>
        </person-group>
        <article-title>Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype</article-title>
        <source>Br J Cancer</source>
        <year>2010</year>
        <volume>103</volume>
        <issue>4</issue>
        <fpage>532</fpage>
        <lpage>541</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.bjc.6605787</pub-id>
        <?supplied-pmid 20664596?>
        <pub-id pub-id-type="pmid">20664596</pub-id>
      </element-citation>
    </ref>
    <ref id="CR311">
      <label>311.</label>
      <mixed-citation publication-type="other">Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One. 2011;6(2):e16915.</mixed-citation>
    </ref>
    <ref id="CR312">
      <label>312.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hannafon</surname>
            <given-names>BN</given-names>
          </name>
          <name>
            <surname>Sebastiani</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>De Las Morenas</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Rosenberg</surname>
            <given-names>CL</given-names>
          </name>
        </person-group>
        <article-title>Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer</article-title>
        <source>Breast Cancer Res</source>
        <year>2011</year>
        <volume>13</volume>
        <issue>2</issue>
        <fpage>R24</fpage>
        <pub-id pub-id-type="doi">10.1186/bcr2839</pub-id>
        <?supplied-pmid 21375733?>
        <pub-id pub-id-type="pmid">21375733</pub-id>
      </element-citation>
    </ref>
    <ref id="CR313">
      <label>313.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Harvel</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Pei</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A systematic evaluation of miRNA: mRNA interactions involved in the migration and invasion of breast cancer cells</article-title>
        <source>J Transl Med</source>
        <year>2013</year>
        <volume>11</volume>
        <fpage>57</fpage>
        <pub-id pub-id-type="doi">10.1186/1479-5876-11-57</pub-id>
        <?supplied-pmid 23497265?>
        <pub-id pub-id-type="pmid">23497265</pub-id>
      </element-citation>
    </ref>
    <ref id="CR314">
      <label>314.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rosenfeld</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNAs accurately identify cancer tissue origin</article-title>
        <source>Nat Biotechnol</source>
        <year>2008</year>
        <volume>26</volume>
        <issue>4</issue>
        <fpage>462</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt1392</pub-id>
        <?supplied-pmid 18362881?>
        <pub-id pub-id-type="pmid">18362881</pub-id>
      </element-citation>
    </ref>
    <ref id="CR315">
      <label>315.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bertoli</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Cava</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Castiglioni</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer</article-title>
        <source>Theranostics</source>
        <year>2015</year>
        <volume>5</volume>
        <issue>10</issue>
        <fpage>1122</fpage>
        <lpage>43</lpage>
        <pub-id pub-id-type="doi">10.7150/thno.11543</pub-id>
        <?supplied-pmid 26199650?>
        <pub-id pub-id-type="pmid">26199650</pub-id>
      </element-citation>
    </ref>
    <ref id="CR316">
      <label>316.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>O'Day</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Lal</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs and their target gene networks in breast cancer</article-title>
        <source>Breast Cancer Res</source>
        <year>2010</year>
        <volume>12</volume>
        <issue>2</issue>
        <fpage>201</fpage>
        <pub-id pub-id-type="doi">10.1186/bcr2484</pub-id>
        <?supplied-pmid 20346098?>
        <pub-id pub-id-type="pmid">20346098</pub-id>
      </element-citation>
    </ref>
    <ref id="CR317">
      <label>317.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yan</surname>
            <given-names>LX</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>XF</given-names>
          </name>
          <name>
            <surname>Shao</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>MY</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>QL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis</article-title>
        <source>RNA</source>
        <year>2008</year>
        <volume>14</volume>
        <fpage>2348</fpage>
        <lpage>60</lpage>
        <pub-id pub-id-type="doi">10.1261/rna.1034808</pub-id>
        <?supplied-pmid 18812439?>
        <pub-id pub-id-type="pmid">18812439</pub-id>
      </element-citation>
    </ref>
    <ref id="CR318">
      <label>318.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bornachea</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours</article-title>
        <source>Sci Rep</source>
        <year>2012</year>
        <volume>2</volume>
        <fpage>434</fpage>
        <pub-id pub-id-type="doi">10.1038/srep00434</pub-id>
        <?supplied-pmid 22666537?>
        <pub-id pub-id-type="pmid">22666537</pub-id>
      </element-citation>
    </ref>
    <ref id="CR319">
      <label>319.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Si</surname>
            <given-names>ML</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miR-21-mediated tumor growth</article-title>
        <source>Oncogene</source>
        <year>2007</year>
        <volume>26</volume>
        <issue>19</issue>
        <fpage>2799</fpage>
        <lpage>803</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.onc.1210083</pub-id>
        <?supplied-pmid 17072344?>
        <pub-id pub-id-type="pmid">17072344</pub-id>
      </element-citation>
    </ref>
    <ref id="CR320">
      <label>320.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Teruya-Feldstein</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Tumour invasion and metastasis initiated by microRNA-10b in breast cancer</article-title>
        <source>Nature</source>
        <year>2007</year>
        <volume>449</volume>
        <fpage>682</fpage>
        <lpage>688</lpage>
        <pub-id pub-id-type="doi">10.1038/nature06174</pub-id>
        <?supplied-pmid 17898713?>
        <pub-id pub-id-type="pmid">17898713</pub-id>
      </element-citation>
    </ref>
    <ref id="CR321">
      <label>321.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model</article-title>
        <source>Nat Biotechnol</source>
        <year>2010</year>
        <volume>28</volume>
        <fpage>341</fpage>
        <lpage>347</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt.1618</pub-id>
        <?supplied-pmid 20351690?>
        <pub-id pub-id-type="pmid">20351690</pub-id>
      </element-citation>
    </ref>
    <ref id="CR322">
      <label>322.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mayr</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hemann</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Bartel</surname>
            <given-names>DP</given-names>
          </name>
        </person-group>
        <article-title>Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation</article-title>
        <source>Science</source>
        <year>2007</year>
        <volume>315</volume>
        <fpage>1576</fpage>
        <lpage>1579</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1137999</pub-id>
        <?supplied-pmid 17322030?>
        <pub-id pub-id-type="pmid">17322030</pub-id>
      </element-citation>
    </ref>
    <ref id="CR323">
      <label>323.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yun</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer</article-title>
        <source>EMBO J</source>
        <year>2011</year>
        <volume>30</volume>
        <fpage>4500</fpage>
        <lpage>4514</lpage>
        <pub-id pub-id-type="doi">10.1038/emboj.2011.312</pub-id>
        <?supplied-pmid 21873975?>
        <pub-id pub-id-type="pmid">21873975</pub-id>
      </element-citation>
    </ref>
    <ref id="CR324">
      <label>324.</label>
      <mixed-citation publication-type="other">Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.</mixed-citation>
    </ref>
    <ref id="CR325">
      <label>325.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Korpal</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization</article-title>
        <source>Nat Med</source>
        <year>2011</year>
        <volume>17</volume>
        <fpage>1101</fpage>
        <lpage>1108</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.2401</pub-id>
        <?supplied-pmid 21822286?>
        <pub-id pub-id-type="pmid">21822286</pub-id>
      </element-citation>
    </ref>
    <ref id="CR326">
      <label>326.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oskarsson</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs</article-title>
        <source>Nat Med</source>
        <year>2011</year>
        <volume>17</volume>
        <fpage>867</fpage>
        <lpage>874</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.2379</pub-id>
        <?supplied-pmid 21706029?>
        <pub-id pub-id-type="pmid">21706029</pub-id>
      </element-citation>
    </ref>
    <ref id="CR327">
      <label>327.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression</article-title>
        <source>Cancer Res</source>
        <year>2012</year>
        <volume>72</volume>
        <fpage>4597</fpage>
        <lpage>4608</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-1045</pub-id>
        <?supplied-pmid 22787120?>
        <pub-id pub-id-type="pmid">22787120</pub-id>
      </element-citation>
    </ref>
    <ref id="CR328">
      <label>328.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Png</surname>
            <given-names>KJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer</article-title>
        <source>Genes Dev</source>
        <year>2011</year>
        <volume>25</volume>
        <fpage>226</fpage>
        <lpage>231</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.1974211</pub-id>
        <?supplied-pmid 21289068?>
        <pub-id pub-id-type="pmid">21289068</pub-id>
      </element-citation>
    </ref>
    <ref id="CR329">
      <label>329.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Muniategui</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pey</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Planes</surname>
            <given-names>FJ</given-names>
          </name>
          <name>
            <surname>Rubio</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Joint analysis of miRNA and mRNA expression data</article-title>
        <source>Brief Bioinform</source>
        <year>2013</year>
        <volume>14</volume>
        <issue>3</issue>
        <fpage>263</fpage>
        <lpage>278</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbs028</pub-id>
        <?supplied-pmid 22692086?>
        <pub-id pub-id-type="pmid">22692086</pub-id>
      </element-citation>
    </ref>
    <ref id="CR330">
      <label>330.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Thomson</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Bracken</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Goodall</surname>
            <given-names>GJ</given-names>
          </name>
        </person-group>
        <article-title>Experimental strategies for microRNA target identification</article-title>
        <source>Nucleic Acids Res</source>
        <year>2011</year>
        <volume>39</volume>
        <issue>16</issue>
        <fpage>6845</fpage>
        <lpage>6853</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkr330</pub-id>
        <?supplied-pmid 21652644?>
        <pub-id pub-id-type="pmid">21652644</pub-id>
      </element-citation>
    </ref>
    <ref id="CR331">
      <label>331.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tsai</surname>
            <given-names>KW</given-names>
          </name>
          <name>
            <surname>Liao</surname>
            <given-names>YL</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>CW</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Aberrant hypermethylation of miR-9 genes in gastric cancer</article-title>
        <source>Epigenetics</source>
        <year>2011</year>
        <volume>6</volume>
        <issue>10</issue>
        <fpage>1189</fpage>
        <lpage>1197</lpage>
        <pub-id pub-id-type="doi">10.4161/epi.6.10.16535</pub-id>
        <?supplied-pmid 21931274?>
        <pub-id pub-id-type="pmid">21931274</pub-id>
      </element-citation>
    </ref>
    <ref id="CR332">
      <label>332.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dudziec</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gogol-Doring</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cookson</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Catto</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells</article-title>
        <source>PLoS ONE</source>
        <year>2012</year>
        <volume>7</volume>
        <issue>3</issue>
        <fpage>e32750</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0032750</pub-id>
        <?supplied-pmid 22412920?>
        <pub-id pub-id-type="pmid">22412920</pub-id>
      </element-citation>
    </ref>
    <ref id="CR333">
      <label>333.</label>
      <mixed-citation publication-type="other">Bossel Ben-Moshe N, Avraham R, Kedmi M, Zeisel A, Yitzhaky A, Yarden Y, et al. Context-specific microRNA analysis: identification of functional microRNAs and their mRNA targets. Nucleic Acids Res. 2012;40:10614–27.</mixed-citation>
    </ref>
    <ref id="CR334">
      <label>334.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Engelmann</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Spang</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>A least angle regression model for the prediction of canonical and non-canonical miRNA mRNA interactions</article-title>
        <source>PLoS One</source>
        <year>2012</year>
        <volume>7</volume>
        <fpage>e40634</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0040634</pub-id>
        <?supplied-pmid 22815777?>
        <pub-id pub-id-type="pmid">22815777</pub-id>
      </element-citation>
    </ref>
    <ref id="CR335">
      <label>335.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vasudevan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tong</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Steitz</surname>
            <given-names>JA</given-names>
          </name>
        </person-group>
        <article-title>Switching from repression to activation: microRNAs can up-regulate translation</article-title>
        <source>Science</source>
        <year>2007</year>
        <volume>318</volume>
        <issue>5858</issue>
        <fpage>1931</fpage>
        <lpage>1934</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1149460</pub-id>
        <?supplied-pmid 18048652?>
        <pub-id pub-id-type="pmid">18048652</pub-id>
      </element-citation>
    </ref>
    <ref id="CR336">
      <label>336.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xiao</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Zuo</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miRecords: an integrated resource for microRNA–target interactions</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>D105</fpage>
        <lpage>D110</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkn851</pub-id>
        <?supplied-pmid 18996891?>
        <pub-id pub-id-type="pmid">18996891</pub-id>
      </element-citation>
    </ref>
    <ref id="CR337">
      <label>337.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hsu</surname>
            <given-names>S-D</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>F-M</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>W-Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miRTarBase: a database curates experimentally validated microRNA–target interactions</article-title>
        <source>Nucleic Acids Res</source>
        <year>2011</year>
        <volume>39</volume>
        <fpage>D163</fpage>
        <lpage>D169</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq1107</pub-id>
        <?supplied-pmid 21071411?>
        <pub-id pub-id-type="pmid">21071411</pub-id>
      </element-citation>
    </ref>
    <ref id="CR338">
      <label>338.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Beck</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ayers</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic syndromes</article-title>
        <source>BMC Med Genomics</source>
        <year>2011</year>
        <volume>4</volume>
        <fpage>19</fpage>
        <pub-id pub-id-type="doi">10.1186/1755-8794-4-19</pub-id>
        <?supplied-pmid 21342535?>
        <pub-id pub-id-type="pmid">21342535</pub-id>
      </element-citation>
    </ref>
    <ref id="CR339">
      <label>339.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ritchie</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Rajasekhar</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Flamant</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Conserved expression patterns predict microRNA targets</article-title>
        <source>PLoS Computat Biol</source>
        <year>2009</year>
        <volume>5</volume>
        <fpage>8</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000513</pub-id>
      </element-citation>
    </ref>
    <ref id="CR340">
      <label>340.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jayaswal</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Lutherborrow</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>DDF</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of microRNAs with regulatory potential using a matched microRNA-mRNA time-course data</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>e60</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkp153</pub-id>
        <?supplied-pmid 19295134?>
        <pub-id pub-id-type="pmid">19295134</pub-id>
      </element-citation>
    </ref>
    <ref id="CR341">
      <label>341.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ragan</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zuker</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ragan</surname>
            <given-names>MA</given-names>
          </name>
        </person-group>
        <article-title>Quantitative Prediction of miRNA-mRNA Interaction Based on Equilibrium Concentrations</article-title>
        <source>PLoS Computat Biol</source>
        <year>2011</year>
        <volume>7</volume>
        <fpage>11</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1001090</pub-id>
      </element-citation>
    </ref>
    <ref id="CR342">
      <label>342.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nogales-Cadenas</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Carmona-Saez</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Vazquez</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>W317</fpage>
        <lpage>W322</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkp416</pub-id>
        <?supplied-pmid 19465387?>
        <pub-id pub-id-type="pmid">19465387</pub-id>
      </element-citation>
    </ref>
    <ref id="CR343">
      <label>343.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Subramanian</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Mootha</surname>
            <given-names>VK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2005</year>
        <volume>102</volume>
        <fpage>15545</fpage>
        <lpage>15550</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id>
        <?supplied-pmid 16199517?>
        <pub-id pub-id-type="pmid">16199517</pub-id>
      </element-citation>
    </ref>
    <ref id="CR344">
      <label>344.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mootha</surname>
            <given-names>VK</given-names>
          </name>
          <name>
            <surname>Lindgren</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Eriksson</surname>
            <given-names>K-F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title>
        <source>Nat Genet</source>
        <year>2003</year>
        <volume>34</volume>
        <fpage>267</fpage>
        <lpage>73</lpage>
        <pub-id pub-id-type="doi">10.1038/ng1180</pub-id>
        <?supplied-pmid 12808457?>
        <pub-id pub-id-type="pmid">12808457</pub-id>
      </element-citation>
    </ref>
    <ref id="CR345">
      <label>345.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Goeman</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>van de Geer</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>de Kort</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>van Houwelingen</surname>
            <given-names>HC</given-names>
          </name>
        </person-group>
        <article-title>A global test for groups of genes: testing association with a clinical outcome</article-title>
        <source>Bioinformatics</source>
        <year>2004</year>
        <volume>20</volume>
        <fpage>93</fpage>
        <lpage>99</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btg382</pub-id>
        <?supplied-pmid 14693814?>
        <pub-id pub-id-type="pmid">14693814</pub-id>
      </element-citation>
    </ref>
    <ref id="CR346">
      <label>346.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Brannon</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Reddy</surname>
            <given-names>AR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma</article-title>
        <source>BMC Syst Biol</source>
        <year>2010</year>
        <volume>4</volume>
        <fpage>51</fpage>
        <pub-id pub-id-type="doi">10.1186/1752-0509-4-51</pub-id>
        <?supplied-pmid 20420713?>
        <pub-id pub-id-type="pmid">20420713</pub-id>
      </element-citation>
    </ref>
    <ref id="CR347">
      <label>347.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gennarino</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Sardiello</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mutarelli</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>HOCTAR database: a unique resource for microRNA target prediction</article-title>
        <source>Gene</source>
        <year>2011</year>
        <volume>480</volume>
        <fpage>51</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1016/j.gene.2011.03.005</pub-id>
        <?supplied-pmid 21435384?>
        <pub-id pub-id-type="pmid">21435384</pub-id>
      </element-citation>
    </ref>
    <ref id="CR348">
      <label>348.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sales</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Coppe</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bisognin</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MAGIA, a web-based tool for miRNA and genes integrated analysis</article-title>
        <source>Nucleic Acids Res</source>
        <year>2010</year>
        <volume>38</volume>
        <fpage>W352</fpage>
        <lpage>W359</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq423</pub-id>
        <?supplied-pmid 20484379?>
        <pub-id pub-id-type="pmid">20484379</pub-id>
      </element-citation>
    </ref>
    <ref id="CR349">
      <label>349.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ritchie</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Flamant</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rasko</surname>
            <given-names>JEJ</given-names>
          </name>
        </person-group>
        <article-title>mimiRNA: a microRNA expression profiler and classification resource designed to identify functional correlations between microRNAs and their targets</article-title>
        <source>Bioinformatics</source>
        <year>2010</year>
        <volume>26</volume>
        <fpage>223</fpage>
        <lpage>227</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp649</pub-id>
        <?supplied-pmid 19933167?>
        <pub-id pub-id-type="pmid">19933167</pub-id>
      </element-citation>
    </ref>
    <ref id="CR350">
      <label>350.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cho</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Jun</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miRGator v2.0: an integrated system for functional investigation of microRNAs</article-title>
        <source>Nucleic Acids Res</source>
        <year>2011</year>
        <volume>39</volume>
        <fpage>D158</fpage>
        <lpage>D162</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq1094</pub-id>
        <?supplied-pmid 21062822?>
        <pub-id pub-id-type="pmid">21062822</pub-id>
      </element-citation>
    </ref>
    <ref id="CR351">
      <label>351.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Gill</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Cooper</surname>
            <given-names>NGF</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Modeling microRNA-mRNA interactions using PLS regression in human colon cancer</article-title>
        <source>BMC Med Genomics</source>
        <year>2011</year>
        <volume>4</volume>
        <fpage>44</fpage>
        <pub-id pub-id-type="doi">10.1186/1755-8794-4-44</pub-id>
        <?supplied-pmid 21595958?>
        <pub-id pub-id-type="pmid">21595958</pub-id>
      </element-citation>
    </ref>
    <ref id="CR352">
      <label>352.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Babak</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Corson</surname>
            <given-names>TW</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Using expression profiling data to identify human microRNA targets</article-title>
        <source>Nat Methods</source>
        <year>2007</year>
        <volume>4</volume>
        <fpage>1045</fpage>
        <lpage>1049</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth1130</pub-id>
        <?supplied-pmid 18026111?>
        <pub-id pub-id-type="pmid">18026111</pub-id>
      </element-citation>
    </ref>
    <ref id="CR353">
      <label>353.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stingo</surname>
            <given-names>FC</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>YA</given-names>
          </name>
          <name>
            <surname>Vannucci</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A Bayesian graphical modeling approach to microRNA regulatory network inference</article-title>
        <source>Ann Appl Stat</source>
        <year>2011</year>
        <volume>4</volume>
        <fpage>2024</fpage>
        <lpage>2048</lpage>
        <pub-id pub-id-type="doi">10.1214/10-AOAS360</pub-id>
        <pub-id pub-id-type="pmid">23946863</pub-id>
      </element-citation>
    </ref>
    <ref id="CR354">
      <label>354.</label>
      <mixed-citation publication-type="other">Su N, Wang Y, Qian M, et al. Predicting MicroRNA targets by integrating sequence and expression data in cancer. IEEE Int Conf Syst Biol. 2011.</mixed-citation>
    </ref>
    <ref id="CR355">
      <label>355.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tavazoie</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Alarcon</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Oskarsson</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Endogenous human microRNAs that suppress breast cancer metastasis</article-title>
        <source>Nature</source>
        <year>2008</year>
        <volume>451</volume>
        <issue>7175</issue>
        <fpage>147</fpage>
        <lpage>152</lpage>
        <pub-id pub-id-type="doi">10.1038/nature06487</pub-id>
        <?supplied-pmid 18185580?>
        <pub-id pub-id-type="pmid">18185580</pub-id>
      </element-citation>
    </ref>
    <ref id="CR356">
      <label>356.</label>
      <mixed-citation publication-type="other">Su N, Wang Y, Qian M, Deng M. Predicting MicroRNA targets by integrating sequence and expression data in cancer. In Systems Biology (ISB), 2011 IEEE International Conference. Zhuhai; 2011;219-24</mixed-citation>
    </ref>
    <ref id="CR357">
      <label>357.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Scott</surname>
            <given-names>GK</given-names>
          </name>
          <name>
            <surname>Goga</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bhaumik</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Berger</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>Sullivan</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>Benz</surname>
            <given-names>CC</given-names>
          </name>
        </person-group>
        <article-title>Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b</article-title>
        <source>J Biol Chem</source>
        <year>2007</year>
        <volume>282</volume>
        <fpage>1479</fpage>
        <lpage>1486</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M609383200</pub-id>
        <?supplied-pmid 17110380?>
        <pub-id pub-id-type="pmid">17110380</pub-id>
      </element-citation>
    </ref>
    <ref id="CR358">
      <label>358.</label>
      <mixed-citation publication-type="other">Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 2013;4(3):e556.</mixed-citation>
    </ref>
    <ref id="CR359">
      <label>359.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Xi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion</article-title>
        <source>Mol Ther</source>
        <year>2012</year>
        <volume>20</volume>
        <issue>12</issue>
        <fpage>2326</fpage>
        <lpage>2334</lpage>
        <pub-id pub-id-type="doi">10.1038/mt.2012.201</pub-id>
        <?supplied-pmid 23032974?>
        <pub-id pub-id-type="pmid">23032974</pub-id>
      </element-citation>
    </ref>
    <ref id="CR360">
      <label>360.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>He</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>LP</given-names>
          </name>
        </person-group>
        <article-title>A microRNA component of the p53 tumour suppressor network</article-title>
        <source>Nature</source>
        <year>2007</year>
        <volume>447</volume>
        <fpage>1130</fpage>
        <lpage>5</lpage>
        <pub-id pub-id-type="doi">10.1038/nature05939</pub-id>
        <?supplied-pmid 17554337?>
        <pub-id pub-id-type="pmid">17554337</pub-id>
      </element-citation>
    </ref>
    <ref id="CR361">
      <label>361.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Weidhaas</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Babar</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Nallur</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Trang</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Roush</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Boehm</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy</article-title>
        <source>Cancer Res</source>
        <year>2007</year>
        <volume>67</volume>
        <issue>23</issue>
        <fpage>11111</fpage>
        <lpage>11116</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2858</pub-id>
        <?supplied-pmid 18056433?>
        <pub-id pub-id-type="pmid">18056433</pub-id>
      </element-citation>
    </ref>
    <ref id="CR362">
      <label>362.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Neilsen</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Noll</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Mattiske</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bracken</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Gregory</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Schulz</surname>
            <given-names>RB</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutant p53 drives invasion in breast tumors through up-regulation of miR-155</article-title>
        <source>Oncogene</source>
        <year>2012</year>
        <volume>32</volume>
        <issue>24</issue>
        <fpage>2992</fpage>
        <lpage>3000</lpage>
        <pub-id pub-id-type="doi">10.1038/onc.2012.305</pub-id>
        <?supplied-pmid 22797073?>
        <pub-id pub-id-type="pmid">22797073</pub-id>
      </element-citation>
    </ref>
    <ref id="CR363">
      <label>363.</label>
      <mixed-citation publication-type="other">Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma Proc. Natl Acad Sci USA. 2012;109:E1695–704.</mixed-citation>
    </ref>
    <ref id="CR364">
      <label>364.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Calin</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Sevignani</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dumitru</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Hyslop</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Noch</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Yendamuri</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2004</year>
        <volume>101</volume>
        <fpage>2999</fpage>
        <lpage>3004</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0307323101</pub-id>
        <?supplied-pmid 14973191?>
        <pub-id pub-id-type="pmid">14973191</pub-id>
      </element-citation>
    </ref>
    <ref id="CR365">
      <label>365.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Greshock</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Megraw</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Giannakakis</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>microRNAs exhibit high frequency genomic alterations in human cancer</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2006</year>
        <volume>103</volume>
        <fpage>9136</fpage>
        <lpage>41</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0508889103</pub-id>
        <?supplied-pmid 16754881?>
        <pub-id pub-id-type="pmid">16754881</pub-id>
      </element-citation>
    </ref>
    <ref id="CR366">
      <label>366.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dvinge</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Git</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gräf</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Salmon-Divon</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Curtis</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sottoriva</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The shaping and functional consequences of the microRNA landscape in breast cancer</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>497</volume>
        <issue>7449</issue>
        <fpage>378</fpage>
        <lpage>382</lpage>
        <pub-id pub-id-type="doi">10.1038/nature12108</pub-id>
        <?supplied-pmid 23644459?>
        <pub-id pub-id-type="pmid">23644459</pub-id>
      </element-citation>
    </ref>
    <ref id="CR367">
      <label>367.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hammond</surname>
            <given-names>SM</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs as oncogenes</article-title>
        <source>Curr Opin Genet Dev</source>
        <year>2006</year>
        <volume>16</volume>
        <fpage>4</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1016/j.gde.2005.12.005</pub-id>
        <?supplied-pmid 16361094?>
        <pub-id pub-id-type="pmid">16361094</pub-id>
      </element-citation>
    </ref>
    <ref id="CR368">
      <label>368.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Volinia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Calin</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Ambs</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Cimmino</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Petrocca</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A microRNA expression signature of human solid tumors defines cancer gene targets</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2006</year>
        <volume>103</volume>
        <fpage>2257</fpage>
        <lpage>61</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0510565103</pub-id>
        <?supplied-pmid 16461460?>
        <pub-id pub-id-type="pmid">16461460</pub-id>
      </element-citation>
    </ref>
    <ref id="CR369">
      <label>369.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Inomata</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tagawa</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>YM</given-names>
          </name>
          <name>
            <surname>Kameoka</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Takahashi</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Sawada</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes</article-title>
        <source>Blood</source>
        <year>2009</year>
        <volume>113</volume>
        <fpage>396</fpage>
        <lpage>402</lpage>
        <pub-id pub-id-type="doi">10.1182/blood-2008-07-163907</pub-id>
        <?supplied-pmid 18941111?>
        <pub-id pub-id-type="pmid">18941111</pub-id>
      </element-citation>
    </ref>
    <ref id="CR370">
      <label>370.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Calin</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Croce</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs and chromosomal abnormalities in cancer cells</article-title>
        <source>Oncogene</source>
        <year>2006</year>
        <volume>25</volume>
        <issue>46</issue>
        <fpage>6202</fpage>
        <lpage>6210</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.onc.1209910</pub-id>
        <?supplied-pmid 17028600?>
        <pub-id pub-id-type="pmid">17028600</pub-id>
      </element-citation>
    </ref>
    <ref id="CR371">
      <label>371.</label>
      <mixed-citation publication-type="other">Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006;45:1033–40.</mixed-citation>
    </ref>
    <ref id="CR372">
      <label>372.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aure</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Leivonen</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Fleischer</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Overgaard</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Alsner</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors</article-title>
        <source>Genome Biol</source>
        <year>2013</year>
        <volume>14</volume>
        <issue>11</issue>
        <fpage>R126</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2013-14-11-r126</pub-id>
        <?supplied-pmid 24257477?>
        <pub-id pub-id-type="pmid">24257477</pub-id>
      </element-citation>
    </ref>
    <ref id="CR373">
      <label>373.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Negrini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rasio</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hampton</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Sabbioni</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rattan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>SL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3</article-title>
        <source>Cancer Res</source>
        <year>1995</year>
        <volume>55</volume>
        <fpage>3003</fpage>
        <lpage>7</lpage>
        <?supplied-pmid 7606718?>
        <pub-id pub-id-type="pmid">7606718</pub-id>
      </element-citation>
    </ref>
    <ref id="CR374">
      <label>374.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Muller</surname>
            <given-names>HM</given-names>
          </name>
          <name>
            <surname>Fiegl</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Goebel</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hubalek</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Widschwendter</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Muller-Holzner</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status</article-title>
        <source>Br J Cancer</source>
        <year>2003</year>
        <volume>89</volume>
        <fpage>1934</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.bjc.6601392</pub-id>
        <?supplied-pmid 14612906?>
        <pub-id pub-id-type="pmid">14612906</pub-id>
      </element-citation>
    </ref>
    <ref id="CR375">
      <label>375.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miR-100 Induces Epithelial-Mesenchymal Transition but Suppresses Tumorigenesis, Migration and Invasion</article-title>
        <source>PLoS Genet</source>
        <year>2014</year>
        <volume>10</volume>
        <issue>2</issue>
        <fpage>e1004177</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pgen.1004177</pub-id>
        <?supplied-pmid 24586203?>
        <pub-id pub-id-type="pmid">24586203</pub-id>
      </element-citation>
    </ref>
    <ref id="CR376">
      <label>376.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nagai</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Negrini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Gillum</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Rosenberg</surname>
            <given-names>AL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer</article-title>
        <source>Cancer Res</source>
        <year>1995</year>
        <volume>55</volume>
        <fpage>1752</fpage>
        <lpage>1757</lpage>
        <?supplied-pmid 7712484?>
        <pub-id pub-id-type="pmid">7712484</pub-id>
      </element-citation>
    </ref>
    <ref id="CR377">
      <label>377.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tarasov</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Jung</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Verdoodt</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Lodygin</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Epanchintsev</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest</article-title>
        <source>Cell Cycle</source>
        <year>2007</year>
        <volume>6</volume>
        <fpage>1586</fpage>
        <lpage>1593</lpage>
        <pub-id pub-id-type="doi">10.4161/cc.6.13.4436</pub-id>
        <?supplied-pmid 17554199?>
        <pub-id pub-id-type="pmid">17554199</pub-id>
      </element-citation>
    </ref>
    <ref id="CR378">
      <label>378.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Greshock</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Shao</surname>
            <given-names>Z</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genomic DNA copy-number alterations of the let-7 family in human cancers</article-title>
        <source>PLoS One</source>
        <year>2012</year>
        <volume>7</volume>
        <issue>9</issue>
        <fpage>e44399</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0044399</pub-id>
        <?supplied-pmid 22970210?>
        <pub-id pub-id-type="pmid">22970210</pub-id>
      </element-citation>
    </ref>
    <ref id="CR379">
      <label>379.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Meng</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Henson</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wehbe</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Maheshwari</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mendell</surname>
            <given-names>JT</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines</article-title>
        <source>Gastroenterology</source>
        <year>2006</year>
        <volume>130</volume>
        <issue>7</issue>
        <fpage>2113</fpage>
        <lpage>2129</lpage>
        <pub-id pub-id-type="doi">10.1053/j.gastro.2006.02.057</pub-id>
        <?supplied-pmid 16762633?>
        <pub-id pub-id-type="pmid">16762633</pub-id>
      </element-citation>
    </ref>
    <ref id="CR380">
      <label>380.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>de Rinaldis</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gazinska</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Mera</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Modrusan</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Fedorowicz</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Burford</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control</article-title>
        <source>BMC Genomics</source>
        <year>2013</year>
        <volume>14</volume>
        <issue>1</issue>
        <fpage>643</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2164-14-643</pub-id>
        <?supplied-pmid 24059244?>
        <pub-id pub-id-type="pmid">24059244</pub-id>
      </element-citation>
    </ref>
    <ref id="CR381">
      <label>381.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Srivastava</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Manvati</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Srivastava</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pal</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kalaiarasan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chattopadhyay</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention</article-title>
        <source>Breast Cancer Res</source>
        <year>2011</year>
        <volume>13</volume>
        <issue>2</issue>
        <fpage>R39</fpage>
        <pub-id pub-id-type="doi">10.1186/bcr2861</pub-id>
        <?supplied-pmid 21463514?>
        <pub-id pub-id-type="pmid">21463514</pub-id>
      </element-citation>
    </ref>
    <ref id="CR382">
      <label>382.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fearon</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>Vogelstein</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>A genetic model for colorectal tumorigenesis</article-title>
        <source>Cell</source>
        <year>1990</year>
        <volume>61</volume>
        <fpage>759</fpage>
        <lpage>767</lpage>
        <pub-id pub-id-type="doi">10.1016/0092-8674(90)90186-I</pub-id>
        <?supplied-pmid 2188735?>
        <pub-id pub-id-type="pmid">2188735</pub-id>
      </element-citation>
    </ref>
    <ref id="CR383">
      <label>383.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hanahan</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Hallmarks of cancer: the next generation</article-title>
        <source>Cell</source>
        <year>2011</year>
        <volume>5</volume>
        <fpage>646</fpage>
        <lpage>74</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
        <pub-id pub-id-type="pmid">21376230</pub-id>
      </element-citation>
    </ref>
    <ref id="CR384">
      <label>384.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vogelstein</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kinzler</surname>
            <given-names>KW</given-names>
          </name>
        </person-group>
        <article-title>Cancer genes and the pathways they control</article-title>
        <source>Nat Med</source>
        <year>2004</year>
        <volume>8</volume>
        <fpage>789</fpage>
        <lpage>99</lpage>
        <pub-id pub-id-type="doi">10.1038/nm1087</pub-id>
        <pub-id pub-id-type="pmid">15286780</pub-id>
      </element-citation>
    </ref>
    <ref id="CR385">
      <label>385.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tam</surname>
            <given-names>WL</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>The epigenetics of epithelial-mesenchymal plasticityin cancer</article-title>
        <source>Nat Med</source>
        <year>2013</year>
        <volume>19</volume>
        <fpage>1438</fpage>
        <lpage>49</lpage>
        <pub-id pub-id-type="doi">10.1038/nm.3336</pub-id>
        <?supplied-pmid 24202396?>
        <pub-id pub-id-type="pmid">24202396</pub-id>
      </element-citation>
    </ref>
    <ref id="CR386">
      <label>386.</label>
      <mixed-citation publication-type="other">Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and Tumor Metastasis. Clinical and Translational Medicine. 2015;1:1–13.</mixed-citation>
    </ref>
    <ref id="CR387">
      <label>387.</label>
      <mixed-citation publication-type="other">Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, et al. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013;10:21087–113.</mixed-citation>
    </ref>
    <ref id="CR388">
      <label>388.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Knudson</surname>
            <given-names>AG</given-names>
          </name>
        </person-group>
        <article-title>Two genetic hits (more or less) to cancer</article-title>
        <source>Nat Rev Cancer</source>
        <year>2001</year>
        <volume>1</volume>
        <fpage>157</fpage>
        <lpage>62</lpage>
        <pub-id pub-id-type="doi">10.1038/35101031</pub-id>
        <?supplied-pmid 11905807?>
        <pub-id pub-id-type="pmid">11905807</pub-id>
      </element-citation>
    </ref>
    <ref id="CR389">
      <label>389.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Meric-Bernstam</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Heterogenic loss of BRCA in breast cancer: the “two-hit” hypothesis takes a hit</article-title>
        <source>Ann Surg Oncol</source>
        <year>2007</year>
        <volume>14</volume>
        <issue>9</issue>
        <fpage>2428</fpage>
        <lpage>2429</lpage>
        <pub-id pub-id-type="doi">10.1245/s10434-007-9379-7</pub-id>
        <?supplied-pmid 17406948?>
        <pub-id pub-id-type="pmid">17406948</pub-id>
      </element-citation>
    </ref>
    <ref id="CR390">
      <label>390.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Konishi</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Mohseni</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tamaki</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2011</year>
        <volume>108</volume>
        <issue>43</issue>
        <fpage>17773</fpage>
        <lpage>17778</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1110969108</pub-id>
        <?supplied-pmid 21987798?>
        <pub-id pub-id-type="pmid">21987798</pub-id>
      </element-citation>
    </ref>
    <ref id="CR391">
      <label>391.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eo</surname>
            <given-names>HS</given-names>
          </name>
          <name>
            <surname>Heo</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hwang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>HS</given-names>
          </name>
        </person-group>
        <article-title>A pathway-based classification of breast cancer integrating data on differentially expressed genes, copy number variations and MicroRNA target genes</article-title>
        <source>Molecules and Cells</source>
        <year>2012</year>
        <volume>34</volume>
        <issue>4</issue>
        <fpage>393</fpage>
        <lpage>398</lpage>
        <pub-id pub-id-type="doi">10.1007/s10059-012-0177-0</pub-id>
        <?supplied-pmid 22983731?>
        <pub-id pub-id-type="pmid">22983731</pub-id>
      </element-citation>
    </ref>
    <ref id="CR392">
      <label>392.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>Cancer Genome Atlas Network</collab>
        </person-group>
        <article-title>Comprehensive molecular portraits of human breast tumours</article-title>
        <source>Nature</source>
        <year>2012</year>
        <volume>490</volume>
        <issue>7418</issue>
        <fpage>61</fpage>
        <lpage>70</lpage>
        <pub-id pub-id-type="doi">10.1038/nature11412</pub-id>
        <pub-id pub-id-type="pmid">23000897</pub-id>
      </element-citation>
    </ref>
    <ref id="CR393">
      <label>393.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kristensen</surname>
            <given-names>VN</given-names>
          </name>
          <name>
            <surname>Vaske</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Ursini-Siegel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Van Loo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Nordgard</surname>
            <given-names>SH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling</article-title>
        <source>Proc Natl Acad Sci</source>
        <year>2012</year>
        <volume>109</volume>
        <issue>8</issue>
        <fpage>2802</fpage>
        <lpage>2807</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1108781108</pub-id>
        <?supplied-pmid 21908711?>
        <pub-id pub-id-type="pmid">21908711</pub-id>
      </element-citation>
    </ref>
    <ref id="CR394">
      <label>394.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vaske</surname>
            <given-names>CJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM</article-title>
        <source>Bioinformatics</source>
        <year>2010</year>
        <volume>26</volume>
        <fpage>i237</fpage>
        <lpage>i245</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btq182</pub-id>
        <?supplied-pmid 20529912?>
        <pub-id pub-id-type="pmid">20529912</pub-id>
      </element-citation>
    </ref>
    <ref id="CR395">
      <label>395.</label>
      <mixed-citation publication-type="other">Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer. 2011;10:135.</mixed-citation>
    </ref>
    <ref id="CR396">
      <label>396.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kristensen</surname>
            <given-names>VN</given-names>
          </name>
          <name>
            <surname>Lingjærde</surname>
            <given-names>OC</given-names>
          </name>
          <name>
            <surname>Russnes</surname>
            <given-names>HG</given-names>
          </name>
          <name>
            <surname>Vollan</surname>
            <given-names>HKM</given-names>
          </name>
          <name>
            <surname>Frigessi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Børresen-Dale</surname>
            <given-names>AL</given-names>
          </name>
        </person-group>
        <article-title>Principles and methods of integrative genomic analyses in cancer</article-title>
        <source>Nat Rev Cancer</source>
        <year>2014</year>
        <volume>14</volume>
        <issue>5</issue>
        <fpage>299</fpage>
        <lpage>313</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc3721</pub-id>
        <?supplied-pmid 24759209?>
        <pub-id pub-id-type="pmid">24759209</pub-id>
      </element-citation>
    </ref>
    <ref id="CR397">
      <label>397.</label>
      <mixed-citation publication-type="other">Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;7403:400–4.</mixed-citation>
    </ref>
    <ref id="CR398">
      <label>398.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Malkin</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>FP</given-names>
          </name>
          <name>
            <surname>Strong</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Fraumeni</surname>
            <given-names>JF</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Nelson</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>DH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms</article-title>
        <source>Science</source>
        <year>1990</year>
        <volume>250</volume>
        <issue>4985</issue>
        <fpage>1233</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1978757</pub-id>
        <?supplied-pmid 1978757?>
        <pub-id pub-id-type="pmid">1978757</pub-id>
      </element-citation>
    </ref>
    <ref id="CR399">
      <label>399.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Herceg</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Hainaut</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis</article-title>
        <source>Mol Oncol</source>
        <year>2007</year>
        <volume>1</volume>
        <issue>1</issue>
        <fpage>26</fpage>
        <lpage>41</lpage>
        <pub-id pub-id-type="doi">10.1016/j.molonc.2007.01.004</pub-id>
        <?supplied-pmid 19383285?>
        <pub-id pub-id-type="pmid">19383285</pub-id>
      </element-citation>
    </ref>
    <ref id="CR400">
      <label>400.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berchuck</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Heron</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Carney</surname>
            <given-names>ME</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Frequency of germline and somatic BRCA1 mutations in ovarian cancer</article-title>
        <source>Clin Cancer Res</source>
        <year>1998</year>
        <volume>4</volume>
        <issue>10</issue>
        <fpage>2433</fpage>
        <lpage>7</lpage>
        <?supplied-pmid 9796975?>
        <pub-id pub-id-type="pmid">9796975</pub-id>
      </element-citation>
    </ref>
    <ref id="CR401">
      <label>401.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bertheau</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Lehmann-Che</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Varna</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dumay</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Poirot</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Porcher</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>p53 in breast cancer subtypes and new insights into response to chemotherapy</article-title>
        <source>Breast</source>
        <year>2013</year>
        <volume>22</volume>
        <issue>Suppl 2</issue>
        <fpage>S27</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1016/j.breast.2013.07.005</pub-id>
        <?supplied-pmid 24074787?>
        <pub-id pub-id-type="pmid">24074787</pub-id>
      </element-citation>
    </ref>
    <ref id="CR402">
      <label>402.</label>
      <mixed-citation publication-type="other">Hainaut. TP53: coordinator of the processes that underlie the hallmarks of cancer p53 in the clinics. Springer. 2013; 1–23</mixed-citation>
    </ref>
    <ref id="CR403">
      <label>403.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Thompson</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Obermiller</surname>
            <given-names>PS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression</article-title>
        <source>Nat Genet</source>
        <year>1995</year>
        <volume>9</volume>
        <issue>4</issue>
        <fpage>444</fpage>
        <lpage>50</lpage>
        <pub-id pub-id-type="doi">10.1038/ng0495-444</pub-id>
        <?supplied-pmid 7795653?>
        <pub-id pub-id-type="pmid">7795653</pub-id>
      </element-citation>
    </ref>
    <ref id="CR404">
      <label>404.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dobrovic</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Simpfendorfer</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Methylation of the BRCA1 gene in sporadic breast cancer</article-title>
        <source>Cancer Res</source>
        <year>1997</year>
        <volume>57</volume>
        <issue>16</issue>
        <fpage>3347</fpage>
        <lpage>50</lpage>
        <?supplied-pmid 9269993?>
        <pub-id pub-id-type="pmid">9269993</pub-id>
      </element-citation>
    </ref>
    <ref id="CR405">
      <label>405.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cleton-Jansen</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Lakhani</surname>
            <given-names>SR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13</article-title>
        <source>Br J Cancer</source>
        <year>1995</year>
        <volume>72</volume>
        <issue>5</issue>
        <fpage>1241</fpage>
        <lpage>4</lpage>
        <pub-id pub-id-type="doi">10.1038/bjc.1995.493</pub-id>
        <?supplied-pmid 7577475?>
        <pub-id pub-id-type="pmid">7577475</pub-id>
      </element-citation>
    </ref>
    <ref id="CR406">
      <label>406.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hamann</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Herbold</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Costa</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer</article-title>
        <source>Cancer Res</source>
        <year>1996</year>
        <volume>56</volume>
        <issue>9</issue>
        <fpage>1988</fpage>
        <lpage>90</lpage>
        <?supplied-pmid 8616837?>
        <pub-id pub-id-type="pmid">8616837</pub-id>
      </element-citation>
    </ref>
    <ref id="CR407">
      <label>407.</label>
      <mixed-citation publication-type="other">van den Akker EB, Verbruggen B, Heijmans BT, Beekman M, Kok JN, Slagboom PE, et al. Integrating protein-protein interaction networks with gene-gene co-expression networks improves gene signatures for classifying breast cancer metastasis. J Integr Bioinformatics. 2011;8:188.</mixed-citation>
    </ref>
    <ref id="CR408">
      <label>408.</label>
      <mixed-citation publication-type="other">Andrews J, Kennette W, Pilon J, Hodgson A, Tuck AB, Chambers AF, et al. Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. PLoS One. 2010;5:e8665.</mixed-citation>
    </ref>
    <ref id="CR409">
      <label>409.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chin</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Hahn</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Getz</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Meyerson</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Making sense of cancer genomic data</article-title>
        <source>Genes Dev</source>
        <year>2011</year>
        <volume>25</volume>
        <fpage>534</fpage>
        <lpage>555</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.2017311</pub-id>
        <?supplied-pmid 21406553?>
        <pub-id pub-id-type="pmid">21406553</pub-id>
      </element-citation>
    </ref>
    <ref id="CR410">
      <label>410.</label>
      <mixed-citation publication-type="other">Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot T, Malta T, Pagnotta SM, Castiglioni I, Ceccarelli M, Noushmehr H and Bontempi G (2015). TCGAbiolinks: An R/Bioconductor package for integrative analysis with TCGA data. Manuscript in preparation<italic>.</italic></mixed-citation>
    </ref>
    <ref id="CR411">
      <label>411.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Colaprico</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cava</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bertoli</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bontempi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Castiglioni</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>Integrative analysis with Monte Carlo cross-validation reveals miRNAs regulating pathways cross-talk in aggressive breast cancer</article-title>
        <source>Biomed Res Int</source>
        <year>2015</year>
        <volume>2015</volume>
        <fpage>831314</fpage>
        <pub-id pub-id-type="doi">10.1155/2015/831314</pub-id>
        <?supplied-pmid 26240829?>
        <pub-id pub-id-type="pmid">26240829</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
